<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Drug treatments for managing cystic fibrosis‐related diabetes - Onady, GM - 2020 | Cochrane Library</title> <meta content="Drug treatments for managing cystic fibrosis‐related diabetes - Onady, GM - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004730.pub5/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Drug treatments for managing cystic fibrosis‐related diabetes - Onady, GM - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004730.pub5/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD004730.pub5" name="dc.identifier" scheme="DOI"/> <meta content="Drug treatments for managing cystic fibrosis‐related diabetes" name="citation_title"/> <meta content="Gary M Onady" name="citation_author"/> <meta content="Wright State University" name="citation_author_institution"/> <meta content="gmonady@gmail.com" name="citation_author_email"/> <meta content="Adrienne Stolfi" name="citation_author"/> <meta content="Children's Medical Center" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD004730.pub5" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/10/19" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004730.pub5/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004730.pub5/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004730.pub5/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Administration, Oral; Bias; Blood Glucose [analysis]; Carbamates [administration &amp; dosage]; Cystic Fibrosis [blood, *complications]; Diabetes Mellitus [blood, *drug therapy, etiology]; Fasting [blood]; Hyperglycemia [drug therapy]; Hypoglycemic Agents [*administration &amp; dosage]; Insulin [*administration &amp; dosage]; Insulin Glargine [administration &amp; dosage]; Insulin, Isophane [administration &amp; dosage]; Piperidines [administration &amp; dosage]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004730.pub5&amp;doi=10.1002/14651858.CD004730.pub5&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004730.pub5&amp;doi=10.1002/14651858.CD004730.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004730.pub5&amp;doi=10.1002/14651858.CD004730.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004730.pub5&amp;doi=10.1002/14651858.CD004730.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004730.pub5&amp;doi=10.1002/14651858.CD004730.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004730.pub5&amp;doi=10.1002/14651858.CD004730.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004730.pub5&amp;doi=10.1002/14651858.CD004730.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004730.pub5&amp;doi=10.1002/14651858.CD004730.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004730.pub5&amp;doi=10.1002/14651858.CD004730.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004730.pub5&amp;doi=10.1002/14651858.CD004730.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004730.pub5&amp;doi=10.1002/14651858.CD004730.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004730.pub5&amp;doi=10.1002/14651858.CD004730.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004730.pub5&amp;doi=10.1002/14651858.CD004730.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004730.pub5&amp;doi=10.1002/14651858.CD004730.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004730.pub5&amp;doi=10.1002/14651858.CD004730.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004730.pub5&amp;doi=10.1002/14651858.CD004730.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004730.pub5&amp;doi=10.1002/14651858.CD004730.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004730.pub5&amp;doi=10.1002/14651858.CD004730.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004730.pub5&amp;doi=10.1002/14651858.CD004730.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004730.pub5&amp;doi=10.1002/14651858.CD004730.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004730.pub5&amp;doi=10.1002/14651858.CD004730.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004730.pub5&amp;doi=10.1002/14651858.CD004730.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004730.pub5&amp;doi=10.1002/14651858.CD004730.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="PSzzz2OT";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD004730\x2epub5\x26doi\x3d10\x2e1002\x2f14651858\x2eCD004730\x2epub5\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004730\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004730\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","fa","fr","ms"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD004730.pub5",title:"Drug treatments for managing cystic fibrosis\\u2010related diabetes",firstPublishedDate:"Oct 19, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Cystic Fibrosis and Genetic Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PSzzz2OT&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004730.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004730.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD004730.pub5/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD004730.pub5/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004730.pub5%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD004730.PUB5" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD004730.pub5/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD004730.PUB5" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD004730.pub5/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD004730.pub5/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2718 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD004730.pub5" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004730.pub5/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004730.pub5/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004730.pub5/full#CD004730-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004730.pub5/full#CD004730-sec-0121"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004730.pub5/full#CD004730-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004730.pub5/full#CD004730-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004730.pub5/full#CD004730-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004730.pub5/full#CD004730-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004730.pub5/full#CD004730-sec-0038"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004730.pub5/full#CD004730-sec-0111"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004730.pub5/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004730.pub5/appendices#CD004730-sec-0126"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004730.pub5/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004730.pub5/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/table_n/CD004730StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/table_n/CD004730StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004730.pub5/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004730.pub5/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004730.pub5/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004730.pub5/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004730.pub5/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD004730.pub5/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Drug treatments for managing cystic fibrosis‐related diabetes</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004730.pub5/information#CD004730-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Gary M Onady</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004730.pub5/information#CD004730-cr-0005">Adrienne Stolfi</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/information/en#CD004730-sec-0131">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 19 October 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD004730.pub5">https://doi.org/10.1002/14651858.CD004730.pub5</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD004730-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004730-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004730-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004730-abs-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD004730-abs-0008">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD004730-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD004730-abs-0001" lang="en"> <section id="CD004730-sec-0001"> <h3 class="title" id="CD004730-sec-0001">Background</h3> <p>The Cystic Fibrosis Foundation recommends both short‐term and long‐acting insulin therapy when cystic fibrosis‐related diabetes (CFRD) has been diagnosed. Diagnosis is based on: an elevated fasting blood glucose level greater than 6.94 mmol/L (125 mg/dL); or oral glucose tolerance tests greater than 11.11 mmol/L (200 mg/dL) at two hours; or symptomatic diabetes for random glucose levels greater than 11.11 mmol/L (200 mg/dL); or glycated hemoglobin levels of at least 6.5%. This is an update of a previously published review. </p> </section> <section id="CD004730-sec-0002"> <h3 class="title" id="CD004730-sec-0002">Objectives</h3> <p>To establish the effectiveness of insulin and oral agents for managing diabetes in people with cystic fibrosis in relation to blood sugar levels, lung function and weight management. </p> </section> <section id="CD004730-sec-0003"> <h3 class="title" id="CD004730-sec-0003">Search methods</h3> <p>We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's Trials Register comprising references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings. We also handsearched abstracts from pulmonary symposia and the North American Cystic Fibrosis Conferences. </p> <p>Date of most recent register search: 10 September 2020.</p> <p>We searched online trials registries; date of most recent searches: 21 March 2020.</p> </section> <section id="CD004730-sec-0004"> <h3 class="title" id="CD004730-sec-0004">Selection criteria</h3> <p>Randomized controlled trials comparing all methods of pharmacological diabetes therapy in people with diagnosed CFRD. </p> </section> <section id="CD004730-sec-0005"> <h3 class="title" id="CD004730-sec-0005">Data collection and analysis</h3> <p>Two authors independently extracted data and assessed the risk of bias in the included studies. Authors also used GRADE to assess the quality of the evidence. </p> </section> <section id="CD004730-sec-0006"> <h3 class="title" id="CD004730-sec-0006">Main results</h3> <p>The searches identified 29 trials (45 references). Four included trials provide results: one short‐term single‐center cross‐over trial (seven adults) comparing insulin with oral repaglinide and no medication in adults with CFRD and normal fasting glucose; one long‐term multicenter trial (61 adults with CFRD) comparing insulin with oral repaglinide and placebo; one long‐term multicenter trial (67 adults) comparing insulin with oral repaglinide; and one 12‐week single‐center cross‐over trial (20 adults) comparing the long‐acting insulin glargine to short‐term neutral protamine Hagedorn insulin. Two ongoing trials of newly approved incretin mimics have been noted for possible future inclusion. </p> <p>Downgrading of the quality of the evidence was mainly due to risks of bias across all domains, but particularly due to concerns surrounding allocation concealment and selective reporting. There were also some concerns due to imprecision from small sample sizes and low event rates. Finally, there may be some bias due to the amounts of insulin and repaglinide given not being comparable. </p> <p>Data from one trial comparing insulin to placebo (39 participants) did not show any difference between groups for the primary outcomes of blood glucose levels (very low‐quality evidence), lung function (low‐quality evidence) or nutritional status (low‐quality evidence). Similarly, no differences between groups were seen for the secondary outcomes of number of hypoglycemic episodes (low‐quality evidence), secondary infection complications or quality of life (QoL). These results were mirrored in the narrative reports for the second trial in this comparison (seven participants). </p> <p>Data from the one‐year trial comparing repaglinide to placebo (38 participants), showed no differences between groups for the primary outcomes of blood glucose levels (very low‐quality evidence), lung function (low‐quality evidence) and nutritional status (low‐quality evidence). Also, no differences were seen between groups for the secondary outcomes of number of hypoglycemic episodes (low‐quality evidence), secondary infection complications or QoL. These findings were mirrored in the narrative reports for the second trial (n = 7) in this comparison. </p> <p>Three trials compared insulin to repaglinide (119 participants). Data from one trial (n = 67) showed no difference in blood glucose levels at either 12 months (high‐quality evidence) or 24 months; narrative reports from one trial (45 participants) reported no difference between groups, but the second trial (7 participants) reported a beneficial effect of insulin over repaglinide. Two trials (112 participants) found no difference between insulin and repaglinide in lung function or nutritional status (moderate‐quality evidence). Two trials (56 participants) reported no difference in the number of hypoglycemic episodes (low‐quality evidence). One trial (45 participants) reported no difference between groups in secondary infections and cystic fibrosis QoL. </p> <p>The single trial comparing glargine to neutral protamine Hagedorn insulin did not report directly on the review's primary outcomes, but did report no differences between groups in post‐prandial glucose values and weight; neither group reported infectious complications. There was no difference in episodes of hypoglycemia (very low‐quality evidence) and while there was no difference reported in QoL, all participants opted to continue treatment with glargine after the trial was completed. </p> <p>Mortality was not reported by any trial in any comparison, but death was not given as a reason for withdrawal in any trial. </p> </section> <section id="CD004730-sec-0007"> <h3 class="title" id="CD004730-sec-0007">Authors' conclusions</h3> <p>This review has not found any conclusive evidence that any agent has a distinct advantage over another in controlling hyperglycemia or the clinical outcomes associated with CFRD. Given the treatment burden already experienced by people with cystic fibrosis, oral therapy may be a viable treatment option. </p> <p>While some cystic fibrosis centers use oral medications to help control diabetes, the Cystic Fibrosis Foundation (USA) clinical practice guidelines support the use of insulin therapy and this remains the most widely‐used treatment method. Randomized controlled trials specifically related to controlling diabetes and its impact on the course of pulmonary disease process in cystic fibrosis continue to be a high priority. Specifically, investigators should evaluate adherence to different therapies and also whether there is benefit in using additional hypoglycemic agents as well as the newly approved incretin mimics. Agents that potentiate insulin action, especially agents with additional anti‐inflammatory potential should also be further investigated as adjuvant therapy to insulin. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD004730-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004730-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004730-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004730-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD004730-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD004730-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD004730-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD004730-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD004730-abs-0002" lang="en"> <h3>Drug treatments for managing cystic fibrosis‐related diabetes</h3> <p><b>Review question</b> </p> <p>We reviewed the evidence regarding different drugs for managing cystic fibrosis‐related diabetes (CFRD). </p> <p><b>Background</b> </p> <p>Cystic fibrosis (CF) is a common life‐limiting genetic condition, mainly causing damage to the lungs and pancreas. The pancreas makes insulin, a hormone which the body needs to take sugar into the cells so it can be converted into energy. In up to 90% of people with CF, problems with the pancreas and digestive enzymes mean nutrients are not properly absorbed. People with CF need high‐calorie and high‐protein diets to provide enough energy to maintain muscle mass so as to support their breathing and make up for breathing difficulties from disease‐damaged lungs. It is important for people with CF to turn sugar into energy efficiently. This is especially challenging for people with CFRD because damage to the pancreas affects insulin production and release. Inflammation seen in CF can reduce insulin production and lessen its effect by causing insulin resistance. Increased life expectancy for people with CF means that 50% of adults with CF are likely to develop CFRD. </p> <p>We wanted to assess different treatments for CFRD to limit any related decline in health. These include artificial sources of insulin (like long‐acting glargine or short‐acting protamine insulin), the control of natural hormones that stimulate insulin release and medications that enhance a person’s own insulin release or affect insulin resistance. </p> <p><b>Search date</b> </p> <p>The evidence is current to: 10 September 2020.</p> <p><b>Study characteristics</b> </p> <p>We included four trials (145 adults). Two trials compared insulin to either no treatment for two months (seven participants) or to a placebo (dummy drug with no active medication) for one year (61 participants). These trials, along with a third trial lasting two years (67 adults), also compared insulin (given via a syringe) to repaglinide tablets. The fourth trial (20 participants) compared the long‐acting insulin glargine to short‐term neutral protamine Hagedorn insulin over a 12‐week period. </p> <p><b>Key results</b> </p> <p>We found results for our primary outcomes of blood glucose levels, lung function and nutritional status and our secondary outcomes of pulmonary exacerbations (flare up of disease), complications and quality of life. We could only analyse limited results and did not find evidence that showed that any one treatment was better than another. Our analysis did not show that either insulin or repaglinide made any difference to any of our outcomes compared to placebo or no treatment at any time point. Similarly, most of our results did not show whether insulin or repaglinide was better, but the evidence was a little stronger that there was no difference in lung function, nutritional status or blood glucose levels at 12 months. Similarly, the evidence was not strong enough to show if there is any difference between glargine and neutral protamine Hagedorn insulin for any of our outcome measures. None of the trials reported if there were any deaths. </p> <p>Given the treatment burden already experienced by people with CF, tablets may be a welcome alternative to injecting insulin. Longer‐term trials with larger numbers of people are still needed to see how controlling CFRD affects lung function. Investigators should also assess how many people keep to their treatment plan when comparing insulin to tablets. Research should look at using the drugs by themselves or together with insulin to enhance insulin action, especially those agents with additional anti‐inflammatory potential. </p> <p><b>Quality of the evidence</b> </p> <p>We had some concerns about the quality of the evidence; mainly that there would be bias because clinicians probably knew in advance which treatment group the next person was going to be put into (e.g. healthier participants might be put into one group to show better results for that treatment) or bias from people taking part knowing which treatment group they were in (e.g. insulin via a syringe or repaglinide as a tablet). There may also be bias because results may only be selectively reported. We had some concerns that the analysis would not be precise due to small numbers of participants and low event rates. Finally, there may be bias in the results as the amounts of insulin and repaglinide given were not comparable. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD004730-sec-0121" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD004730-sec-0121"></div> <h3 class="title" id="CD004730-sec-0122">Implications for practice</h3> <section id="CD004730-sec-0122"> <p>There is currently no conclusive evidence that any agent (long‐acting insulins, short‐acting insulins or oral hypoglycemic agents) have a distinct advantage over one another in controlling hyperglycemia or clinical outcomes associated with cystic fibrosis‐related diabetes (CFRD). A single‐center long term prospective prognostic cohort trial is currently the best evidence available to date that demonstrates that insulin therapy for both normal and elevated fasting hypoglycemia improves the control of microvascular disease in people with CFRD (<a href="./references#CD004730-bbs2-0049" title="SchwarzenbergSJ , ThomasW , OlsenTW , GroverT , WalkD , MillaC , et al. Microvascular complications in cystic fibrosis-related diabetes. Diabetes Care2007;30(5):1056-61.">Schwarzenberg 2007</a>). Outside of this singularly important clinical outcome, the impact on clinical outcomes important to people with cystic fibrosis (pwCF), namely long‐term body mass index (BMI) and pulmonary function measures, have yet to be conclusively demonstrated. </p> <p>Results from this updated Cochrane Review (after factoring out the lead‐in bias as noted in the 2010 Moran study) do not allow conclusions to be drawn with regards to the optimal therapy for people with CFRD, despite recommendations in the current version of the CFRD Clinical Practice Guidelines to treat this subgroup of people with CFRD at meal times only with a short‐acting insulin (<a href="./references#CD004730-bbs2-0043" title="MoranA , BrunzellC , CohenRC , KatzM , MarshallBC , OnadyG , et al. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care2010;33(12):2697-708.">Moran 2010</a>). Contrary to the current CFRD Clinical Practice Guidelines which recommend the use of insulin only for managing CFRD, the results of this Cochrane Review do not show that insulin therapy offers greater clinical benefit compared to the oral hypoglycemic agent repaglinide. However, given the treatment burden which pwCF already bear, treatment with oral agents should be considered for managing CFRD. </p> </section> <h3 class="title" id="CD004730-sec-0123">Implications for research</h3> <section id="CD004730-sec-0123"> <p>Multicenter randomised controlled trials (RCTs) are still required in order to best assess the effectiveness of therapeutic options in the control of CFRD. This Cochrane Review suggests the potential for achieving tighter glycemic control with long‐acting insulin for people with CF with fasting hyperglycemia and this could likely be demonstrated in future studies with the use of insulin infusion pumps.  </p> <p>The newer classes of injectable and oral incretin associated therapeutics options have recently demonstrated a beneficial effect in people with CF who are observed to have impaired glucose tolerance (<a href="./references#CD004730-bbs2-0011" title="GeyerMC , SullivanT , TaiA , MortonJM , EdwardsS , MartinAJ , et al. Exenatide corrects postprandial hyperglycaemia in young people with cystic fibrosis and impaired glucose tolerance: a randomized crossover trial. Diabetes, Obesity &amp; Metabolism2019;21:700-704. [CFGD REGISTER: CO69] ">Geyer 2019</a>). There are no trials reported to date, that demonstrate their effectiveness in treating CFRD. This potential class of agents opens up a whole series of therapeutic intervention RCTs to assess their effectiveness compared to insulin, both in their effectiveness in conjunction with insulin compared to insulin alone. </p> <p>The use of therapeutic agents which may provide additional impact in CF based on the inflammatory effects of insulin sensitivity and the control of levels of inflammatory mediators by mechanisms such as peroxisome proliferator activated receptor gamma (PPARg) receptor agonists still remains to be demonstrated. The concerns with this class of agents are the side effects associated with the glitazones. Cardiac effects associated with the glitazones are less applicable to people with CF, with such a low incidence of coronary artery disease; and osteoporosis concerns may be less problematic in CF due to interleukin inhibitory effect of PPARg agonists on IL‐6. Finally, the potential value of metformin in people with CF without hepatic dysfunction demonstrates another potential option in treating CFRD. These additional agents may provide a unique advantage, perhaps as adjuvant therapy to insulin, for a population that is highly adversely impacted by inflammatory disease. </p> <p>Outcomes of greatest interest in future trials comparing long‐acting versus short‐acting insulins, or insulins to oral agents and incretin mimics should be powered such that they can include BMI, FEV<sub>1</sub>, performance on the six‐minute walk test, frequency of hospital admissions and effects on bone metabolism. A further important outcome would be to measure varying adherence rates between insulin therapy and treatment with less burdensome oral agents. </p> <p>Furthermore, epidemiology demonstrates increased morbidity and mortality for people with CF with glucose intolerance, which prompts RCTs to examine the use of the expanding choices of anti‐diabetic agents in the management of pre‐diabetics who are screened as glucose intolerant verses conservative observation. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD004730-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD004730-sec-0008"></div> <div class="table" id="CD004730-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings: insulin versus placebo for CFRD</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Insulin versus placebo for cystic fibrosis‐related diabetes</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: adults with CFRD </p> <p><b>Settings</b>: outpatients </p> <p><b>Intervention</b>: insulin (0.5 unit insulin aspart/15 g dietary carbohydrate) 3 times daily </p> <p><b>Comparison:</b> oral placebo 3 times daily </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Insulin</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HbA1c</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>1 study reported that HbA1C levels did not significantly change in either the insulin or the placebo group (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>a,c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data were available for this outcome and results have been reported narratively (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). </p> <p>One trial (n = 7) reported that there was a benefit seen glucose AUC (reduction) at both the two‐hour time point (P &lt; 0.05) and the five‐hour time point (P &lt; 0.05) (<a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> % predicted</b>: change from baseline </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FEV<sub>1</sub> % predicted in the control group was<br/>‐ 3% predicted. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FEV<sub>1</sub> % predicted in the intervention group was 1.2% higher (5.6% lower to 8.0% higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD</b> 1.20 (‐5.63 to 8.03) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>b,c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No difference was observed between groups, P = 0.3 for overall effect (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FVC % predicted</b>: </p> <p>change from baseline</p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FVC % predicted in the control group was ‐1.1% predicted.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FVC % predicted in the intervention group was 0.6% higher (5.7% lower to 6.9% higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD</b> 0.60 (‐5.67 to 6.87) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>b,c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No difference was observed between groups,</p> <p>P = 0.85 for overall effect (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>BMI</b> <b>(kg/m²)</b>: </p> <p>change from baseline</p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in BMI in the control group was ‐0.02 kg/m².</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in BMI in the intervention groups was 0.41 kg/m² higher (0.23 kg/m² lower to 1.1 kg/m² higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD</b> 0.41 (‐0.23 to 1.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>b,c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no significant difference between the placebo group and intervention group, P = 0.21 for overall effect (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hypoglycemia</b>: </p> <p>number of episodes</p> <p>Follow‐up: 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There were no hypoglycemic events in the placebo group, therefore it is not possible to calculate the corresponding risk. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR</b> 9.23 (0.53 to 159.14) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>b,d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no significant difference between groups after 3 months, but it is not clear whether the hypoglycemic events occurred in those with CFRD or those with impaired glucose tolerance (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). </p> <p>The earlier Moran trial (n = 7) reported hypoglycemic events at 2 months and these data did not give a significant result, RR 2.00 (95% CI 0.23 to 17.34) (<a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>BMI</b> : body mass index; <b>CFRD</b> : cystic fibrosis‐related diabetes; <b>CI</b> : confidence interval; <b>HbA1c</b> : glycated hemoglobin; <b>FEV<sub>1</sub> </b> : forced expiratory volume in 1 second; <b>FVC</b> : forced vital capacity; <b>MD</b> : mean difference; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>a. Downgraded twice due to risk of bias in the included study, particularly around the domains of allocation concealment and selective outcome reporting. No data were reported for this outcome. </p> <p>b. Downgraded once due to an unclear risk of bias in the single included study. Although the study was deemed to be at low risk across the domains of randomization and blinding, the allocation process was not clearly described. The study was also deemed to be at high risk of bias due to selective reporting, although that does not affect this particular outcome. </p> <p>c. Downgraded once due to imprecision from small sample size; one study was 3‐armed study which therefore reduces the number of participants in each arm. </p> <p>d. Downgraded once due to imprecision from both small sample size and low event rates.</p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD004730-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings: repaglinide versus placebo for CFRD</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Repaglinide versus placebo for CFRD</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: adults with CFRD </p> <p><b>Settings</b>: outpatients </p> <p><b>Intervention</b>: repaglinide (2.0 mg) orally 3 times daily </p> <p><b>Comparison</b>: oral placebo 3 times daily </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Repaglinide</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>HbA1c</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>1 trial reported that HbA1C levels did not significantly change in either the repaglinide or the placebo group (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>a,b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data were available for this outcome and results have been reported narratively (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> % predicted</b>; change from baseline </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FEV<sub>1</sub> % predicted in the control group was<br/>‐3% predicted. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FEV<sub>1</sub> % predicted in the intervention group was 1.7% higher (5.1% lower to 8.5% higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD</b> 1.70 (‐5.13 to 8.53) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>b,c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No difference was observed between groups, P = 0.6 for overall effect (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FVC % predicted</b>: change from baseline </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FVC % predicted in the control group was ‐1.1% predicted.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FVC % predicted in the intervention groups was 1.0% higher (7.4% lower to 5.4% higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD</b> ‐1.00 (‐7.40 to 5.40) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>b,c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No difference was observed between groups, P = 0.76 for overall effect (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>BMI (kg/m²)</b>: </p> <p>change from baseline</p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in BMI in the control group was ‐0.02 kg/m².</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in BMI in the intervention groups was 0.2 kg/m² higher (0.5 kg/m² lower to 0.8 kg/m² higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD</b> 0.17 (‐0.47 to 0.81) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>b,c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no significant difference between the placebo group and intervention group, P = 0.6 for overall effect (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hypoglycemia</b>: </p> <p>number of episodes</p> <p>Follow‐up: 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There were mild hypoglycemic events reported in 23% of repaglinide participants, but no placebo participants reported hypoglycemia (P &lt; 0.04); therefore it is not possible to calculate the corresponding risk. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR</b> 12.52 (0.74 to 211.20) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>a,d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The earlier Moran study also reported on this outcome but at 2 months. These data did not give a significant result, RR 2.00 (95% CI 0.23 to 17.34) (<a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>BMI</b> : body mass index; <b>CFRD</b> : cystic fibrosis‐related diabetes; <b>CI</b> : confidence interval; <b>HbA1c</b> : glycated hemoglobin; <b>FEV<sub>1</sub> </b> : forced expiratory volume in 1 second; <b>FVC</b> : forced vital capacity; <b>MD</b> : mean difference; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>a. Downgraded twice due to risk of bias in the included study, particularly around the domains of allocation concealment and selective outcome reporting. No data were reported for this outcome. </p> <p>b. Downgraded once due to imprecision from small sample size. This was a 3‐armed study which therefore reduces the number of participants in each arm. </p> <p>c. Downgraded once due to an unclear risk of bias in the single included trial. Although the study was deemed to be at low risk across the domains of randomisation and blinding, the allocation process was not clearly described. The trial was also deemed to be at high risk of bias due to selective reporting although that does not affect this particular outcome. </p> <p>d. Downgraded once due to imprecision from both small sample size and low event rates.</p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD004730-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings: repaglinide versus insulin for CFRD</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Repaglinide versus insulin for CFRD</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children over 12 and adults with CFRD </p> <p><b>Settings:</b> home </p> <p><b>Intervention:</b> oral repaglinide (0.5 mg ‐ 2 mg) 3 times daily </p> <p><b>Comparison:</b> insulin 3 times daily </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Insulin</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Repaglinide</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HbA1c (%)</b> </p> <p>change from baseline</p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in HbA1c in the control group was ‐0.1%.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in HbA1c in the intervention group was 0.3% higher<br/>(0.14% lower to 0.74% higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD</b> 0.30 (‐0.14 to 0.74) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ballmann also reported the change from baseline in HbA1c at 24 months, but found no significant difference between groups MD 0.4% (95% CI ‐0.09 to 0.89) (<a href="./references#CD004730-bbs2-0001" title="BallmannM , HubertD , AssaelBM , KronfeldK , HonerM , HollRW , et al. Open randomised prospective comparative multi-centre intervention study of patients with cystic fibrosis and early diagnosed diabetes mellitus. BMC Pediatrics2014;14:70. [CENTRAL: 1000301] [CFGD REGISTER: CO53c] [JID: 100967804] [OID: NLM: PMC3975280] [PMCID: PMC3975280] [PMID: 24620855]BallmannM , HubertD , AssaelBM , Mosnier-PudarH , Barao OcampoM , ScheunigN , et al. Repaglinide versus insulin in the treatment of CFRD diagnosed by screening: an open prospective randomized study. Pediatric Pulmonology2013;48 Suppl 26:421. [ABSTRACT NO.: 582] [CENTRAL: 962122] [CFGD REGISTER: CO53b] BallmannM , HubertD , AssaelBM , Mosnier-PudarH , SmacznyC , KesslerL , et al. Treatment of early diagnosed CFRD with oral drugs verus insulin: An open prospective randomized study. Journal of Cystic Fibrosis2013;12 Suppl 1:S32. [ABSTRACT NO.: WS16.1] [CENTRAL: 962115] [CFGD REGISTER: CO53a] BallmannM , HubertD , AssaelBM , StaabD , HebestreitA , NaehrlichL , et al. Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. The Lancet Diabetes and Endocrinology2018;6(2):114-21. [CFGD REGISTER: CO53e] [DOI: 10.1016/S2213-8587(17)30400-X]SchmidK , FinkK , HollRW , HebestreitH , BallmannM . Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2014;13(1):80-5. [CENTRAL: 1000302] [CFGD REGISTER: CO53d] [JID: 101128966] [PMID: 23809507] [SI: ClinicalTrials.gov/NCT00662714]">Ballmann 2018b</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> % predicted</b> </p> <p>change from baseline</p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FEV<sub>1</sub> % predicted ranged across control groups from ‐1.8% to ‐1.7%. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean FEV<sub>1</sub> in the intervention groups was<br/>0.51% lower (4.22% lower to 3.2% higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD</b> ‐0.51 (‐4.22 to 3.20) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112<br/>(2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The Ballmann study also reported this outcome at 24 months, but found no significant difference between groups MD ‐0.10% predicted (95% CI ‐4.12 to 3.92) (<a href="./references#CD004730-bbs2-0001" title="BallmannM , HubertD , AssaelBM , KronfeldK , HonerM , HollRW , et al. Open randomised prospective comparative multi-centre intervention study of patients with cystic fibrosis and early diagnosed diabetes mellitus. BMC Pediatrics2014;14:70. [CENTRAL: 1000301] [CFGD REGISTER: CO53c] [JID: 100967804] [OID: NLM: PMC3975280] [PMCID: PMC3975280] [PMID: 24620855]BallmannM , HubertD , AssaelBM , Mosnier-PudarH , Barao OcampoM , ScheunigN , et al. Repaglinide versus insulin in the treatment of CFRD diagnosed by screening: an open prospective randomized study. Pediatric Pulmonology2013;48 Suppl 26:421. [ABSTRACT NO.: 582] [CENTRAL: 962122] [CFGD REGISTER: CO53b] BallmannM , HubertD , AssaelBM , Mosnier-PudarH , SmacznyC , KesslerL , et al. Treatment of early diagnosed CFRD with oral drugs verus insulin: An open prospective randomized study. Journal of Cystic Fibrosis2013;12 Suppl 1:S32. [ABSTRACT NO.: WS16.1] [CENTRAL: 962115] [CFGD REGISTER: CO53a] BallmannM , HubertD , AssaelBM , StaabD , HebestreitA , NaehrlichL , et al. Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. The Lancet Diabetes and Endocrinology2018;6(2):114-21. [CFGD REGISTER: CO53e] [DOI: 10.1016/S2213-8587(17)30400-X]SchmidK , FinkK , HollRW , HebestreitH , BallmannM . Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2014;13(1):80-5. [CENTRAL: 1000302] [CFGD REGISTER: CO53d] [JID: 101128966] [PMID: 23809507] [SI: ClinicalTrials.gov/NCT00662714]">Ballmann 2018b</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FVC % predicted</b> </p> <p>change from baseline</p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FVC % predicted ranged across control groups from ‐0.8% to ‐0.5%.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FVC % predicted in the intervention groups was<br/>1.0% lower (4.29% lower to 2.3% higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD</b> ‐1.00 (‐4.29 to 2.29) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112<br/>(2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The Ballmann study also reported this outcome at 24 months, but found no significant difference between groups MD ‐3.40% predicted (95% CI ‐7.37 to 0.57) (<a href="./references#CD004730-bbs2-0001" title="BallmannM , HubertD , AssaelBM , KronfeldK , HonerM , HollRW , et al. Open randomised prospective comparative multi-centre intervention study of patients with cystic fibrosis and early diagnosed diabetes mellitus. BMC Pediatrics2014;14:70. [CENTRAL: 1000301] [CFGD REGISTER: CO53c] [JID: 100967804] [OID: NLM: PMC3975280] [PMCID: PMC3975280] [PMID: 24620855]BallmannM , HubertD , AssaelBM , Mosnier-PudarH , Barao OcampoM , ScheunigN , et al. Repaglinide versus insulin in the treatment of CFRD diagnosed by screening: an open prospective randomized study. Pediatric Pulmonology2013;48 Suppl 26:421. [ABSTRACT NO.: 582] [CENTRAL: 962122] [CFGD REGISTER: CO53b] BallmannM , HubertD , AssaelBM , Mosnier-PudarH , SmacznyC , KesslerL , et al. Treatment of early diagnosed CFRD with oral drugs verus insulin: An open prospective randomized study. Journal of Cystic Fibrosis2013;12 Suppl 1:S32. [ABSTRACT NO.: WS16.1] [CENTRAL: 962115] [CFGD REGISTER: CO53a] BallmannM , HubertD , AssaelBM , StaabD , HebestreitA , NaehrlichL , et al. Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. The Lancet Diabetes and Endocrinology2018;6(2):114-21. [CFGD REGISTER: CO53e] [DOI: 10.1016/S2213-8587(17)30400-X]SchmidK , FinkK , HollRW , HebestreitH , BallmannM . Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2014;13(1):80-5. [CENTRAL: 1000302] [CFGD REGISTER: CO53d] [JID: 101128966] [PMID: 23809507] [SI: ClinicalTrials.gov/NCT00662714]">Ballmann 2018b</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>BMI (kg/m²)</b> change from baseline </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in BMI kg/m² in the control group was 0.15 kg/m².</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the intervention group was 0.24 kg/m² higher (0.34 kg/m² lower to 0.82 kg/m² higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD</b> 0.24 (‐0.34 to 0.82) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>b,c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A further trial reported BMI z score and found no significant improvement in z score in the repaglinide treatment group compared to insulin at 12 months (n = 67), MD 0.00 (95%CI ‐0.49 to 0.49). This difference remained non‐significant at 24 months (n = 67), MD 0.40 (95% CI ‐0.09 to 0.89) (<a href="./references#CD004730-bbs2-0001" title="BallmannM , HubertD , AssaelBM , KronfeldK , HonerM , HollRW , et al. Open randomised prospective comparative multi-centre intervention study of patients with cystic fibrosis and early diagnosed diabetes mellitus. BMC Pediatrics2014;14:70. [CENTRAL: 1000301] [CFGD REGISTER: CO53c] [JID: 100967804] [OID: NLM: PMC3975280] [PMCID: PMC3975280] [PMID: 24620855]BallmannM , HubertD , AssaelBM , Mosnier-PudarH , Barao OcampoM , ScheunigN , et al. Repaglinide versus insulin in the treatment of CFRD diagnosed by screening: an open prospective randomized study. Pediatric Pulmonology2013;48 Suppl 26:421. [ABSTRACT NO.: 582] [CENTRAL: 962122] [CFGD REGISTER: CO53b] BallmannM , HubertD , AssaelBM , Mosnier-PudarH , SmacznyC , KesslerL , et al. Treatment of early diagnosed CFRD with oral drugs verus insulin: An open prospective randomized study. Journal of Cystic Fibrosis2013;12 Suppl 1:S32. [ABSTRACT NO.: WS16.1] [CENTRAL: 962115] [CFGD REGISTER: CO53a] BallmannM , HubertD , AssaelBM , StaabD , HebestreitA , NaehrlichL , et al. Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. The Lancet Diabetes and Endocrinology2018;6(2):114-21. [CFGD REGISTER: CO53e] [DOI: 10.1016/S2213-8587(17)30400-X]SchmidK , FinkK , HollRW , HebestreitH , BallmannM . Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2014;13(1):80-5. [CENTRAL: 1000302] [CFGD REGISTER: CO53d] [JID: 101128966] [PMID: 23809507] [SI: ClinicalTrials.gov/NCT00662714]">Ballmann 2018b</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hypoglycemia</b> </p> <p>number of episodes</p> <p>Follow‐up: 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>167 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>230 per 1000</b><br/>(80 to 670) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR</b> 1.38 (0.48 to 4.01) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56<br/>(2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>b,c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The earlier Moran trial also reported on episodes of hypoglycaemia over 2 months, but reported no significant differences between groups, RR 0.50 (95% CI 0.06 to 4.33) (<a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>BMI</b> : body mass index; <b>CFRD</b> : cystic fibrosis‐related diabetes; <b>CI</b> : confidence interval; <b>HbA1c</b> : glycated hemoglobin; <b>FEV<sub>1</sub> </b> : forced expiratory volume in 1 second; <b>FVC</b> : forced vital capacity; <b>MD</b> : mean difference; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>a. Downgraded once due to risk of bias within the included studies. The larger Ballmann study was at low of risk of bias across most domains but was deemed to be at high risk of performance bias due to the study being open‐label. The Moran study was at high or unclear risk of bias across 3 domains and so, when taken together, there was enough risk of bias to affect the results. </p> <p>b. Downgraded once due to an unclear risk of bias in the single included study. Although the study was deemed to be at low risk across the domains of randomisation and blinding, the allocation process wasn't clearly described. The study was also deemed to be at high risk of bias due to selective reporting although that does not affect this particular outcome. </p> <p>c. Downgraded once due to imprecision from small sample size. This was a 3‐armed study which therefore reduces the number of participants in each arm. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD004730-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Summary of findings: NPH insulin versus glargine for CFRD</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>NPH insulin versus glargine for CFRD</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: adults with CFRD and fasting hyperglycemia </p> <p><b>Settings</b>: home </p> <p><b>Intervention</b>: NPH insulin (individually dosed based on insulin to carbohydrate ratio) at bedtime </p> <p><b>Comparison</b>: insulin glargine given at bedtime </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Insulin glargine</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>NPH insulin</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HbA1c</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study reported on fasting and 2‐hour post‐prandial glucose. There was no significant difference between groups for either measure, MD 10.00 mg/dL (95% CI ‐12.86 to 32.86) and MD 8.00 mg/dL (95% CI ‐10.07 to 26.07) respectively (<a href="./references#CD004730-bbs2-0002" title="GroverP , ThomasW , MoranA . Glargine versus NPH insulin in cystic fibrosis related diabetes. Journal of Cystic Fibrosis2008;7(2):134-6. [CFGD REGISTER: CO39] ">Grover 2008</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> % predicted</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FVC % predicted</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>BMI kg/m²</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BMI was not reported for this comparison. The Grover study did however report on mean change in: weight, MD ‐1.00 kg (95% CI ‐2.39 to 0.39); fat mass, MD ‐0.30 kg (95% CI ‐1.41 to 0.81); and lean mass, MD ‐0.20 kg (95% CI ‐0.75 to 0.35). None of the results showed any significant difference between NPH insulin and glargine (<a href="./references#CD004730-bbs2-0002" title="GroverP , ThomasW , MoranA . Glargine versus NPH insulin in cystic fibrosis related diabetes. Journal of Cystic Fibrosis2008;7(2):134-6. [CFGD REGISTER: CO39] ">Grover 2008</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hypoglycemia</b> </p> <p>mean number of events per participant</p> <p>Follow‐up: 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of hypoglycaemic events in the control group was 6 per participant.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of hypoglycaemic events in the intervention group was 1 event lower (4 events lower to 2 events higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD</b> ‐1.00 (‐3.77 to 1.77) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>a,b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>BMI</b> : body mass index; <b>CFRD</b> : cystic fibrosis‐related diabetes; <b>CI</b> : confidence interval; <b>HbA1c</b> : glycated hemoglobin; <b>FEV<sub>1</sub> </b> : forced expiratory volume in 1 second; <b>FVC</b> : forced vital capacity; <b>MD</b> : mean difference; <b>NPH</b>: neutral protamine hagedorn. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>a. Downgraded twice for risk of bias. There was an unclear or high risk of bias across all domains for this study. </p> <p>b. Downgraded once due to imprecision caused by small sample size and low event rates.</p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD004730-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD004730-sec-0009"></div> <section id="CD004730-sec-0010"> <h3 class="title" id="CD004730-sec-0010">Description of the condition</h3> <p>Survival of people with cystic fibrosis (pwCF) now extends well into adulthood, and as a consequence secondary disease processes are increasingly being recognized. Cystic fibrosis‐related diabetes (CFRD) represents the highest secondary prevalence in cystic fibrosis (CF) and is seen in nearly 20% of adolescents and 40% to 50% of adults with CF (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). The diagnosis of CFRD is currently made during a period of stable baseline health according to standard American Diabetic Association (ADA) criteria. This diagnosis is therefore made if the two‐hour oral glucose tolerance plasma glucose is elevated (greater than or equal to 200 mg/dL (11.1 mmol/L)); there is a fasting plasma glucose greater than or equal to 126; A1C is greater than or equal to 6.5%; or if polyuria or polydipsia are in the presence of a casual glucose level of greater than or equal to 200 mg/dL. The diagnosis of CFRD can additionally be considered in pwCF with acute illness when they maintain fasting plasma glucose elevations, or two‐hour post‐prandial plasma glucose levels greater than or equal to 200 mg/dL for more than 48 hours (<a href="./references#CD004730-bbs2-0043" title="MoranA , BrunzellC , CohenRC , KatzM , MarshallBC , OnadyG , et al. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care2010;33(12):2697-708.">Moran 2010</a>). There is a 36% occurrence of microvascular complications that includes kidney disease and retinopathy in CFRD, compared to 18% in the non‐CF diabetic population (<a href="./references#CD004730-bbs2-0039" title="LandersA , MathaloneB , ByiKM , HodsonME . Diabetic retinopathy in patients with cystic fibrosis related diabetes (CFRD). Pediatric Pulmonology1997;24 (Suppl 14):306.">Landers 1997</a>; <a href="./references#CD004730-bbs2-0049" title="SchwarzenbergSJ , ThomasW , OlsenTW , GroverT , WalkD , MillaC , et al. Microvascular complications in cystic fibrosis-related diabetes. Diabetes Care2007;30(5):1056-61.">Schwarzenberg 2007</a>). Microvascular complications result from prolonged periods of hyperglycemia which inflict pathological changes within small blood vessels. These factors may impact on a reported 60% survival to age 30 years for pwCF but without diabetes, compared to 25% for pwCF and diabetes (<a href="./references#CD004730-bbs2-0035" title="FinkelsteinSM , WielinskiCL , ElliottGR , WarwickWJ , BarbosaJ , WuSC , et al. Diabetes mellitus associated with cystic fibrosis. Journal of Pediatrics1988;112(3):373-7.">Finkelstein 1988</a>). The negative impact of diabetes has been more specifically linked to rapid decline in pulmonary function and body mass index (BMI) in pwCF (<a href="./references#CD004730-bbs2-0040" title="LanngS , ThorsteinssonB , NerupJ , KochC . Diabetes mellitus in cystic fibrosis: effect of insulin therapy on lung function and infections. Acta Paediatrica1994;83(8):849-53.">Lanng 1994</a>), and most recently, a link to the quality of diabetes management has been reported (<a href="./references#CD004730-bbs2-0041" title="MoheetA , MoranA . CF-related diabetes: Containing the metabolic miscreant of cystic fibrosis. Pediatric Pulmonology2017;52(S48):S37-S43. [DOI: 10.1002/ppul.23762]">Moheet 2017</a>). These findings have important implications, as end‐stage lung disease is the ultimate event leading to mortality in nearly all pwCF, and the added complication of diabetes may hasten this process, as well as the additional impacts on secondary disease processes as a consequence of improved survival of pwCF. A recent European study places the potential development of these complications for pwCF into a more realistic perspective in their multicenter observational findings that many people with CFRD remain untreated due to resistance of patient acceptance to current practice guideline recommendations (<a href="./references#CD004730-bbs2-0031" title="Ballmann, MW, WosnickJ , FischerD . Treatment of CFRD diagnosed by annual OGT screening: real life data from a longitudinal registry study from Germany. Pediatric Pulmonology2018;53 Supplement 2:398. [ABSTRACT NO.: 651]">Ballmann 2018a</a>). </p> </section> <section id="CD004730-sec-0011"> <h3 class="title" id="CD004730-sec-0011">Description of the intervention</h3> <p>The Cystic Fibrosis Foundation (CFF) guidelines recommend insulin as the treatment of choice, based on evidence supported by observation of increasing trends toward insulin deficiency over time (<a href="./references#CD004730-bbs2-0042" title="MoranA , DiemJ , KleinDF , LevittMD , RobertsonRP . Pancreatic endocrine function in cystic fibrosis. Journal of Pediatrics1991;118(5):715-23.">Moran 1991</a>; <a href="./references#CD004730-bbs2-0043" title="MoranA , BrunzellC , CohenRC , KatzM , MarshallBC , OnadyG , et al. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care2010;33(12):2697-708.">Moran 2010</a>); however, insulin deficiency is seldom absolute, as ketoacidosis is a very uncommon complication in CF. Increasing insulin resistance has further been correlated to the progressive development of impaired glucose tolerance seen in CF (<a href="./references#CD004730-bbs2-0036" title="HardinDS , SyJP . Effects of growth hormone treatment in children with cystic fibrosis: the National Cooperative Growth Study experience. Journal of Pediatrics1997;131(1 Pt 2):S65-9.">Hardin 1997</a>). The implication of both a relative decrease in pancreatic insulin release, and an increase in insulin resistance to glucose metabolism by the body suggests potential roles for oral insulin‐releasing hypoglycemic medications and the newer classes of injectable and oral insulin‐sensitizing medications (which influence the role of the hormone incretin in enhancing insulin action) and sodium‐glucose cotransporter‐2 (SGLT2) inhibitors that block glucose uptake in the kidney as potential additional agents for use in the management of CFRD insulin therapy. </p> <p>Insulin used to treat people with diabetes is manufactured either by genetic engineering or by chemical manipulation, or a combination of both, to create synthetic variants of human insulin, each manipulation causing changes in insulin rate of absorption, onset and duration of action. Insulin is typically injected, usually just under the skin or in the case of insulin pumps, through a catheter just below the skin. Insulin can also be delivered in the hospital setting though direct infusion into a vein. </p> <p>Alternatives to insulin are as follows.</p> <p> <ul id="CD004730-list-0001"> <li> <p>Oral hypoglycemic medications to increase insulin secretion in individuals still able to produce insulin, such as slower‐acting sulfonylureas and more rapid acting meglitinides, are typically taken with meals and given once or twice daily depending on their duration of action. </p> </li> <li> <p>Bigunides ‐ the only drug of this class currently available is metformin, which is given as an oral dose once to three times daily. </p> </li> <li> <p>Glitazones are taken orally, with pioglitazone taken once daily not in association with meals. </p> </li> <li> <p>Medications impacting incretin (a hormone that regulates the body’s own insulin release and slows the body’s ability to absorb glucose) for individuals still able to produce insulin, such as the liptin class of drugs (dipeptidyl‐peptidase 4 inhibitors) given orally, once or twice daily, depending on the brand used, with or without meals; and synthetic incretin given as subcutaneous injections once a week and not associated with meals. </p> </li> <li> <p>SGLT2 inhibitors given once daily as an oral medication.</p> </li> </ul> </p> </section> <section id="CD004730-sec-0012"> <h3 class="title" id="CD004730-sec-0012">How the intervention might work</h3> <p>Therapeutic reports for CFRD which have discussed the impact on pulmonary function and body weight (as a proportion to the square of the height known as the BMI) have been limited to individuals managed by insulin therapy. The institution of insulin therapy aimed toward optimizing glycemic control to the range recommended by the ADA (<a href="./references#CD004730-bbs2-0030" title="American Diabetes Association. Standards of medical care in diabetes. Diabetes Care2004;27:S15-35.">ADA 2004</a>) has been recently demonstrated to have a positive impact toward improving glycemic control based on HbA1c measurements and to minimize long‐term microvascular disease based on correlations from a recent prognostic cohort study (<a href="./references#CD004730-bbs2-0049" title="SchwarzenbergSJ , ThomasW , OlsenTW , GroverT , WalkD , MillaC , et al. Microvascular complications in cystic fibrosis-related diabetes. Diabetes Care2007;30(5):1056-61.">Schwarzenberg 2007</a>). The effect of maintaining HbA1c at or below 7% in CFRD is now significantly associated with minimizing the complications of diabetes on microvascular disease at a prevalence even more reduced than is seen for type 1 and type 2 diabetes. </p> <p>The specific actions of the intervention classes listed above are as follows.</p> <p> <ul id="CD004730-list-0002"> <li> <p>Insulin acts through a tyrosine kinase receptor protein on insulin‐responsive cells. Once bound, insulin uses a phosphorylation reaction to activate a sequence of intracellular reactions that ultimately insert a glucose transport protein (GLUTE4 in fat and muscle) into the cell membrane, thereby allowing glucose to enter the cell for metabolic utilization. </p> </li> <li> <p>Oral hypoglycemic medications ‐ the slower‐acting sulfonylureas and more rapid acting meglitinides work by increasing insulin secretion in individuals still able to produce insulin by closing ATP‐sensitive K‐channels in the insulin‐secreting beta‐cell plasma membrane within the pancreas, which initiates a chain of events resulting in the release of insulin. </p> </li> <li> <p>Bigunides, work by reducing liver glucose production; however, in addition these drugs have an anti‐inflammatory effect that may be beneficial toward the glucose resistance seen in chronic inflammatory conditions, such as CF. </p> </li> <li> <p>Glitazone class of drugs, including glitazone and pioglitazone, enhance insulin sensitivity and also have anti‐inflammatory actions. Pioglitazone has not been shown to have the cardiovascular risk of earlier glitazones, and a recent meta‐analysis has shown there is no increased risk of bladder cancer associated with its use (<a href="./references#CD004730-bbs2-0034" title="FilipovaE , UzunovaK , KalinovK , VekovT . Pioglitazone and the risk of bladder cancer: a meta-analysis. Diabetes Therapy2017;8(4):705-26. [DOI: 10.1007/s13300-017-0273-4]">Filipova 2017</a>). </p> </li> <li> <p>Medications impacting incretin (glucagon‐like peptide‐1 (GLP‐1)) ‐ there are currently two classes of medications that impact on the action of this hormone which is secreted by the gut and regulates the body’s own insulin release and as well as slowing the body’s ability to absorb glucose. The liptin class of drugs (dipeptidyl‐peptidase 4 inhibitors) slows the inactivation of incretin, thereby increasing its concentration and assisting in increasing insulin release. The second class of drugs acts as a synthetic form of incretin. </p> </li> <li> <p>SGLT2 inhibitors inhibit glucose absorption from the kidney.</p> </li> </ul> </p> </section> <section id="CD004730-sec-0013"> <h3 class="title" id="CD004730-sec-0013">Why it is important to do this review</h3> <p>The CFF guidelines only recommend insulin for treating CFRD (<a href="./references#CD004730-bbs2-0043" title="MoranA , BrunzellC , CohenRC , KatzM , MarshallBC , OnadyG , et al. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care2010;33(12):2697-708.">Moran 2010</a>), but a recent multicenter European study indicated that this may lead to a significant number of people with CFRD being undertreated or refusing insulin therapy (<a href="./references#CD004730-bbs2-0031" title="Ballmann, MW, WosnickJ , FischerD . Treatment of CFRD diagnosed by annual OGT screening: real life data from a longitudinal registry study from Germany. Pediatric Pulmonology2018;53 Supplement 2:398. [ABSTRACT NO.: 651]">Ballmann 2018a</a>). The mechanistic potential of utilizing additional agents other than insulin to manage CFRD, reflects a missed opportunity in effectively managing diabetes in pwCF. Reports of the use of oral hypoglycemic agents for controlling HbA1c are limited. There is only one case‐based published study reporting the effects of insulin‐sensitizing agents (<a href="./references#CD004730-bbs2-0020" title="OnadyGM , LangdonLJ . Insulin versus oral agents in the management of Cystic Fibrosis Related Diabetes: a case based study. BMC Endocrine Disorders2006;6:4. [PMID: 16790062]">Onady 2006</a>). Recommendations for glycemic control by the ADA emphasize the importance of optimizing the secondary prevention of the complication of microvascular disease in type 1 and type 2 diabetes, but there is still uncertainty as to how this control impacts on microvascular disease in CFRD, pulmonary function or optimal weight through improved carbohydrate metabolism (<a href="./references#CD004730-bbs2-0030" title="American Diabetes Association. Standards of medical care in diabetes. Diabetes Care2004;27:S15-35.">ADA 2004</a>). </p> <p>This version of the review is an update of previous versions (<a href="./references#CD004730-bbs2-0051" title="OnadyGM , StolfiA . Insulin and oral agents for managing cystic fibrosis-related diabetes. Cochrane Database of Systematic Reviews2005, Issue 3. Art. No: CD004730. [DOI: 10.1002/14651858.CD004730.pub2]">Onady 2005</a>; <a href="./references#CD004730-bbs2-0052" title="OnadyGM , StolfiA . Insulin and oral agents for managing cystic fibrosis-related diabetes. Cochrane Database of Systematic Reviews2013, Issue 7. Art. No: CD004730. [DOI: 10.1002/14651858.CD004730.pub3]">Onady 2013</a>; <a href="./references#CD004730-bbs2-0053" title="OnadyGM , StolfiA . Insulin and oral agents for managing cystic fibrosis-related diabetes. Cochrane Database of Systematic Reviews2016, Issue 4. Art. No: CD004730. [DOI: 10.1002/14651858.CD004730.pub4]">Onady 2016</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD004730-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD004730-sec-0014"></div> <p>To establish the effectiveness of drugs (injectable and oral agents) for managing diabetes in people with cystic fibrosis (pwCF) in relation to blood sugar levels, lung function and weight management. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD004730-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD004730-sec-0015"></div> <section id="CD004730-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD004730-sec-0017"> <h4 class="title">Types of studies</h4> <p>Randomized controlled trials.</p> </section> <section id="CD004730-sec-0018"> <h4 class="title">Types of participants</h4> <p>Participants of all ages established as having CF, as determined by a positive diagnostic test for CF that may include sweat, nasal epithelial and genotype testing associated with pulmonary or gastrointestinal disease or both. Diabetes from this cohort will be further established by oral glucose tolerance testing, A1C data, two fasting or random blood sugars as defined by ADA standards (<a href="./references#CD004730-bbs2-0030" title="American Diabetes Association. Standards of medical care in diabetes. Diabetes Care2004;27:S15-35.">ADA 2004</a>). The CFF Guidelines (USA) related to a diagnosis during pulmonary exacerbations and in those with CF requiring feeding tubes may also be additionally used in establishing diagnostic criteria for CFRD. </p> </section> <section id="CD004730-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We aimed to compare different insulin regimens, either alone or in conjunction with additional oral or injectable diabetic medications, to regimens of oral diabetic medications to injectable diabetic medications (post hoc change). In a further post hoc change, we planned to compare injectable medications to placebo, insulin or oral medications. We originally did not plan to include trials comparing an active treatment‐only regimen with a placebo arm, as we thought therapy for diabetes was unlikely to be withheld on ethical grounds; however, we did identify such trials and included them (post hoc change). </p> <p>Insulin preparations</p> <p> <ol id="CD004730-list-0003"> <li> <p>short‐acting insulin, with duration of action typically lasting two to four hours</p> </li> <li> <p>intermediate‐acting insulin, with duration of action typically to 12 hours</p> </li> <li> <p>long‐acting insulin, with duration of actions approaching 24 hours</p> </li> </ol> </p> <p>Oral agents (split by class in a post hoc change)</p> <p> <ol id="CD004730-list-0004"> <li> <p>sulphonyureas and related agents</p> </li> <li> <p>biguanides and related agents</p> </li> <li> <p>glitazones and related agents</p> </li> <li> <p>other agents that specifically manage hyperglycemia, such as dipeptidyl peptidase‐4 (DPP‐4) inhibitors (gliptins) </p> </li> </ol> </p> <p>Injectable agents (post hoc addition)</p> <p> <ol id="CD004730-list-0005"> <li> <p>incretin‐based therapy including GLP‐1 receptor agonists</p> </li> </ol> </p> </section> <section id="CD004730-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD004730-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD004730-list-0006"> <li> <p>Biochemical measures of glycemic control, i.e. HbA1c, fasting and two‐hour post‐meal serum blood sugar values </p> </li> <li> <p>Pulmonary function (absolute values and change from baseline)</p> <ol id="CD004730-list-0007"> <li> <p>forced expiratory volume (FEV<sub>1</sub>) ( % predicted and L) </p> </li> <li> <p>forced vital capacity (FVC) ( % predicted and L)</p> </li> </ol> </li> <li> <p>Assessment of nutritional status (e.g. body mass index (BMI))</p> </li> </ol> </p> </section> <section id="CD004730-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD004730-list-0008"> <li> <p>Prevalence of microvascular and macrovascular disease</p> <ol id="CD004730-list-0009"> <li> <p>retinopathy</p> </li> <li> <p>neuropathy</p> </li> <li> <p>nephropathy</p> </li> </ol> </li> <li> <p>Rate of pulmonary exacerbations (post hoc change)</p> </li> <li> <p>Complications of therapeutic management</p> <ol id="CD004730-list-0010"> <li> <p>hypoglycemia (specifically related to oral hypoglycemic and insulin agents)</p> </li> <li> <p>liver toxicity (specifically related to the thiazolidinedione class)</p> </li> <li> <p>metabolic effects on acid‐base status (specifically related to biguanides (metformin))</p> </li> </ol> </li> <li> <p>Clinical status (post hoc change)</p> <ol id="CD004730-list-0011"> <li> <p>six‐minute walk test</p> </li> <li> <p>health‐related quality of life (HRQoL) instrument (e.g. the Cystic Fibrosis Questionnaire‐Revised (CFQ‐R) (<a href="./references#CD004730-bbs2-0045" title="QuittnerAL , ModiAC , WainwrightC , OttoK , KiriharaJ , MontgomeryAB . Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest2009;135(6):1610-8.">Quittner 2009</a>)) </p> </li> <li> <p>mortality</p> </li> </ol> </li> </ol> </p> </section> </section> </section> <section id="CD004730-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <p>We searched for all relevant published and unpublished trials without restrictions on language, year or publication status. </p> <section id="CD004730-sec-0024"> <h4 class="title">Electronic searches</h4> <p>Relevant trials were sought from the Group's Cystic Fibrosis Trials Register using the terms: insulin OR diabetes. </p> <p>The Cystic Fibrosis Trials Register is compiled from electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (updated each new issue of the <i>Cochrane Library</i> ), weekly searches of MEDLINE, a search of Embase to 1995 and the prospective handsearching of two journals ‐ <i>Pediatric Pulmonology</i> and the <i>Journal of Cystic Fibrosis</i>. Unpublished work is identified by searching the abstract books of three major cystic fibrosis conferences: the International Cystic Fibrosis Conference; the European Cystic Fibrosis Conference and the North American Cystic Fibrosis Conference. For full details of all searching activities for the register, please see the relevant sections of the Cochrane Cystic Fibrosis and Genetic Disorders Group's <a href="http://cfgd.cochrane.org/our-specialised-trials-registers" target="_blank">website</a>. </p> <p>Date of the most recent search of the Group's CF Trials Register: 10 September 2020.</p> <p>We also searched the following databases and registries:</p> <p> <ul id="CD004730-list-0012"> <li> <p>PubMed (<a href="https://www.ncbi.nlm.nih.gov/pubmed/" target="_blank">https://www.ncbi.nlm.nih.gov/pubmed/</a>;1946 to 21 March 2020); </p> </li> <li> <p>US National Institutes of Health Ongoing Trials Register Clinicaltrials.gov (<a href="http://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov;</a> searched 21 March 2020); </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) (<a href="http://apps.who.int/trialsearch" target="_blank">apps.who.int/trialsearch</a>; attempted search 17 May 2020, but the site was not available to search due to Covid‐19). </p> </li> </ul> </p> <p>For details of our search strategies, please see <a href="./appendices#CD004730-sec-0127">Appendix 1</a>. </p> </section> <section id="CD004730-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We checked the bibliographies of included studies and any relevant systematic reviews identified for further references to relevant trials. We also handsearched abstracts from pulmonary and North American Cystic Fibrosis Conference symposia from 2004 up to 2018. </p> </section> </section> <section id="CD004730-sec-0026"> <h3 class="title" id="CD004730-sec-0026">Data collection and analysis</h3> <section id="CD004730-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two authors independently selected trials to be included in the review. No disagreement occurred between the authors, but if in future these do occur the authors will resolve these by discussion. </p> </section> <section id="CD004730-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Each author independently extracted data using standard data acquisition forms; however, the authors judged the data from one of the included cross‐over trials to have been more appropriately analysed in the original paper and since they were not able to obtain first‐arm data from the trial investigators, they have reported results narratively directly from the publication (<a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>). If it is necessary for future updates of the review, the review authors will request individual or additional summary data from the trial authors. </p> <p>The authors have presented the different classes of agents in separate comparisons.</p> <p>The authors planned to measure outcome data at 1, 3, 6, 12 months and annually thereafter. They were able to report data for glucose levels, weight, fat mass and lean mass and hypoglycemic events at three months and for BMI, FEV<sub>1</sub> and FVC at 12 months. If, for future updates, trial investigators report any other relevant time points, then the review authors will give consideration to these too. </p> <p>For any data presented as means and standard errors (SEs) in the cross‐over trial by Grover and the parallel trial by Moran (<a href="./references#CD004730-bbs2-0002" title="GroverP , ThomasW , MoranA . Glargine versus NPH insulin in cystic fibrosis related diabetes. Journal of Cystic Fibrosis2008;7(2):134-6. [CFGD REGISTER: CO39] ">Grover 2008</a>; <a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>), the review authors converted the SEs to standard deviations (SDs) to allow the to enter data in the analysis. They did not combine data from the cross‐over trial with any data from the parallel trial. </p> </section> <section id="CD004730-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>In order to establish a risk of bias for the included trials, for the original review each author assessed the methodological quality of the trial. In future, authors will also monitor the consistency of inclusion and exclusion criteria, the appropriateness of comparisons and the rate of attrition. </p> <p>For the updates from 2013 onwards, the authors assessed the risk of bias of the included trials according to the methods recommended by Cochrane (<a href="./references#CD004730-bbs2-0038" title="HigginsJP , AltmanDG . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). These methods examine internal validity by addressing selection, performance and attrition bias. Authors also assessed concealment of treatment allocation using this methodology. Authors prioritized external validity to assure the availability of adequate information regarding the characteristics of participants and their results in the included trials. Authors also compared the outcomes listed in the methods section of the trial publication to the results reported to assess for selective outcome reporting. For each included trial, the authors gave a judgement of low, high or unclear risk of bias for each of the criteria examined. </p> </section> <section id="CD004730-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>In future updates of this review, for binary outcomes the authors plan to calculate a pooled estimate of treatment effect for each outcome across trials using the risk ratios (RRs) and their 95% confidence intervals (CIs). </p> <p>For continuous outcomes, the authors measured the mean change from baseline for each group or mean post‐treatment or post‐intervention values and SD for each group. Where it was necessary, they calculated the SD from the SE which was presented in the trial publication. The authors used a pooled estimate of treatment effect by calculating the mean difference (MD) with 95% CIs. </p> </section> <section id="CD004730-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>Cross‐over trials may be relevant when both insulin and oral agents are involved and indeed two of the included trials were of crossover design (<a href="./references#CD004730-bbs2-0002" title="GroverP , ThomasW , MoranA . Glargine versus NPH insulin in cystic fibrosis related diabetes. Journal of Cystic Fibrosis2008;7(2):134-6. [CFGD REGISTER: CO39] ">Grover 2008</a>; <a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>). The authors treated the data from the Grover trial as if it had been a parallel trial since the first‐arm trial data were not available as confirmed by the trial authors (<a href="./references#CD004730-bbs2-0002" title="GroverP , ThomasW , MoranA . Glargine versus NPH insulin in cystic fibrosis related diabetes. Journal of Cystic Fibrosis2008;7(2):134-6. [CFGD REGISTER: CO39] ">Grover 2008</a>). No first‐arm data were available for analysis from the Moran trial despite the review authors contacting the trial authors for more information, and on previous advice from a statistician the results from this trial, which were analysed more appropriately in the original trial publication, are reported in the review narratively (<a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>). The authors did not combine data from the cross‐over trial with those from the parallel trial. If, in the future, the authors include further cross‐over trials, they will decide whether to report these results narratively also, or they may decide to analyse the cross‐over trials as if they had been parallel trials (assuming a correlation of zero as the most conservative estimate). Elbourne says that this approach produces conservative results as it does not take into account within‐patient correlation. Also each participant appears in both the treatment and control group, so the two groups are not independent (<a href="./references#CD004730-bbs2-0033" title="ElbourneDR , AltmanDG , HigginsJPT , CurtinF , WorthingtonHV , A Vail. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology2002;31(1):140-9.">Elbourne 2002</a>). </p> </section> <section id="CD004730-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>For the current version of the review, the authors have presented the data which are reported in the trial publications. They have tried to obtain first‐arm data from the authors of two trials, but the investigators informed the review authors that it was not possible to provide these data as they were no longer available (<a href="./references#CD004730-bbs2-0002" title="GroverP , ThomasW , MoranA . Glargine versus NPH insulin in cystic fibrosis related diabetes. Journal of Cystic Fibrosis2008;7(2):134-6. [CFGD REGISTER: CO39] ">Grover 2008</a>; <a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>). In future updates of this review, the authors will seek data on the number of participants with each outcome measure by allocated treated group, irrespective of compliance or otherwise excluded from treatment at follow up. If these data are not available in publications, the authors will make every attempt to contact the trial investigators for further information. </p> </section> <section id="CD004730-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>When the authors are able to include a sufficient number of trials in the review, they will test for heterogeneity between trial results using a standard Chi² test and the I² statistic (<a href="./references#CD004730-bbs2-0037" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60.">Higgins 2003</a>). This measure describes the percentage of total variation across trials that are due to heterogeneity rather than by chance. The values of I² lie between 0% and 100%, and a simplified categorization of heterogeneity that we plan to use is of low (I² value of 25%), moderate (I² value of 50%), and high (I² value of 75%) (<a href="./references#CD004730-bbs2-0037" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60.">Higgins 2003</a>). </p> </section> <section id="CD004730-sec-0034"> <h4 class="title">Data synthesis</h4> <p>The authors have analysed data using the fixed‐effect model and will continue to do so for future updates, unless additional data result in statistical heterogeneity (I² value of over 50%) in which case they will use a random‐effects model when combining data from trials. </p> </section> <section id="CD004730-sec-0035"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>In future, if sufficient trials (n = 10) are included and there is significant heterogeneity between the trials, the authors plan to perform subgroup analyses investigating: </p> <p> <ul id="CD004730-list-0013"> <li> <p>age (pediatric versus adult participants (0 to 18 years versus over 18 years of age);</p> </li> <li> <p>severity of baseline pulmonary function with mild disease (down to an FEV<sub>1</sub> of 80% predicted), moderate disease (between 80% and 40% predicted) and severe disease (less than 40% predicted); </p> </li> <li> <p>stratification of various levels glycemic control as identified through HbA1c with adequate control at less than 7%, intermediate control between 7% to 8% and in poor control greater than 8%. </p> </li> </ul> </p> <p>’End‐of‐life’ onset of diabetes may imply a different quality of diabetic control than for the younger diabetic identified earlier and with a milder baseline chronic pulmonary disease setting. </p> </section> <section id="CD004730-sec-0036"> <h4 class="title">Sensitivity analysis</h4> <p>When we are able to include sufficient trials we plan to perform a sensitivity analysis based on the potential diversity in trial parameters. As an example, many trials from North America omit correlations of diabetic control to HbA1c; whereas European trials tend to follow this closely. Plotting effect estimates against risk of bias measures or performing cumulative meta‐analysis based on quality order may also be effective at addressing problems surrounding composite scales. </p> </section> <section id="CD004730-sec-0037"> <h4 class="title">Summary of findings tables</h4> <p>We constructed a summary of findings table for each comparison in the review and presented results for the following outcomes at six months: </p> <p> <ol id="CD004730-list-0014"> <li> <p>HbA1c;</p> </li> <li> <p>FEV<sub>1</sub> (% predicted) change from baseline; </p> </li> <li> <p>FVC (% predicted) change from baseline;</p> </li> <li> <p>BMI;</p> </li> <li> <p>hypoglycemia.</p> </li> </ol> </p> <p>We used the GRADE approach, described in Chapter 12 of <i>the Cochrane Handbook of Systematic Review for Interventions</i> (<a href="./references#CD004730-bbs2-0048" title="SchünemannHJ , OxmanAD , VistGE , HigginsJP , DeeksJJ , GlasziouP , et al on behalf of the Cochrane Applicability and Recommendations Methods Group and the Cochrane Statistical Methods Group. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S, (editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Schünemann 2011</a>) to classify the body of evidence for each outcome as high, moderate, low or very low. The quality of the evidence was downgraded across five domains; risk of bias, indirectness, inconsistency, imprecision and publication bias. Where there was serious risk of bias we downgraded by one level and where it was very serious we downgraded it by two levels. Where we judged the evidence not to be high quality, we described the rationale for this judgement in footnotes to the table. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD004730-sec-0038" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD004730-sec-0038"></div> <section id="CD004730-sec-0039"> <h3 class="title">Description of studies</h3> <section id="CD004730-sec-0040"> <h4 class="title">Results of the search</h4> <p>The searches identified 29 trials (46 references). Four trials are included in the review, 22 trials were excluded and one trial is as yet only available as an abstract and is listed as 'Awaiting classification' until the full paper is published (<a href="./references#CD004730-bbs2-0027" title="deLind van Wijngaarden-van den BergJMW , van derMeerR , HeijermanHGM . A placebo-controlled trial of insulin therapy with or without adjuvant metformin in patients with cystic fibrosis-related diabetes (CFRD). Journal of Cystic Fibrosis2014;13 Suppl 2:S12. [ABSTRACT NO.: WS6.4] [CENTRAL: 996580] [CFGD REGISTER: CO56 ] ">de Lind 2014</a>). Two trials are listed as ongoing (<a href="./references#CD004730-bbs2-0028" title="NCT01851694. Beta-cell Response to Incretin Hormones in Cystic Fibrosis. clinicaltrials.gov/show/nct01851694 (first posted 10 May 2013). ">NCT01851694</a>; <a href="./references#CD004730-bbs2-0029" title="NCT02202876. Redox Imbalance and the Development of Cystic Fibrosis Diabetes. clinicaltrials.gov/show/nct02202876 (first posted 29 July 2014). ">NCT02202876</a>). </p> </section> <section id="CD004730-sec-0041"> <h4 class="title">Included studies</h4> <p>Four trials (nine references) were included in this review (<a href="./references#CD004730-bbs2-0001" title="BallmannM , HubertD , AssaelBM , KronfeldK , HonerM , HollRW , et al. Open randomised prospective comparative multi-centre intervention study of patients with cystic fibrosis and early diagnosed diabetes mellitus. BMC Pediatrics2014;14:70. [CENTRAL: 1000301] [CFGD REGISTER: CO53c] [JID: 100967804] [OID: NLM: PMC3975280] [PMCID: PMC3975280] [PMID: 24620855]BallmannM , HubertD , AssaelBM , Mosnier-PudarH , Barao OcampoM , ScheunigN , et al. Repaglinide versus insulin in the treatment of CFRD diagnosed by screening: an open prospective randomized study. Pediatric Pulmonology2013;48 Suppl 26:421. [ABSTRACT NO.: 582] [CENTRAL: 962122] [CFGD REGISTER: CO53b] BallmannM , HubertD , AssaelBM , Mosnier-PudarH , SmacznyC , KesslerL , et al. Treatment of early diagnosed CFRD with oral drugs verus insulin: An open prospective randomized study. Journal of Cystic Fibrosis2013;12 Suppl 1:S32. [ABSTRACT NO.: WS16.1] [CENTRAL: 962115] [CFGD REGISTER: CO53a] BallmannM , HubertD , AssaelBM , StaabD , HebestreitA , NaehrlichL , et al. Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. The Lancet Diabetes and Endocrinology2018;6(2):114-21. [CFGD REGISTER: CO53e] [DOI: 10.1016/S2213-8587(17)30400-X]SchmidK , FinkK , HollRW , HebestreitH , BallmannM . Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2014;13(1):80-5. [CENTRAL: 1000302] [CFGD REGISTER: CO53d] [JID: 101128966] [PMID: 23809507] [SI: ClinicalTrials.gov/NCT00662714]">Ballmann 2018b</a>; <a href="./references#CD004730-bbs2-0002" title="GroverP , ThomasW , MoranA . Glargine versus NPH insulin in cystic fibrosis related diabetes. Journal of Cystic Fibrosis2008;7(2):134-6. [CFGD REGISTER: CO39] ">Grover 2008</a>; <a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>; <a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). </p> <section id="CD004730-sec-0042"> <h5 class="title">Trial Design</h5> <p>Two trials were of cross‐over design (<a href="./references#CD004730-bbs2-0002" title="GroverP , ThomasW , MoranA . Glargine versus NPH insulin in cystic fibrosis related diabetes. Journal of Cystic Fibrosis2008;7(2):134-6. [CFGD REGISTER: CO39] ">Grover 2008</a>; <a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>) and two were of parallel design (<a href="./references#CD004730-bbs2-0001" title="BallmannM , HubertD , AssaelBM , KronfeldK , HonerM , HollRW , et al. Open randomised prospective comparative multi-centre intervention study of patients with cystic fibrosis and early diagnosed diabetes mellitus. BMC Pediatrics2014;14:70. [CENTRAL: 1000301] [CFGD REGISTER: CO53c] [JID: 100967804] [OID: NLM: PMC3975280] [PMCID: PMC3975280] [PMID: 24620855]BallmannM , HubertD , AssaelBM , Mosnier-PudarH , Barao OcampoM , ScheunigN , et al. Repaglinide versus insulin in the treatment of CFRD diagnosed by screening: an open prospective randomized study. Pediatric Pulmonology2013;48 Suppl 26:421. [ABSTRACT NO.: 582] [CENTRAL: 962122] [CFGD REGISTER: CO53b] BallmannM , HubertD , AssaelBM , Mosnier-PudarH , SmacznyC , KesslerL , et al. Treatment of early diagnosed CFRD with oral drugs verus insulin: An open prospective randomized study. Journal of Cystic Fibrosis2013;12 Suppl 1:S32. [ABSTRACT NO.: WS16.1] [CENTRAL: 962115] [CFGD REGISTER: CO53a] BallmannM , HubertD , AssaelBM , StaabD , HebestreitA , NaehrlichL , et al. Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. The Lancet Diabetes and Endocrinology2018;6(2):114-21. [CFGD REGISTER: CO53e] [DOI: 10.1016/S2213-8587(17)30400-X]SchmidK , FinkK , HollRW , HebestreitH , BallmannM . Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2014;13(1):80-5. [CENTRAL: 1000302] [CFGD REGISTER: CO53d] [JID: 101128966] [PMID: 23809507] [SI: ClinicalTrials.gov/NCT00662714]">Ballmann 2018b</a>; <a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). Both cross‐over trials included a washout period. Grover used used a one‐month washout period (<a href="./references#CD004730-bbs2-0002" title="GroverP , ThomasW , MoranA . Glargine versus NPH insulin in cystic fibrosis related diabetes. Journal of Cystic Fibrosis2008;7(2):134-6. [CFGD REGISTER: CO39] ">Grover 2008</a>) and Moran utilized three separate single doses of different interventions over a one‐month to two‐month period (<a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>). The later Moran trial also compared three interventions but in a parallel design (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). Duration of the trials ranged from a single‐dose trial (<a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>) to 24 months (<a href="./references#CD004730-bbs2-0001" title="BallmannM , HubertD , AssaelBM , KronfeldK , HonerM , HollRW , et al. Open randomised prospective comparative multi-centre intervention study of patients with cystic fibrosis and early diagnosed diabetes mellitus. BMC Pediatrics2014;14:70. [CENTRAL: 1000301] [CFGD REGISTER: CO53c] [JID: 100967804] [OID: NLM: PMC3975280] [PMCID: PMC3975280] [PMID: 24620855]BallmannM , HubertD , AssaelBM , Mosnier-PudarH , Barao OcampoM , ScheunigN , et al. Repaglinide versus insulin in the treatment of CFRD diagnosed by screening: an open prospective randomized study. Pediatric Pulmonology2013;48 Suppl 26:421. [ABSTRACT NO.: 582] [CENTRAL: 962122] [CFGD REGISTER: CO53b] BallmannM , HubertD , AssaelBM , Mosnier-PudarH , SmacznyC , KesslerL , et al. Treatment of early diagnosed CFRD with oral drugs verus insulin: An open prospective randomized study. Journal of Cystic Fibrosis2013;12 Suppl 1:S32. [ABSTRACT NO.: WS16.1] [CENTRAL: 962115] [CFGD REGISTER: CO53a] BallmannM , HubertD , AssaelBM , StaabD , HebestreitA , NaehrlichL , et al. Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. The Lancet Diabetes and Endocrinology2018;6(2):114-21. [CFGD REGISTER: CO53e] [DOI: 10.1016/S2213-8587(17)30400-X]SchmidK , FinkK , HollRW , HebestreitH , BallmannM . Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2014;13(1):80-5. [CENTRAL: 1000302] [CFGD REGISTER: CO53d] [JID: 101128966] [PMID: 23809507] [SI: ClinicalTrials.gov/NCT00662714]">Ballmann 2018b</a>). Two included trials were multicenter; one was undertaken in 14 centers in the USA, Canada and the UK (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>) and the second was undertaken in 49 centers across Austria, France, Germany and Italy (<a href="./references#CD004730-bbs2-0001" title="BallmannM , HubertD , AssaelBM , KronfeldK , HonerM , HollRW , et al. Open randomised prospective comparative multi-centre intervention study of patients with cystic fibrosis and early diagnosed diabetes mellitus. BMC Pediatrics2014;14:70. [CENTRAL: 1000301] [CFGD REGISTER: CO53c] [JID: 100967804] [OID: NLM: PMC3975280] [PMCID: PMC3975280] [PMID: 24620855]BallmannM , HubertD , AssaelBM , Mosnier-PudarH , Barao OcampoM , ScheunigN , et al. Repaglinide versus insulin in the treatment of CFRD diagnosed by screening: an open prospective randomized study. Pediatric Pulmonology2013;48 Suppl 26:421. [ABSTRACT NO.: 582] [CENTRAL: 962122] [CFGD REGISTER: CO53b] BallmannM , HubertD , AssaelBM , Mosnier-PudarH , SmacznyC , KesslerL , et al. Treatment of early diagnosed CFRD with oral drugs verus insulin: An open prospective randomized study. Journal of Cystic Fibrosis2013;12 Suppl 1:S32. [ABSTRACT NO.: WS16.1] [CENTRAL: 962115] [CFGD REGISTER: CO53a] BallmannM , HubertD , AssaelBM , StaabD , HebestreitA , NaehrlichL , et al. Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. The Lancet Diabetes and Endocrinology2018;6(2):114-21. [CFGD REGISTER: CO53e] [DOI: 10.1016/S2213-8587(17)30400-X]SchmidK , FinkK , HollRW , HebestreitH , BallmannM . Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2014;13(1):80-5. [CENTRAL: 1000302] [CFGD REGISTER: CO53d] [JID: 101128966] [PMID: 23809507] [SI: ClinicalTrials.gov/NCT00662714]">Ballmann 2018b</a>). </p> </section> <section id="CD004730-sec-0043"> <h5 class="title">Participants</h5> <p>The number of participants enrolled in the trials ranged from seven (<a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>) to 100 (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). However, the proportion of withdrawals ranged from 0% (<a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>) to 27% (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>) and of the participants in the later Moran trial, 20 were diagnosed with impaired glucose tolerance (IGT) and not CFRD meaning the number of participants for whom data are available ranges from seven (<a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>) to 67 participants (<a href="./references#CD004730-bbs2-0001" title="BallmannM , HubertD , AssaelBM , KronfeldK , HonerM , HollRW , et al. Open randomised prospective comparative multi-centre intervention study of patients with cystic fibrosis and early diagnosed diabetes mellitus. BMC Pediatrics2014;14:70. [CENTRAL: 1000301] [CFGD REGISTER: CO53c] [JID: 100967804] [OID: NLM: PMC3975280] [PMCID: PMC3975280] [PMID: 24620855]BallmannM , HubertD , AssaelBM , Mosnier-PudarH , Barao OcampoM , ScheunigN , et al. Repaglinide versus insulin in the treatment of CFRD diagnosed by screening: an open prospective randomized study. Pediatric Pulmonology2013;48 Suppl 26:421. [ABSTRACT NO.: 582] [CENTRAL: 962122] [CFGD REGISTER: CO53b] BallmannM , HubertD , AssaelBM , Mosnier-PudarH , SmacznyC , KesslerL , et al. Treatment of early diagnosed CFRD with oral drugs verus insulin: An open prospective randomized study. Journal of Cystic Fibrosis2013;12 Suppl 1:S32. [ABSTRACT NO.: WS16.1] [CENTRAL: 962115] [CFGD REGISTER: CO53a] BallmannM , HubertD , AssaelBM , StaabD , HebestreitA , NaehrlichL , et al. Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. The Lancet Diabetes and Endocrinology2018;6(2):114-21. [CFGD REGISTER: CO53e] [DOI: 10.1016/S2213-8587(17)30400-X]SchmidK , FinkK , HollRW , HebestreitH , BallmannM . Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2014;13(1):80-5. [CENTRAL: 1000302] [CFGD REGISTER: CO53d] [JID: 101128966] [PMID: 23809507] [SI: ClinicalTrials.gov/NCT00662714]">Ballmann 2018b</a>). In all four included trials there were roughly equal numbers of male and female participants enrolled overall. The mean (SD) age ranged from 22 (8.9) years (<a href="./references#CD004730-bbs2-0001" title="BallmannM , HubertD , AssaelBM , KronfeldK , HonerM , HollRW , et al. Open randomised prospective comparative multi-centre intervention study of patients with cystic fibrosis and early diagnosed diabetes mellitus. BMC Pediatrics2014;14:70. [CENTRAL: 1000301] [CFGD REGISTER: CO53c] [JID: 100967804] [OID: NLM: PMC3975280] [PMCID: PMC3975280] [PMID: 24620855]BallmannM , HubertD , AssaelBM , Mosnier-PudarH , Barao OcampoM , ScheunigN , et al. Repaglinide versus insulin in the treatment of CFRD diagnosed by screening: an open prospective randomized study. Pediatric Pulmonology2013;48 Suppl 26:421. [ABSTRACT NO.: 582] [CENTRAL: 962122] [CFGD REGISTER: CO53b] BallmannM , HubertD , AssaelBM , Mosnier-PudarH , SmacznyC , KesslerL , et al. Treatment of early diagnosed CFRD with oral drugs verus insulin: An open prospective randomized study. Journal of Cystic Fibrosis2013;12 Suppl 1:S32. [ABSTRACT NO.: WS16.1] [CENTRAL: 962115] [CFGD REGISTER: CO53a] BallmannM , HubertD , AssaelBM , StaabD , HebestreitA , NaehrlichL , et al. Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. The Lancet Diabetes and Endocrinology2018;6(2):114-21. [CFGD REGISTER: CO53e] [DOI: 10.1016/S2213-8587(17)30400-X]SchmidK , FinkK , HollRW , HebestreitH , BallmannM . Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2014;13(1):80-5. [CENTRAL: 1000302] [CFGD REGISTER: CO53d] [JID: 101128966] [PMID: 23809507] [SI: ClinicalTrials.gov/NCT00662714]">Ballmann 2018b</a>) to 34 (8) years (<a href="./references#CD004730-bbs2-0002" title="GroverP , ThomasW , MoranA . Glargine versus NPH insulin in cystic fibrosis related diabetes. Journal of Cystic Fibrosis2008;7(2):134-6. [CFGD REGISTER: CO39] ">Grover 2008</a>). All trials stated that participants were clinically well and two trials required that participants had not experienced acute illness in the previous two (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>) or three months (<a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>). </p> </section> <section id="CD004730-sec-0044"> <h5 class="title">Interventions</h5> <p>The four included trials employed different interventions (<a href="./references#CD004730-bbs2-0001" title="BallmannM , HubertD , AssaelBM , KronfeldK , HonerM , HollRW , et al. Open randomised prospective comparative multi-centre intervention study of patients with cystic fibrosis and early diagnosed diabetes mellitus. BMC Pediatrics2014;14:70. [CENTRAL: 1000301] [CFGD REGISTER: CO53c] [JID: 100967804] [OID: NLM: PMC3975280] [PMCID: PMC3975280] [PMID: 24620855]BallmannM , HubertD , AssaelBM , Mosnier-PudarH , Barao OcampoM , ScheunigN , et al. Repaglinide versus insulin in the treatment of CFRD diagnosed by screening: an open prospective randomized study. Pediatric Pulmonology2013;48 Suppl 26:421. [ABSTRACT NO.: 582] [CENTRAL: 962122] [CFGD REGISTER: CO53b] BallmannM , HubertD , AssaelBM , Mosnier-PudarH , SmacznyC , KesslerL , et al. Treatment of early diagnosed CFRD with oral drugs verus insulin: An open prospective randomized study. Journal of Cystic Fibrosis2013;12 Suppl 1:S32. [ABSTRACT NO.: WS16.1] [CENTRAL: 962115] [CFGD REGISTER: CO53a] BallmannM , HubertD , AssaelBM , StaabD , HebestreitA , NaehrlichL , et al. Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. The Lancet Diabetes and Endocrinology2018;6(2):114-21. [CFGD REGISTER: CO53e] [DOI: 10.1016/S2213-8587(17)30400-X]SchmidK , FinkK , HollRW , HebestreitH , BallmannM . Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2014;13(1):80-5. [CENTRAL: 1000302] [CFGD REGISTER: CO53d] [JID: 101128966] [PMID: 23809507] [SI: ClinicalTrials.gov/NCT00662714]">Ballmann 2018b</a>; <a href="./references#CD004730-bbs2-0002" title="GroverP , ThomasW , MoranA . Glargine versus NPH insulin in cystic fibrosis related diabetes. Journal of Cystic Fibrosis2008;7(2):134-6. [CFGD REGISTER: CO39] ">Grover 2008</a>; <a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>; <a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). </p> <section id="CD004730-sec-0045"> <h6 class="title">Insulin versus control</h6> <p>Two three‐arm trials by Moran compared insulin to control (<a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>; <a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). The earlier trial compared single‐dose treatment of insulin (0.1 unit/kg) administered 10 minutes prior to a meal to no medication (<a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>), while the later trial compared insulin (0.5 unit insulin aspart/15 g dietary carbohydrate) to placebo three times daily before meals (time frame not stated) (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). </p> </section> <section id="CD004730-sec-0046"> <h6 class="title">Repaglinide versus control</h6> <p>Both Moran trials also compared repaglinide to control (<a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>; <a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). The earlier trial compared single‐dose treatment of repaglinide (1 mg) administered 10 minutes prior to a meal to no medication (<a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>), while the later trial compared 2 mg repaglinide to placebo three times daily before meals (time frame not stated) (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). In this second trial by Moran, 17% of participants had doses of repaglinide reduced due to hypoglycemia (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). </p> </section> <section id="CD004730-sec-0047"> <h6 class="title">Insulin versus repaglinide</h6> <p>Three trials compared insulin with oral repaglinide (<a href="./references#CD004730-bbs2-0001" title="BallmannM , HubertD , AssaelBM , KronfeldK , HonerM , HollRW , et al. Open randomised prospective comparative multi-centre intervention study of patients with cystic fibrosis and early diagnosed diabetes mellitus. BMC Pediatrics2014;14:70. [CENTRAL: 1000301] [CFGD REGISTER: CO53c] [JID: 100967804] [OID: NLM: PMC3975280] [PMCID: PMC3975280] [PMID: 24620855]BallmannM , HubertD , AssaelBM , Mosnier-PudarH , Barao OcampoM , ScheunigN , et al. Repaglinide versus insulin in the treatment of CFRD diagnosed by screening: an open prospective randomized study. Pediatric Pulmonology2013;48 Suppl 26:421. [ABSTRACT NO.: 582] [CENTRAL: 962122] [CFGD REGISTER: CO53b] BallmannM , HubertD , AssaelBM , Mosnier-PudarH , SmacznyC , KesslerL , et al. Treatment of early diagnosed CFRD with oral drugs verus insulin: An open prospective randomized study. Journal of Cystic Fibrosis2013;12 Suppl 1:S32. [ABSTRACT NO.: WS16.1] [CENTRAL: 962115] [CFGD REGISTER: CO53a] BallmannM , HubertD , AssaelBM , StaabD , HebestreitA , NaehrlichL , et al. Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. The Lancet Diabetes and Endocrinology2018;6(2):114-21. [CFGD REGISTER: CO53e] [DOI: 10.1016/S2213-8587(17)30400-X]SchmidK , FinkK , HollRW , HebestreitH , BallmannM . Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2014;13(1):80-5. [CENTRAL: 1000302] [CFGD REGISTER: CO53d] [JID: 101128966] [PMID: 23809507] [SI: ClinicalTrials.gov/NCT00662714]">Ballmann 2018b</a>; <a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>; <a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). Ballmann compared insulin, with doses starting at 0.05 units/kg body weight and then adjusted to maintain a post‐prandial glucose over 160 mg/dL, to oral repaglinide, with doses ranging from 0.5 mg to 12 mg/dL again adjusted to keep postprandial glucose at over 160 mg/dl (<a href="./references#CD004730-bbs2-0001" title="BallmannM , HubertD , AssaelBM , KronfeldK , HonerM , HollRW , et al. Open randomised prospective comparative multi-centre intervention study of patients with cystic fibrosis and early diagnosed diabetes mellitus. BMC Pediatrics2014;14:70. [CENTRAL: 1000301] [CFGD REGISTER: CO53c] [JID: 100967804] [OID: NLM: PMC3975280] [PMCID: PMC3975280] [PMID: 24620855]BallmannM , HubertD , AssaelBM , Mosnier-PudarH , Barao OcampoM , ScheunigN , et al. Repaglinide versus insulin in the treatment of CFRD diagnosed by screening: an open prospective randomized study. Pediatric Pulmonology2013;48 Suppl 26:421. [ABSTRACT NO.: 582] [CENTRAL: 962122] [CFGD REGISTER: CO53b] BallmannM , HubertD , AssaelBM , Mosnier-PudarH , SmacznyC , KesslerL , et al. Treatment of early diagnosed CFRD with oral drugs verus insulin: An open prospective randomized study. Journal of Cystic Fibrosis2013;12 Suppl 1:S32. [ABSTRACT NO.: WS16.1] [CENTRAL: 962115] [CFGD REGISTER: CO53a] BallmannM , HubertD , AssaelBM , StaabD , HebestreitA , NaehrlichL , et al. Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. The Lancet Diabetes and Endocrinology2018;6(2):114-21. [CFGD REGISTER: CO53e] [DOI: 10.1016/S2213-8587(17)30400-X]SchmidK , FinkK , HollRW , HebestreitH , BallmannM . Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2014;13(1):80-5. [CENTRAL: 1000302] [CFGD REGISTER: CO53d] [JID: 101128966] [PMID: 23809507] [SI: ClinicalTrials.gov/NCT00662714]">Ballmann 2018b</a>). The earlier Moran trial compared single‐dose treatments of insulin (0.1 unit/kg) versus repaglinide (1 mg); both insulin and repaglinide were administered 10 minutes prior to a meal (<a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>). The later Moran trial compared insulin (0.5 unit insulin aspart/15 g dietary carbohydrate) to repaglinide (2 mg) three times daily before meals (time frame not stated) (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). In this second trial by Moran, 17% of participants had doses of repaglinide reduced due to hypoglycemia (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). </p> </section> <section id="CD004730-sec-0048"> <h6 class="title">Neutral protamine Hagedorn (NPH) insulin versus glargine</h6> <p>The trial comparing neutral protamine Hagedorn (NPH) insulin to glargine administered both treatments once daily at bedtime (<a href="./references#CD004730-bbs2-0002" title="GroverP , ThomasW , MoranA . Glargine versus NPH insulin in cystic fibrosis related diabetes. Journal of Cystic Fibrosis2008;7(2):134-6. [CFGD REGISTER: CO39] ">Grover 2008</a>). The average total daily insulin dose observed was 0.7 units/kg/day for each insulin, with mean (SD) insulin to carbohydrate ratios of 1.5 (0.2) NPH and 1.3 (0.1) glargine aspart/15 g carbohydrate, P = 0.05. The mean (SD) dose of glargine was 46 (4)% and of NPH 38 (3)% of the total daily insulin dose (<a href="./references#CD004730-bbs2-0002" title="GroverP , ThomasW , MoranA . Glargine versus NPH insulin in cystic fibrosis related diabetes. Journal of Cystic Fibrosis2008;7(2):134-6. [CFGD REGISTER: CO39] ">Grover 2008</a>). </p> </section> </section> <section id="CD004730-sec-0049"> <h5 class="title">Outcome measures</h5> <p>Three of the four trials reported on blood glucose levels and adverse events (<a href="./references#CD004730-bbs2-0002" title="GroverP , ThomasW , MoranA . Glargine versus NPH insulin in cystic fibrosis related diabetes. Journal of Cystic Fibrosis2008;7(2):134-6. [CFGD REGISTER: CO39] ">Grover 2008</a>; <a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>; <a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). The two longer trials also reported quality of life (QoL) along with measures of nutritional status including body mass index (BMI), weight, fat and lean mass (<a href="./references#CD004730-bbs2-0002" title="GroverP , ThomasW , MoranA . Glargine versus NPH insulin in cystic fibrosis related diabetes. Journal of Cystic Fibrosis2008;7(2):134-6. [CFGD REGISTER: CO39] ">Grover 2008</a>; <a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). The second Moran trial reported on lung function and National Institute for Health (NIH) prognostic score (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). While the fourth, and most recent, trial did not report hypoglycemic events, the authors did report on FEV<sub>1</sub> and BMI z scores, glycaemic control (mean change in HbA 1c), and adverse events (pulmonary events and pulmonary events leading to hospital admission) (<a href="./references#CD004730-bbs2-0001" title="BallmannM , HubertD , AssaelBM , KronfeldK , HonerM , HollRW , et al. Open randomised prospective comparative multi-centre intervention study of patients with cystic fibrosis and early diagnosed diabetes mellitus. BMC Pediatrics2014;14:70. [CENTRAL: 1000301] [CFGD REGISTER: CO53c] [JID: 100967804] [OID: NLM: PMC3975280] [PMCID: PMC3975280] [PMID: 24620855]BallmannM , HubertD , AssaelBM , Mosnier-PudarH , Barao OcampoM , ScheunigN , et al. Repaglinide versus insulin in the treatment of CFRD diagnosed by screening: an open prospective randomized study. Pediatric Pulmonology2013;48 Suppl 26:421. [ABSTRACT NO.: 582] [CENTRAL: 962122] [CFGD REGISTER: CO53b] BallmannM , HubertD , AssaelBM , Mosnier-PudarH , SmacznyC , KesslerL , et al. Treatment of early diagnosed CFRD with oral drugs verus insulin: An open prospective randomized study. Journal of Cystic Fibrosis2013;12 Suppl 1:S32. [ABSTRACT NO.: WS16.1] [CENTRAL: 962115] [CFGD REGISTER: CO53a] BallmannM , HubertD , AssaelBM , StaabD , HebestreitA , NaehrlichL , et al. Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. The Lancet Diabetes and Endocrinology2018;6(2):114-21. [CFGD REGISTER: CO53e] [DOI: 10.1016/S2213-8587(17)30400-X]SchmidK , FinkK , HollRW , HebestreitH , BallmannM . Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2014;13(1):80-5. [CENTRAL: 1000302] [CFGD REGISTER: CO53d] [JID: 101128966] [PMID: 23809507] [SI: ClinicalTrials.gov/NCT00662714]">Ballmann 2018b</a>). </p> </section> </section> <section id="CD004730-sec-0050"> <h4 class="title">Excluded studies</h4> <p>We excluded 22 trials (34 references) identified in the searches. Of these, 13 were not randomized controlled trials (<a href="./references#CD004730-bbs2-0006" title="BorowitzD , GossC , LimauroS , MurrayF , CaseyS , CohenM . A dose-ranging study of efficacy of TheraCLEC-Total for treatment of pancreatic insufficiency. Pediatric Pulmonology2005;40 (Suppl 28):348. [CFGD REGISTER: GN203a] BorowitzD , GossCH , LimauroS , MurrayF , CaseyS , CohenM , et al. A phase 2 study of TheraCLEC-Total enzymes in CF patients with pancreatic insufficiency (PI). Pediatric Pulmonology2005;40 (Suppl 28):142. [CFGD REGISTER: GN203b] BorowitzD , KonstanMW , GossC , LimauroSE , MurrayFT , CaseyS , et al. Treatment with ALTU-135 results in a positive inverse relationship between coefficient of fat absorption with stool weight in subjects with cystic fibrosis-related pancreatic insufficiency. Journal of Cystic Fibrosis2006;5 Suppl:S56. [CFGD REGISTER: GN203c] BorowitzD , KonstanMW , GossC , LimauroSE , MurrayFT . Enhanced coefficient of fat absorption using a novel pancreatic enzyme preparation, ALTU-135, with concomitant use of a proton pump inhibitor. Journal of Cystic Fibrosis2006;5 Suppl:S56. [CFGD REGISTER: CO203d] MurrayFT , BorowitzD , KonstanMW , LimauroSE , GossC . Changes in coefficients of fat and nitrogen absorption in subjects with cystic fibrosis, pancreatic insufficiency, and cystic fibrosis-related diabetes mellitus receiving a novel pancreatic enzyme product, ALTU-135. Pediatric Pulmonology2006;41 Suppl 29:386. [CFGD REGISTER: GN203e] ">Borowitz 2005</a>; <a href="./references#CD004730-bbs2-0007" title="ChernoffRG , IreysHT , DeVetKA , KimYJ . A randomized, controlled trial of a community-based support program for families of children with chronic illness: pediatric outcomes. Archives of Pediatrics and Adolescent Medicine2002;156(6):533-9. [CFGD REGISTER: MH13b] IreysHT , ChernoffR , DeVetKA , KimY . Maternal outcomes of a randomized controlled trial of a community-based support program for families of children with chronic illnesses. Archives of Pediatrics and Adolescent Medicine2001;155(7):771-7. [CFGD REGISTER: MH13a] ">Chernoff 2002</a>; <a href="./references#CD004730-bbs2-0010" title="FranzeseA , SpagnuoloMI , SepeA , ValerioG , MozzilloE , RaiaV . Can glargine reduce the number of lung infections in patients with cystic fibrosis-related diabetes?Diabetes Care2005;28(9):2333. ">Franzese 2005</a>; <a href="./references#CD004730-bbs2-0012" title="HardinDS , RiceJ , RiceM , RosenblattR . Use of the insulin pump in treat cystic fibrosis related diabetes. Journal of Cystic Fibrosis2009;8(3):174-8. ">Hardin 2009</a>; <a href="./references#CD004730-bbs2-0013" title="KönigP , GoldsteinD , PoehlmannM , RifeD , GeB , HewettJ . Effect of nebulized albuterol on blood glucose in patients with diabetes mellitus with and without cystic fibrosis. Pediatric Pulmonology2005;40(2):105-8. [CFGD REGISTER: CO23] ">König 2005</a>; <a href="./references#CD004730-bbs2-0014" title="MahroukhR , ChapmanK , StewartC , KellyE , HannaA , WilsonDC , et al. Changes in response to insulin and the effects of varying glucose tolerance on whole-body protein metabolism in patients with cystic fibrosis. American Journal of Clinical Nutrition2005;81(2):421-6. ">Mahroukh 2005</a>; <a href="./references#CD004730-bbs2-0015" title="MarshallBC , ButlerSM , StoddardM , MoranAM , LiouTG , MorganWJ , et al. Epidemiology of cystic fibrosis-related diabetes. Journal of Pediatrics2005;146(5):681-7. ">Marshall 2005</a>; <a href="./references#CD004730-bbs2-0016" title="MillaCE , BillingsJ , MoranA . Diabetes is associated with dramatically decreased survival in female but not male subjects with cystic fibrosis. Diabetes Care2005;28(9):2141-4. ">Milla 2005</a>; <a href="./references#CD004730-bbs2-0020" title="OnadyGM , LangdonLJ . Insulin versus oral agents in the management of Cystic Fibrosis Related Diabetes: a case based study. BMC Endocrine Disorders2006;6:4. [PMID: 16790062]">Onady 2006</a>; <a href="./references#CD004730-bbs2-0021" title="PeraldoM , FasuloA , ChiappiniE , MilioC , MarianelliL . Evaluation of glucose tolerance and insulin secretion in cystic fibrosis patients. Hormone Research1998;49(2):65-71. ">Peraldo 1998</a>; <a href="./references#CD004730-bbs2-0022" title="RealiMF , FestiniF , NeriAS , TaccettiG , RepettoT , ChiarelliF , et al. Use of continuous subcutaneous insulin infusion in cystic fibrosis patients with cystic fibrosis-related diabetes awaiting transplantation. Journal of Cystic Fibrosis2006;5(1):67-8. ">Reali 2006</a>; <a href="./references#CD004730-bbs2-0024" title="SulliN , BertasiS , ZulloS , ShashajB . Use of continuous subcutaneous insulin infusion in patients with cystic fibrosis related diabetes: Three case reports. Journal of Cystic Fibrosis2007;6(3):237-40. ">Sulli 2007</a>; <a href="./references#CD004730-bbs2-0026" title="WardSA , TomezskoJL , HolsclawDS , PaoloneAM . Energy expenditure and substrate utilization in adults with cystic fibrosis and diabetes mellitus. American Journal of Clinical Nutrition1999;69(5):913-9. ">Ward 1999</a>). One trial was of type 1 diabetes not CFRD (<a href="./references#CD004730-bbs2-0025" title="TeeterJG , the Exubera ® Phase 3 Study Group, Pfizer Global Research and Development GCU . One-year pulmonary safety and efficacy of inhaled insulin as adjunctive therapy in type 2 diabetes patients poorly controlled on oral agent monotherapy. European Respiratory Journal2004;24(Suppl 48):P3773. [CFGD REGISTER: CO36] ">Teeter 2004</a>); three trials included participants with glucose intolerance and not CFRD (<a href="./references#CD004730-bbs2-0011" title="GeyerMC , SullivanT , TaiA , MortonJM , EdwardsS , MartinAJ , et al. Exenatide corrects postprandial hyperglycaemia in young people with cystic fibrosis and impaired glucose tolerance: a randomized crossover trial. Diabetes, Obesity &amp; Metabolism2019;21:700-704. [CFGD REGISTER: CO69] ">Geyer 2019</a>; <a href="./references#CD004730-bbs2-0017" title="MinicucciL , CasciaroR , De AlessandriA , HauptM , CasoM , LucidiV , et al. Efficacy of slow release insulin in patients with cystic fibrosis and glucide intolerance. Journal of Cystic Fibrosis2009;8 (Suppl 2):S82. [ABSTRACT NO.: 331] [CFGD REGISTER: CO42b] MinicucciL , HauptM , CasciaroR , De AlessandriA , BagnascoF , LucidiV , et al. Slow-release insulin in cystic fibrosis patients with glucose intolerance: a randomized clinical trial. Pediatric Diabetes2012;13(2):197-202. [CFGD REGISTER: CO42c] MinicucciL . New diagnostic and therapeutic approaches in cystic fibrosis related diabetes (CFRD). Journal of Cystic Fibrosis2008;7(Suppl 3):S6. [ABSTRACT NO.: R25] [CFGD REGISTER: CO42a] ">Minicucci 2012</a>; <a href="./references#CD004730-bbs2-0018" title="NCT01149005. Cystic Fibrosis (CF) Exacerbation and Insulin Treatment. clinicaltrials.gov/show/nct01149005 (first posted 23 June 2010). ">NCT01149005</a>) and one participants who were pre‐diabetic (<a href="./references#CD004730-bbs2-0019" title="NCT02496780. The impact of insulin therapy on protein turnover in pre-diabetic cystic fibrosis patients. clinicaltrials.gov/ct2/show/NCT02496780 (first posted 14 July 2015). ">NCT02496780</a>); one trial was of interventions to promote treatment adherence in children with type 1 diabetes or CF and not a comparison of treatments for CFRD (<a href="./references#CD004730-bbs2-0008" title="DriscollKA , JohnsonSB , BarkerD , QuittnerAL , DeebLC , GellerDE , et al. Risk factors associated with depressive symptoms in caregivers of children with type 1 diabetes or cystic fibrosis. Journal of Pediatric Psychology2010;35(8):814-22. [CFGD REGISTER: CO49b] 5500100000011199 DriscollKA , JohnsonSB , TangY , YangF , DeebLC , SilversteinJH . Does blood glucose monitoring increase prior to clinic visits in children with type 1 diabetes?Diabetes Care2011;34(10):2170-3. [CFGD REGISTER: CO49c] 5500100000011200 DriscollKA , KillianM , JohnsonSB , SilversteinJH , DeebLC . Predictors of study completion and withdrawal in a randomized clinical trial of a pediatric diabetes adherence intervention. Contemporary Clinical Trials2009;30(3):212-20. [CFGD REGISTER: CO49a] 5500100000011198 ">Driscoll 2009</a>). A short‐term comparison of a non‐pharmacological approach (exercise) to controlling glucose in people with CF (<a href="./references#CD004730-bbs2-0005" title="BeaudoinN , BouvetGF , CoriatiA , Rabasa-LhoretR , BerthiaumeY . Combined exercise training improves glycemic control in adult with cystic fibrosis. Medicine and Science in Sports and Exercise2017;49(2):231-7. [CFGD REGISTER: CO62b] BeaudoinN , BouvetGF , CoriatiA , Rabasa-LhoretR , BerthiaumeY . Combined exercise training improves glycemic control in adult with cystic fibrosis. Medicine and Science in Sports and Exercise2017;49(2):231-7. Supplemental digital content. [CFGD REGISTER: CO62c] BeaudoinN , BouvetGF , Rabasa-LhoretR , BerthiaumeY . Effects of a partially supervised combined exercise program on glycemic control in cystic fibrosis: pilot study. Pediatric Pulmonology2015;50 Suppl 41:367. [ABSTRACT NO.: 466] [CFGD REGISTER: CO62a] ">Beaudoin 2015</a>) did not include an intervention used in this review. Two additional studies reported on glucose trends in pwCF but no CFRD, one in a group that were pancreatic insufficient (<a href="./references#CD004730-bbs2-0009" title="EielJN , NyirjesyS , PeleckisAJ , De LeonD , HadjiliadisD , KubrakC , et al. Effects of GLP-1 and GIP on insulin secretion in glucose intolerant, pancreatic insufficient cystic fibrosis. Diabetes2018;67(Supplement 1):A484. [CFGD REGISTER: CO68] KellyA , NyirjesyS , PeleckisA , EielJ , De LeonD , HadjiliadisD , et al. Effect of GLP-1 and GIP on insulin secretion in glucose intolerant, pancreatic insufficient cystic fibrosis. Pediatric Pulmonology2019;54 Suppl 2:222. [CENTRAL: CN-01988358] [CFGD REGISTER: CO68b] [EMBASE: 629388555]NyirjesySC , SheikhS , HadjiliadisD , De LeonDD , PeleckisAJ , EielJN , et al. β-Cell secretory defects are present in pancreatic insufficient cystic fibrosis with 1-hour oral glucose tolerance test glucose ≥155 mg/dL. Pediatric Diabetes2018;19(7):1173-82. [DOI: 10.1111/pedi.12700]">Eiel 2018</a>) and another only followed during pulmonary exacerbation (<a href="./references#CD004730-bbs2-0023" title="ScNN , ShoseyovD , KeremE , ZangenDH . Patients with cystic fibrosis and normoglycemia exhibit diabetic glucose tolerance during pulmonary exacerbation. Journal of Cystic Fibrosis2010;9(3):199-204. [DOI: 10.1016/j.jcf.2010.02.001]">Sc 2010</a>); these were excluded as they did not meet inclusion criteria for this review. </p> <section id="CD004730-sec-0051"> <h5 class="title">Studies awaiting classification</h5> <p>We have listed one trial as 'Awaiting classification' as it is currently only available as a single abstract (<a href="./references#CD004730-bbs2-0027" title="deLind van Wijngaarden-van den BergJMW , van derMeerR , HeijermanHGM . A placebo-controlled trial of insulin therapy with or without adjuvant metformin in patients with cystic fibrosis-related diabetes (CFRD). Journal of Cystic Fibrosis2014;13 Suppl 2:S12. [ABSTRACT NO.: WS6.4] [CENTRAL: 996580] [CFGD REGISTER: CO56 ] ">de Lind 2014</a>). The trial is a randomized, triple‐blind cross‐over trial comparing insulin therapy plus metformin to placebo. It consists of two three‐month therapy periods separated by a four‐week washout period. The trial recruited 17 adults with CF, of whom 14 have completed the trial. Outcomes measured include insulin need, HbA1c levels and glucose levels (<a href="./references#CD004730-bbs2-0027" title="deLind van Wijngaarden-van den BergJMW , van derMeerR , HeijermanHGM . A placebo-controlled trial of insulin therapy with or without adjuvant metformin in patients with cystic fibrosis-related diabetes (CFRD). Journal of Cystic Fibrosis2014;13 Suppl 2:S12. [ABSTRACT NO.: WS6.4] [CENTRAL: 996580] [CFGD REGISTER: CO56 ] ">de Lind 2014</a>). </p> </section> <section id="CD004730-sec-0052"> <h5 class="title">Ongoing studies</h5> <p>Two trials are listed as ongoing (<a href="./references#CD004730-bbs2-0028" title="NCT01851694. Beta-cell Response to Incretin Hormones in Cystic Fibrosis. clinicaltrials.gov/show/nct01851694 (first posted 10 May 2013). ">NCT01851694</a>; <a href="./references#CD004730-bbs2-0029" title="NCT02202876. Redox Imbalance and the Development of Cystic Fibrosis Diabetes. clinicaltrials.gov/show/nct02202876 (first posted 29 July 2014). ">NCT02202876</a>). </p> <p>The mechanistic study may not be eligible for inclusion in this review as the outcome is to detail the insulin response in CF to incretin stimulus to the pancreas (<a href="./references#CD004730-bbs2-0028" title="NCT01851694. Beta-cell Response to Incretin Hormones in Cystic Fibrosis. clinicaltrials.gov/show/nct01851694 (first posted 10 May 2013). ">NCT01851694</a>). Their outcomes, if resulting in a significant insulin response, would support the need for more relevant clinical trials following the glycemic outcomes more relevant to this review. The mechanistic study looking at redox effects in CFRD will monitor cysteine/cysteine ratio response to performing the oral glucose tolerance test, versus a meal (<a href="./references#CD004730-bbs2-0029" title="NCT02202876. Redox Imbalance and the Development of Cystic Fibrosis Diabetes. clinicaltrials.gov/show/nct02202876 (first posted 29 July 2014). ">NCT02202876</a>). These outcomes will yield minimal clinical relevance to supporting the treatment options of interest for this review. </p> </section> </section> </section> <section id="CD004730-sec-0053"> <h3 class="title">Risk of bias in included studies</h3> <section id="CD004730-sec-0054"> <h4 class="title">Allocation</h4> <section id="CD004730-sec-0055"> <h5 class="title">Generation of randomization sequence</h5> <p>Two trials were judged to have an unclear risk of bias for sequence generation (<a href="./references#CD004730-bbs2-0002" title="GroverP , ThomasW , MoranA . Glargine versus NPH insulin in cystic fibrosis related diabetes. Journal of Cystic Fibrosis2008;7(2):134-6. [CFGD REGISTER: CO39] ">Grover 2008</a>; <a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>). Grover did not provide details of the randomization sequence, but made a statement that groups were similar in demographic characteristics and gender proportion, although a table of baseline comparisons was not provided (<a href="./references#CD004730-bbs2-0002" title="GroverP , ThomasW , MoranA . Glargine versus NPH insulin in cystic fibrosis related diabetes. Journal of Cystic Fibrosis2008;7(2):134-6. [CFGD REGISTER: CO39] ">Grover 2008</a>). In the earlier trial, Moran does state that the interventions were given in random order, but does not describe how this order was generated (<a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>). </p> <p>We judged the remaining two trials to have a low risk of bias from the generation of the randomization sequence (<a href="./references#CD004730-bbs2-0001" title="BallmannM , HubertD , AssaelBM , KronfeldK , HonerM , HollRW , et al. Open randomised prospective comparative multi-centre intervention study of patients with cystic fibrosis and early diagnosed diabetes mellitus. BMC Pediatrics2014;14:70. [CENTRAL: 1000301] [CFGD REGISTER: CO53c] [JID: 100967804] [OID: NLM: PMC3975280] [PMCID: PMC3975280] [PMID: 24620855]BallmannM , HubertD , AssaelBM , Mosnier-PudarH , Barao OcampoM , ScheunigN , et al. Repaglinide versus insulin in the treatment of CFRD diagnosed by screening: an open prospective randomized study. Pediatric Pulmonology2013;48 Suppl 26:421. [ABSTRACT NO.: 582] [CENTRAL: 962122] [CFGD REGISTER: CO53b] BallmannM , HubertD , AssaelBM , Mosnier-PudarH , SmacznyC , KesslerL , et al. Treatment of early diagnosed CFRD with oral drugs verus insulin: An open prospective randomized study. Journal of Cystic Fibrosis2013;12 Suppl 1:S32. [ABSTRACT NO.: WS16.1] [CENTRAL: 962115] [CFGD REGISTER: CO53a] BallmannM , HubertD , AssaelBM , StaabD , HebestreitA , NaehrlichL , et al. Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. The Lancet Diabetes and Endocrinology2018;6(2):114-21. [CFGD REGISTER: CO53e] [DOI: 10.1016/S2213-8587(17)30400-X]SchmidK , FinkK , HollRW , HebestreitH , BallmannM . Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2014;13(1):80-5. [CENTRAL: 1000302] [CFGD REGISTER: CO53d] [JID: 101128966] [PMID: 23809507] [SI: ClinicalTrials.gov/NCT00662714]">Ballmann 2018b</a>; <a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). The randomization list in the Ballmann trial was generated by a geigy random number table and stratified by gender and age (10 to 15 years and over 15 years of age) (<a href="./references#CD004730-bbs2-0001" title="BallmannM , HubertD , AssaelBM , KronfeldK , HonerM , HollRW , et al. Open randomised prospective comparative multi-centre intervention study of patients with cystic fibrosis and early diagnosed diabetes mellitus. BMC Pediatrics2014;14:70. [CENTRAL: 1000301] [CFGD REGISTER: CO53c] [JID: 100967804] [OID: NLM: PMC3975280] [PMCID: PMC3975280] [PMID: 24620855]BallmannM , HubertD , AssaelBM , Mosnier-PudarH , Barao OcampoM , ScheunigN , et al. Repaglinide versus insulin in the treatment of CFRD diagnosed by screening: an open prospective randomized study. Pediatric Pulmonology2013;48 Suppl 26:421. [ABSTRACT NO.: 582] [CENTRAL: 962122] [CFGD REGISTER: CO53b] BallmannM , HubertD , AssaelBM , Mosnier-PudarH , SmacznyC , KesslerL , et al. Treatment of early diagnosed CFRD with oral drugs verus insulin: An open prospective randomized study. Journal of Cystic Fibrosis2013;12 Suppl 1:S32. [ABSTRACT NO.: WS16.1] [CENTRAL: 962115] [CFGD REGISTER: CO53a] BallmannM , HubertD , AssaelBM , StaabD , HebestreitA , NaehrlichL , et al. Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. The Lancet Diabetes and Endocrinology2018;6(2):114-21. [CFGD REGISTER: CO53e] [DOI: 10.1016/S2213-8587(17)30400-X]SchmidK , FinkK , HollRW , HebestreitH , BallmannM . Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2014;13(1):80-5. [CENTRAL: 1000302] [CFGD REGISTER: CO53d] [JID: 101128966] [PMID: 23809507] [SI: ClinicalTrials.gov/NCT00662714]">Ballmann 2018b</a>). Moran stated that stated that block randomization using a pseudo‐random number generator with stratification by center was employed (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). </p> </section> <section id="CD004730-sec-0056"> <h5 class="title">Concealment of allocation</h5> <p>Three trials were judged to have an unclear risk of bias for allocation concealment as they did not provide any details in their respective publications (<a href="./references#CD004730-bbs2-0002" title="GroverP , ThomasW , MoranA . Glargine versus NPH insulin in cystic fibrosis related diabetes. Journal of Cystic Fibrosis2008;7(2):134-6. [CFGD REGISTER: CO39] ">Grover 2008</a>; <a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>; <a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). </p> <p>We judged one trial to have a low risk of bias from allocation concealment as participants and clinicians were informed of randomization by a central fax (<a href="./references#CD004730-bbs2-0001" title="BallmannM , HubertD , AssaelBM , KronfeldK , HonerM , HollRW , et al. Open randomised prospective comparative multi-centre intervention study of patients with cystic fibrosis and early diagnosed diabetes mellitus. BMC Pediatrics2014;14:70. [CENTRAL: 1000301] [CFGD REGISTER: CO53c] [JID: 100967804] [OID: NLM: PMC3975280] [PMCID: PMC3975280] [PMID: 24620855]BallmannM , HubertD , AssaelBM , Mosnier-PudarH , Barao OcampoM , ScheunigN , et al. Repaglinide versus insulin in the treatment of CFRD diagnosed by screening: an open prospective randomized study. Pediatric Pulmonology2013;48 Suppl 26:421. [ABSTRACT NO.: 582] [CENTRAL: 962122] [CFGD REGISTER: CO53b] BallmannM , HubertD , AssaelBM , Mosnier-PudarH , SmacznyC , KesslerL , et al. Treatment of early diagnosed CFRD with oral drugs verus insulin: An open prospective randomized study. Journal of Cystic Fibrosis2013;12 Suppl 1:S32. [ABSTRACT NO.: WS16.1] [CENTRAL: 962115] [CFGD REGISTER: CO53a] BallmannM , HubertD , AssaelBM , StaabD , HebestreitA , NaehrlichL , et al. Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. The Lancet Diabetes and Endocrinology2018;6(2):114-21. [CFGD REGISTER: CO53e] [DOI: 10.1016/S2213-8587(17)30400-X]SchmidK , FinkK , HollRW , HebestreitH , BallmannM . Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2014;13(1):80-5. [CENTRAL: 1000302] [CFGD REGISTER: CO53d] [JID: 101128966] [PMID: 23809507] [SI: ClinicalTrials.gov/NCT00662714]">Ballmann 2018b</a>). </p> </section> </section> <section id="CD004730-sec-0057"> <h4 class="title">Blinding</h4> <p>We estimate the risk of bias from blinding as high in three trials (<a href="./references#CD004730-bbs2-0001" title="BallmannM , HubertD , AssaelBM , KronfeldK , HonerM , HollRW , et al. Open randomised prospective comparative multi-centre intervention study of patients with cystic fibrosis and early diagnosed diabetes mellitus. BMC Pediatrics2014;14:70. [CENTRAL: 1000301] [CFGD REGISTER: CO53c] [JID: 100967804] [OID: NLM: PMC3975280] [PMCID: PMC3975280] [PMID: 24620855]BallmannM , HubertD , AssaelBM , Mosnier-PudarH , Barao OcampoM , ScheunigN , et al. Repaglinide versus insulin in the treatment of CFRD diagnosed by screening: an open prospective randomized study. Pediatric Pulmonology2013;48 Suppl 26:421. [ABSTRACT NO.: 582] [CENTRAL: 962122] [CFGD REGISTER: CO53b] BallmannM , HubertD , AssaelBM , Mosnier-PudarH , SmacznyC , KesslerL , et al. Treatment of early diagnosed CFRD with oral drugs verus insulin: An open prospective randomized study. Journal of Cystic Fibrosis2013;12 Suppl 1:S32. [ABSTRACT NO.: WS16.1] [CENTRAL: 962115] [CFGD REGISTER: CO53a] BallmannM , HubertD , AssaelBM , StaabD , HebestreitA , NaehrlichL , et al. Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. The Lancet Diabetes and Endocrinology2018;6(2):114-21. [CFGD REGISTER: CO53e] [DOI: 10.1016/S2213-8587(17)30400-X]SchmidK , FinkK , HollRW , HebestreitH , BallmannM . Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2014;13(1):80-5. [CENTRAL: 1000302] [CFGD REGISTER: CO53d] [JID: 101128966] [PMID: 23809507] [SI: ClinicalTrials.gov/NCT00662714]">Ballmann 2018b</a>; <a href="./references#CD004730-bbs2-0002" title="GroverP , ThomasW , MoranA . Glargine versus NPH insulin in cystic fibrosis related diabetes. Journal of Cystic Fibrosis2008;7(2):134-6. [CFGD REGISTER: CO39] ">Grover 2008</a>; <a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>). The participants in the Ballmann trial either received insulin via a syringe or oral repaglinide (<a href="./references#CD004730-bbs2-0001" title="BallmannM , HubertD , AssaelBM , KronfeldK , HonerM , HollRW , et al. Open randomised prospective comparative multi-centre intervention study of patients with cystic fibrosis and early diagnosed diabetes mellitus. BMC Pediatrics2014;14:70. [CENTRAL: 1000301] [CFGD REGISTER: CO53c] [JID: 100967804] [OID: NLM: PMC3975280] [PMCID: PMC3975280] [PMID: 24620855]BallmannM , HubertD , AssaelBM , Mosnier-PudarH , Barao OcampoM , ScheunigN , et al. Repaglinide versus insulin in the treatment of CFRD diagnosed by screening: an open prospective randomized study. Pediatric Pulmonology2013;48 Suppl 26:421. [ABSTRACT NO.: 582] [CENTRAL: 962122] [CFGD REGISTER: CO53b] BallmannM , HubertD , AssaelBM , Mosnier-PudarH , SmacznyC , KesslerL , et al. Treatment of early diagnosed CFRD with oral drugs verus insulin: An open prospective randomized study. Journal of Cystic Fibrosis2013;12 Suppl 1:S32. [ABSTRACT NO.: WS16.1] [CENTRAL: 962115] [CFGD REGISTER: CO53a] BallmannM , HubertD , AssaelBM , StaabD , HebestreitA , NaehrlichL , et al. Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. The Lancet Diabetes and Endocrinology2018;6(2):114-21. [CFGD REGISTER: CO53e] [DOI: 10.1016/S2213-8587(17)30400-X]SchmidK , FinkK , HollRW , HebestreitH , BallmannM . Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2014;13(1):80-5. [CENTRAL: 1000302] [CFGD REGISTER: CO53d] [JID: 101128966] [PMID: 23809507] [SI: ClinicalTrials.gov/NCT00662714]">Ballmann 2018b</a>). The Grover article states that this was a cross‐over trial, so that once randomized to start either therapy (bedtime NPH‐ Aspart OR bedtime glargine) the participant (and physician) would be aware of the treatment given due to the frequency of dosing (<a href="./references#CD004730-bbs2-0002" title="GroverP , ThomasW , MoranA . Glargine versus NPH insulin in cystic fibrosis related diabetes. Journal of Cystic Fibrosis2008;7(2):134-6. [CFGD REGISTER: CO39] ">Grover 2008</a>). The earlier Moran paper does not discuss blinding of participants, clinicians or outcome assessors, however, as the interventions were either no medication, insulin via a syringe or oral repaglinide it would have been impossible to blind the participants or the clinicians to the treatment group (<a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>). </p> <p>In the later Moran trial, participants were blinded when receiving either the oral agent or the oral placebo, which leads to a low risk of bias (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). However, it should be noted that it was not possible to blind participants receiving insulin, so this arm of the trial is at risk of bias from blinding (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). </p> </section> <section id="CD004730-sec-0058"> <h4 class="title">Incomplete outcome data</h4> <p>We judged two trials to be at high risk of bias from incomplete outcome data (<a href="./references#CD004730-bbs2-0001" title="BallmannM , HubertD , AssaelBM , KronfeldK , HonerM , HollRW , et al. Open randomised prospective comparative multi-centre intervention study of patients with cystic fibrosis and early diagnosed diabetes mellitus. BMC Pediatrics2014;14:70. [CENTRAL: 1000301] [CFGD REGISTER: CO53c] [JID: 100967804] [OID: NLM: PMC3975280] [PMCID: PMC3975280] [PMID: 24620855]BallmannM , HubertD , AssaelBM , Mosnier-PudarH , Barao OcampoM , ScheunigN , et al. Repaglinide versus insulin in the treatment of CFRD diagnosed by screening: an open prospective randomized study. Pediatric Pulmonology2013;48 Suppl 26:421. [ABSTRACT NO.: 582] [CENTRAL: 962122] [CFGD REGISTER: CO53b] BallmannM , HubertD , AssaelBM , Mosnier-PudarH , SmacznyC , KesslerL , et al. Treatment of early diagnosed CFRD with oral drugs verus insulin: An open prospective randomized study. Journal of Cystic Fibrosis2013;12 Suppl 1:S32. [ABSTRACT NO.: WS16.1] [CENTRAL: 962115] [CFGD REGISTER: CO53a] BallmannM , HubertD , AssaelBM , StaabD , HebestreitA , NaehrlichL , et al. Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. The Lancet Diabetes and Endocrinology2018;6(2):114-21. [CFGD REGISTER: CO53e] [DOI: 10.1016/S2213-8587(17)30400-X]SchmidK , FinkK , HollRW , HebestreitH , BallmannM . Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2014;13(1):80-5. [CENTRAL: 1000302] [CFGD REGISTER: CO53d] [JID: 101128966] [PMID: 23809507] [SI: ClinicalTrials.gov/NCT00662714]">Ballmann 2018b</a>; <a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>). For the Ballmann trial, 75 participants were initially randomised (34 to receive repaglinide and 41 to receive insulin), but four participants did not commence treatment leaving 71 participants in the trial (33 in the repaglinide group and 38 in the insulin group). Of these, three participants from the repaglinide arm and one participant from the insulin arm were not included due to no recording of HbA1c after the baseline reading, so 67 participants were included in the analysis (30 in the repaglinide group and 37 in the insulin group). In addition, missing data at defined times were imputed with available measurements before and after the missing visit (<a href="./references#CD004730-bbs2-0001" title="BallmannM , HubertD , AssaelBM , KronfeldK , HonerM , HollRW , et al. Open randomised prospective comparative multi-centre intervention study of patients with cystic fibrosis and early diagnosed diabetes mellitus. BMC Pediatrics2014;14:70. [CENTRAL: 1000301] [CFGD REGISTER: CO53c] [JID: 100967804] [OID: NLM: PMC3975280] [PMCID: PMC3975280] [PMID: 24620855]BallmannM , HubertD , AssaelBM , Mosnier-PudarH , Barao OcampoM , ScheunigN , et al. Repaglinide versus insulin in the treatment of CFRD diagnosed by screening: an open prospective randomized study. Pediatric Pulmonology2013;48 Suppl 26:421. [ABSTRACT NO.: 582] [CENTRAL: 962122] [CFGD REGISTER: CO53b] BallmannM , HubertD , AssaelBM , Mosnier-PudarH , SmacznyC , KesslerL , et al. Treatment of early diagnosed CFRD with oral drugs verus insulin: An open prospective randomized study. Journal of Cystic Fibrosis2013;12 Suppl 1:S32. [ABSTRACT NO.: WS16.1] [CENTRAL: 962115] [CFGD REGISTER: CO53a] BallmannM , HubertD , AssaelBM , StaabD , HebestreitA , NaehrlichL , et al. Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. The Lancet Diabetes and Endocrinology2018;6(2):114-21. [CFGD REGISTER: CO53e] [DOI: 10.1016/S2213-8587(17)30400-X]SchmidK , FinkK , HollRW , HebestreitH , BallmannM . Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2014;13(1):80-5. [CENTRAL: 1000302] [CFGD REGISTER: CO53d] [JID: 101128966] [PMID: 23809507] [SI: ClinicalTrials.gov/NCT00662714]">Ballmann 2018b</a>). In the Moran trial, while there was no attrition over this brief five‐hour period, the paper stated outcomes were measured at 20‐minute intervals, but only presented data for two and five‐hour time points (<a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>). </p> <p>We judged one trial to have an unclear risk of bias (<a href="./references#CD004730-bbs2-0002" title="GroverP , ThomasW , MoranA . Glargine versus NPH insulin in cystic fibrosis related diabetes. Journal of Cystic Fibrosis2008;7(2):134-6. [CFGD REGISTER: CO39] ">Grover 2008</a>). The Grover trial reported that one male participant dropped out of the group who received NPH first, however, no reason was given for this and it was also not stated in which arm of the trial the dropout occurred (<a href="./references#CD004730-bbs2-0002" title="GroverP , ThomasW , MoranA . Glargine versus NPH insulin in cystic fibrosis related diabetes. Journal of Cystic Fibrosis2008;7(2):134-6. [CFGD REGISTER: CO39] ">Grover 2008</a>). </p> <p>We judged one trial to have a low risk of bias (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). All individuals dropping out from this trial were detailed and there were no significant differences in baseline characteristics for individuals dropping out, with the exception of the CFQOL measure, for which it was noted that those stopping early had lower eating disturbance scores and social or marginalization scales (P &lt; 0.05) (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). </p> </section> <section id="CD004730-sec-0059"> <h4 class="title">Selective reporting</h4> <p>We judged three included trials to have a high risk of bias due to selective reporting (<a href="./references#CD004730-bbs2-0002" title="GroverP , ThomasW , MoranA . Glargine versus NPH insulin in cystic fibrosis related diabetes. Journal of Cystic Fibrosis2008;7(2):134-6. [CFGD REGISTER: CO39] ">Grover 2008</a>; <a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>; <a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). Although all four mention all outcomes which are stated in the ’Methods’ section in their respective ’Results’ sections, they do not always provide data and often there are just statements that there was no difference between treatment groups. We contacted the authors for the data to enter in our analysis, but the data are not available, for this reason we judge there to be a high risk of selective reporting bias. </p> <p>We judged one trial to have a low risk of bias as all stated outcomes were recorded and reported (<a href="./references#CD004730-bbs2-0001" title="BallmannM , HubertD , AssaelBM , KronfeldK , HonerM , HollRW , et al. Open randomised prospective comparative multi-centre intervention study of patients with cystic fibrosis and early diagnosed diabetes mellitus. BMC Pediatrics2014;14:70. [CENTRAL: 1000301] [CFGD REGISTER: CO53c] [JID: 100967804] [OID: NLM: PMC3975280] [PMCID: PMC3975280] [PMID: 24620855]BallmannM , HubertD , AssaelBM , Mosnier-PudarH , Barao OcampoM , ScheunigN , et al. Repaglinide versus insulin in the treatment of CFRD diagnosed by screening: an open prospective randomized study. Pediatric Pulmonology2013;48 Suppl 26:421. [ABSTRACT NO.: 582] [CENTRAL: 962122] [CFGD REGISTER: CO53b] BallmannM , HubertD , AssaelBM , Mosnier-PudarH , SmacznyC , KesslerL , et al. Treatment of early diagnosed CFRD with oral drugs verus insulin: An open prospective randomized study. Journal of Cystic Fibrosis2013;12 Suppl 1:S32. [ABSTRACT NO.: WS16.1] [CENTRAL: 962115] [CFGD REGISTER: CO53a] BallmannM , HubertD , AssaelBM , StaabD , HebestreitA , NaehrlichL , et al. Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. The Lancet Diabetes and Endocrinology2018;6(2):114-21. [CFGD REGISTER: CO53e] [DOI: 10.1016/S2213-8587(17)30400-X]SchmidK , FinkK , HollRW , HebestreitH , BallmannM . Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2014;13(1):80-5. [CENTRAL: 1000302] [CFGD REGISTER: CO53d] [JID: 101128966] [PMID: 23809507] [SI: ClinicalTrials.gov/NCT00662714]">Ballmann 2018b</a>). </p> </section> <section id="CD004730-sec-0060"> <h4 class="title">Other potential sources of bias</h4> <p>We judged the Ballmann trial to have an unclear risk of bias due to industry sponsorship. While this trial was sponsored by Novo Nordisc, they were only one of three sponsors or collaborators and it is not clear how much influence they had over the trial (<a href="./references#CD004730-bbs2-0001" title="BallmannM , HubertD , AssaelBM , KronfeldK , HonerM , HollRW , et al. Open randomised prospective comparative multi-centre intervention study of patients with cystic fibrosis and early diagnosed diabetes mellitus. BMC Pediatrics2014;14:70. [CENTRAL: 1000301] [CFGD REGISTER: CO53c] [JID: 100967804] [OID: NLM: PMC3975280] [PMCID: PMC3975280] [PMID: 24620855]BallmannM , HubertD , AssaelBM , Mosnier-PudarH , Barao OcampoM , ScheunigN , et al. Repaglinide versus insulin in the treatment of CFRD diagnosed by screening: an open prospective randomized study. Pediatric Pulmonology2013;48 Suppl 26:421. [ABSTRACT NO.: 582] [CENTRAL: 962122] [CFGD REGISTER: CO53b] BallmannM , HubertD , AssaelBM , Mosnier-PudarH , SmacznyC , KesslerL , et al. Treatment of early diagnosed CFRD with oral drugs verus insulin: An open prospective randomized study. Journal of Cystic Fibrosis2013;12 Suppl 1:S32. [ABSTRACT NO.: WS16.1] [CENTRAL: 962115] [CFGD REGISTER: CO53a] BallmannM , HubertD , AssaelBM , StaabD , HebestreitA , NaehrlichL , et al. Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. The Lancet Diabetes and Endocrinology2018;6(2):114-21. [CFGD REGISTER: CO53e] [DOI: 10.1016/S2213-8587(17)30400-X]SchmidK , FinkK , HollRW , HebestreitH , BallmannM . Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2014;13(1):80-5. [CENTRAL: 1000302] [CFGD REGISTER: CO53d] [JID: 101128966] [PMID: 23809507] [SI: ClinicalTrials.gov/NCT00662714]">Ballmann 2018b</a>). </p> <p>We judged three included trials to be at high risk from other potential sources of bias (<a href="./references#CD004730-bbs2-0002" title="GroverP , ThomasW , MoranA . Glargine versus NPH insulin in cystic fibrosis related diabetes. Journal of Cystic Fibrosis2008;7(2):134-6. [CFGD REGISTER: CO39] ">Grover 2008</a>; <a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>; <a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). </p> <p>In the Grover trial, diabetic participants with normal fasting blood sugars were excluded from the trial (<a href="./references#CD004730-bbs2-0002" title="GroverP , ThomasW , MoranA . Glargine versus NPH insulin in cystic fibrosis related diabetes. Journal of Cystic Fibrosis2008;7(2):134-6. [CFGD REGISTER: CO39] ">Grover 2008</a>). The Grover trial was of cross‐over design, but we analysed the data as if the trial was of parallel design since first arm data were not available. This approach produces conservative results as it does not take into account within‐patient correlation. Also, each participant appears in both the treatment and control group, so the two groups are not independent (<a href="./references#CD004730-bbs2-0033" title="ElbourneDR , AltmanDG , HigginsJPT , CurtinF , WorthingtonHV , A Vail. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology2002;31(1):140-9.">Elbourne 2002</a>); hence there is an additional risk of bias to the results. </p> <p>In the 2001 Moran trial, the insulin doses were chosen at a pharmacological optimal dose range (0.1 unit/kg/body weight); while repaglinide dosing at 1 mg only represents 25% of the recommended maximal dose (<a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>). </p> <p>In the later Moran trial, diabetic participants with fasting hyperglycemia were excluded from the trial. Furthermore, after the trial was started four repaglinide participants (17%) had doses of medication reduced compared to only two insulin‐only participants, which could explain the reason the repaglinide lost statistical significance after the first six months of the trial (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). </p> </section> </section> <section id="CD004730-sec-0061"> <h3 class="title" id="CD004730-sec-0061">Effects of interventions</h3> <p>See: <a href="./full#CD004730-tbl-0001"><b>Summary of findings 1</b> Summary of findings: insulin versus placebo for CFRD</a>; <a href="./full#CD004730-tbl-0002"><b>Summary of findings 2</b> Summary of findings: repaglinide versus placebo for CFRD</a>; <a href="./full#CD004730-tbl-0003"><b>Summary of findings 3</b> Summary of findings: repaglinide versus insulin for CFRD</a>; <a href="./full#CD004730-tbl-0004"><b>Summary of findings 4</b> Summary of findings: NPH insulin versus glargine for CFRD</a> </p> <p>In the section below only those comparisons and outcomes for which information or data are available are presented. Data from the cross‐over trials were not combined with those from the parallel trials. The effects of interventions are summarised in the summary of findings tables, the quality of the evidence has been graded for pre‐defined outcomes (see above) and definitions of these gradings provided (<a href="./full#CD004730-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD004730-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD004730-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD004730-tbl-0004">summary of findings Table 4</a>). </p> <section id="CD004730-sec-0062"> <h4 class="title">Insulin versus control</h4> <p>Two trials (n = 68) presented results for this comparison (<a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>; <a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>), but we were only able to enter data in the graphs for the placebo‐controlled trial (n = 61 for three arms, n = 39 for this comparison) (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). We have presented the results from the earlier trial comparing insulin to no treatment narratively. A summary of these findings is presented in the tables (<a href="./full#CD004730-tbl-0001">summary of findings Table 1</a>). </p> <section id="CD004730-sec-0063"> <h5 class="title">Primary outcomes</h5> <section id="CD004730-sec-0064"> <h6 class="title">1. Biochemical measures of glycemic control</h6> <p>In the comparison of insulin lispro versus placebo the earlier Moran trial reported that there was a benefit seen glucose AUC (reduction) at both the two‐hour time point (P &lt; 0.05) and the five‐hour time point (P &lt; 0.05) (<a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>). Peak insulin levels fur AUCs were not measured in the later Moran trial (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). </p> <p>Specific data were not reported, but the authors commented that postprandial glucose in participants receiving insulin therapy did not achieve statistical significance, and that HbA1C levels did not significantly change in either this group of participants or those on placebo (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>) (very low‐quality evidence). </p> </section> <section id="CD004730-sec-0065"> <h6 class="title">2. Pulmonary function</h6> <p>The earlier Moran trial did not report on this outcome (<a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>). </p> <p>In the later trial, Moran reported data for change in FEV<sub>1</sub> (% predicted) and FVC (% predicted) at 12 months (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). There were no statistically significant differences detected in treatment groups between insulin compared to placebo for CFRD participants; for FEV<sub>1</sub>, MD 1.20 (95% CI ‐5.63 to 8.03) (<a href="./references#CD004730-fig-0001" title="">Analysis 1.1</a>) and for FVC, MD 0.60 (95% CI ‐5.67 to 6.87) (<a href="./references#CD004730-fig-0002" title="">Analysis 1.2</a>) (both low‐quality evidence). </p> </section> <section id="CD004730-sec-0066"> <h6 class="title">3. Assessment of nutritional status</h6> <p>The later Moran trial reported on this outcome (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>) and demonstrated a mean change in BMI at 12 months for insulin of 0.39 compared to placebo of ‐0.02, resulting in a non‐significant MD of 0.41 (95% CI ‐0.23 to 1.05) (<a href="./references#CD004730-fig-0003" title="">Analysis 1.3</a>) (low‐quality evidence). </p> </section> </section> <section id="CD004730-sec-0067"> <h5 class="title">Secondary Outcomes</h5> <section id="CD004730-sec-0068"> <h6 class="title">2. Prevalence of secondary infection complications</h6> <p>The 2001 trial did not report on this outcome (<a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>). While the later trial did not specifically report these data, the authors commented that there were no differences in the number of episodes of acute illness during the year of study in either the insulin or placebo arms (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). </p> </section> <section id="CD004730-sec-0069"> <h6 class="title">3. Complications of therapeutic management</h6> <section id="CD004730-sec-0070"> <p><b>a. hypoglycemia (specifically related to oral hypoglycemic and insulin agents)</b></p> <p>In the earlier trial, the investigators reported two incidences of hypoglycemia (glucose level 48 to 54 mg/dl, 2.7 to 3.0 mmol/l) after receiving insulin and one after the test meal with no medication. In all cases catecholamine‐related symptoms were present but easily tolerated. These episodes occurred on average four hours after the test meal and resolved spontaneously without glucose administration after 10 to 15 minutes (<a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>). When entered in the graphs, these data did not give a significant result, RR 2.00 (95% CI 0.23 to 17.34) (<a href="./references#CD004730-fig-0004" title="">Analysis 1.4</a>). </p> <p>In the later trial, no serious episode of hypoglycemia was recorded, but in the first three months mild hypoglycemic events were reported in 16% of insulin participants and none receiving placebo (P &lt; 0.04). When entered into the graphs these data did not give a significant result, RR 9.23 (95% CI 0.53 to 159.14) (<a href="./references#CD004730-fig-0004" title="">Analysis 1.4</a>) (low‐quality evidence). However, caution is advised on interpreting these results since Moran does not provide information as to whether these events occurred in those with CFRD or those with impaired glucose tolerance (IGT). After this time point, there were no significant differences between groups in the frequency of hypoglycemia, and some participants in the placebo group reported episodes of mild hypoglycemia (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). </p> </section> </section> <section id="CD004730-sec-0071"> <h6 class="title">4. Clinical status</h6> <section id="CD004730-sec-0072"> <p><b>b. HRQoL</b></p> <p>Specific data were not included for insulin‐treated participants from either trial (<a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>; <a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>); however, the 2009 trial report did state that CFQOL scores did not differ between insulin or placebo groups at baseline or between these groups at the end of the treatment year (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). </p> </section> <section id="CD004730-sec-0073"> <p><b>c. Mortality</b></p> <p>Mortality was not specifically reported for either trial, but details of participants leaving the trial were recorded and none from insulin, repaglinide nor the placebo groups were excluded as a result of mortality (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). </p> </section> </section> </section> </section> <section id="CD004730-sec-0074"> <h4 class="title">Repaglinide versus control</h4> <p>Two trials reported on this comparison (n = 45) (<a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>; <a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>) and a summary of the evidence is presented in the tables (<a href="./full#CD004730-tbl-0002">summary of findings Table 2</a>). </p> <section id="CD004730-sec-0075"> <h5 class="title">Primary outcomes</h5> <section id="CD004730-sec-0076"> <h6 class="title">1. Biochemical measures of glycemic control</h6> <p>Both trials only reported this outcome narratively (without actual data) (<a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>; <a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). In the earlier trial (n = 7), for the comparison of repaglinide versus placebo, there was a significant decrease in glucose AUC in the repaglinide group at the five‐hour time point (P = 0.03); however, there was no significant benefit found at the two‐hour time point (<a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>). The later trial reported that HbA1C levels did not significantly change in either the repaglinide and placebo groups (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>) (very low‐quality evidence). </p> </section> <section id="CD004730-sec-0077"> <h6 class="title">2. Pulmonary function</h6> <p>Moran only reported the change from baseline in FEV<sub>1</sub> (% predicted) and FVC (% predicted) in the later trial (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). At 12 months, there were no significant differences between the repaglinide or the placebo groups for either the change in FEV<sub>1</sub> % predicted, MD 1.70 (95% CI ‐5.13 to 8.53) (<a href="./references#CD004730-fig-0005" title="">Analysis 2.1</a>) or the change in FVC % predicted, MD ‐1.00 (95% CI ‐7.40 to 5.40) (<a href="./references#CD004730-fig-0006" title="">Analysis 2.2</a>) (both low‐quality evidence). </p> </section> <section id="CD004730-sec-0078"> <h6 class="title">3. Assessment of nutritional status</h6> <p>Moran reported that repaglinide demonstrated a mean difference for BMI change of 0.15 compared to placebo of ‐0.02, resulting in a non‐significant MD of 0.17 (95% CI ‐0.47 to 0.81) (<a href="./references#CD004730-fig-0007" title="">Analysis 2.3</a>) (low‐quality evidence). </p> </section> </section> <section id="CD004730-sec-0079"> <h5 class="title">Secondary Outcomes</h5> <section id="CD004730-sec-0080"> <h6 class="title">2. Prevalence of secondary infection complications</h6> <p>The prevalence of secondary infection was not detailed in the included trials, but the authors from the later trial did state that there were no differences in the number of episodes of acute illness during the year of study in either the repaglinide or the placebo arm (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). </p> </section> <section id="CD004730-sec-0081"> <h6 class="title">3. Complications of therapeutic management</h6> <section id="CD004730-sec-0082"> <p><b>a. hypoglycemia (specifically related to oral hypoglycemic and insulin agents)</b></p> <p>In the earlier trial, one episode of hypoglycemia (glucose level 48 to 54 mg/dL, 2.7 to 3.0 mmol/L) occurred in each group (<a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>). In all cases catecholamine‐related symptoms were present but easily tolerated. These episodes occurred on average four hours after the test meal and resolved spontaneously without glucose administration after 10 to 15 minutes (<a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>). When analysed, these data showed no difference between groups, RR 1.00 (95% CI 0.08 to 13.02) (<a href="./references#CD004730-fig-0008" title="">Analysis 2.4</a>). </p> <p>As for the previous comparison, up to three months there were mild hypoglycemic events reported in 23% of repaglinide participants, but no placebo participants reported hypoglycemia (P &lt; 0.04). When entered into the graphs, the result is not significant, RR 12.52 (95% CI 0.74 to 211.20) (<a href="./references#CD004730-fig-0008" title="">Analysis 2.4</a>) (very low‐quality evidence). However, caution is advised on interpreting these results since Moran does not provide information as to whether these events occurred in participants with CFRD or participants with IGT. After three months, this difference was no longer detected (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). </p> </section> </section> <section id="CD004730-sec-0083"> <h6 class="title">4. Clinical status</h6> <section id="CD004730-sec-0084"> <p><b>b. HRQoL</b></p> <p>Specific data were not presented; however, the authors did state that CFQOL scores did not differ between groups at the end of the treatment year (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). </p> </section> <section id="CD004730-sec-0085"> <p><b>c. mortality</b></p> <p>Mortality was not specifically reported for this trial, but participants leaving the trial were detailed and none from the repaglinide group nor the placebo group were excluded as a result of mortality (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). </p> </section> </section> </section> </section> <section id="CD004730-sec-0086"> <h4 class="title">Insulin versus repaglinide</h4> <p>Three trials reported on this comparison (n = 119) (<a href="./references#CD004730-bbs2-0001" title="BallmannM , HubertD , AssaelBM , KronfeldK , HonerM , HollRW , et al. Open randomised prospective comparative multi-centre intervention study of patients with cystic fibrosis and early diagnosed diabetes mellitus. BMC Pediatrics2014;14:70. [CENTRAL: 1000301] [CFGD REGISTER: CO53c] [JID: 100967804] [OID: NLM: PMC3975280] [PMCID: PMC3975280] [PMID: 24620855]BallmannM , HubertD , AssaelBM , Mosnier-PudarH , Barao OcampoM , ScheunigN , et al. Repaglinide versus insulin in the treatment of CFRD diagnosed by screening: an open prospective randomized study. Pediatric Pulmonology2013;48 Suppl 26:421. [ABSTRACT NO.: 582] [CENTRAL: 962122] [CFGD REGISTER: CO53b] BallmannM , HubertD , AssaelBM , Mosnier-PudarH , SmacznyC , KesslerL , et al. Treatment of early diagnosed CFRD with oral drugs verus insulin: An open prospective randomized study. Journal of Cystic Fibrosis2013;12 Suppl 1:S32. [ABSTRACT NO.: WS16.1] [CENTRAL: 962115] [CFGD REGISTER: CO53a] BallmannM , HubertD , AssaelBM , StaabD , HebestreitA , NaehrlichL , et al. Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. The Lancet Diabetes and Endocrinology2018;6(2):114-21. [CFGD REGISTER: CO53e] [DOI: 10.1016/S2213-8587(17)30400-X]SchmidK , FinkK , HollRW , HebestreitH , BallmannM . Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2014;13(1):80-5. [CENTRAL: 1000302] [CFGD REGISTER: CO53d] [JID: 101128966] [PMID: 23809507] [SI: ClinicalTrials.gov/NCT00662714]">Ballmann 2018b</a>; <a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>; <a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>) and a summary of the evidence is presented in the tables (<a href="./full#CD004730-tbl-0003">summary of findings Table 3</a>). </p> <section id="CD004730-sec-0087"> <h5 class="title">Primary outcomes</h5> <section id="CD004730-sec-0088"> <h6 class="title">1. Biochemical measures of glycemic control</h6> <p>Only one trial reported data for analysis (<a href="./references#CD004730-bbs2-0001" title="BallmannM , HubertD , AssaelBM , KronfeldK , HonerM , HollRW , et al. Open randomised prospective comparative multi-centre intervention study of patients with cystic fibrosis and early diagnosed diabetes mellitus. BMC Pediatrics2014;14:70. [CENTRAL: 1000301] [CFGD REGISTER: CO53c] [JID: 100967804] [OID: NLM: PMC3975280] [PMCID: PMC3975280] [PMID: 24620855]BallmannM , HubertD , AssaelBM , Mosnier-PudarH , Barao OcampoM , ScheunigN , et al. Repaglinide versus insulin in the treatment of CFRD diagnosed by screening: an open prospective randomized study. Pediatric Pulmonology2013;48 Suppl 26:421. [ABSTRACT NO.: 582] [CENTRAL: 962122] [CFGD REGISTER: CO53b] BallmannM , HubertD , AssaelBM , Mosnier-PudarH , SmacznyC , KesslerL , et al. Treatment of early diagnosed CFRD with oral drugs verus insulin: An open prospective randomized study. Journal of Cystic Fibrosis2013;12 Suppl 1:S32. [ABSTRACT NO.: WS16.1] [CENTRAL: 962115] [CFGD REGISTER: CO53a] BallmannM , HubertD , AssaelBM , StaabD , HebestreitA , NaehrlichL , et al. Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. The Lancet Diabetes and Endocrinology2018;6(2):114-21. [CFGD REGISTER: CO53e] [DOI: 10.1016/S2213-8587(17)30400-X]SchmidK , FinkK , HollRW , HebestreitH , BallmannM . Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2014;13(1):80-5. [CENTRAL: 1000302] [CFGD REGISTER: CO53d] [JID: 101128966] [PMID: 23809507] [SI: ClinicalTrials.gov/NCT00662714]">Ballmann 2018b</a>) and two trials did not report specific data (<a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>; <a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). </p> <p>The more recent trial (n = 67) reported that mean change in HbA1c( % ) levels were not significantly different between the repaglinide group and the insulin group after 12 months (<a href="./references#CD004730-bbs2-0001" title="BallmannM , HubertD , AssaelBM , KronfeldK , HonerM , HollRW , et al. Open randomised prospective comparative multi-centre intervention study of patients with cystic fibrosis and early diagnosed diabetes mellitus. BMC Pediatrics2014;14:70. [CENTRAL: 1000301] [CFGD REGISTER: CO53c] [JID: 100967804] [OID: NLM: PMC3975280] [PMCID: PMC3975280] [PMID: 24620855]BallmannM , HubertD , AssaelBM , Mosnier-PudarH , Barao OcampoM , ScheunigN , et al. Repaglinide versus insulin in the treatment of CFRD diagnosed by screening: an open prospective randomized study. Pediatric Pulmonology2013;48 Suppl 26:421. [ABSTRACT NO.: 582] [CENTRAL: 962122] [CFGD REGISTER: CO53b] BallmannM , HubertD , AssaelBM , Mosnier-PudarH , SmacznyC , KesslerL , et al. Treatment of early diagnosed CFRD with oral drugs verus insulin: An open prospective randomized study. Journal of Cystic Fibrosis2013;12 Suppl 1:S32. [ABSTRACT NO.: WS16.1] [CENTRAL: 962115] [CFGD REGISTER: CO53a] BallmannM , HubertD , AssaelBM , StaabD , HebestreitA , NaehrlichL , et al. Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. The Lancet Diabetes and Endocrinology2018;6(2):114-21. [CFGD REGISTER: CO53e] [DOI: 10.1016/S2213-8587(17)30400-X]SchmidK , FinkK , HollRW , HebestreitH , BallmannM . Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2014;13(1):80-5. [CENTRAL: 1000302] [CFGD REGISTER: CO53d] [JID: 101128966] [PMID: 23809507] [SI: ClinicalTrials.gov/NCT00662714]">Ballmann 2018b</a>), MD ‐0.30 % (95% CI ‐0.14 to 0.74) or after two years of intervention, MD 0.40 % (95% CI ‐0.08 to 0.88) (<a href="./references#CD004730-fig-0009" title="">Analysis 3.1</a>) (high‐quality evidence). In the later Moran trial (n = 45), investigators commented that postprandial glucose in participants receiving insulin compared to repaglinide therapy did not achieve statistical significance, and that A1C levels did not significantly changed between these groups of treated participants (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). </p> <p>The earlier Moran trial (n = 7) reported that insulin lispro seemed to have a more beneficial effect than repaglinide on post‐meal glucose excursion in CFRD; P &lt; 0.05 when comparing insulin to repaglinide at both two and five hours post‐meal (<a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>). Investigators reported significant differences between the two drugs in the peak glucose level (P = 0.02), the two‐hour glucose area under the curve (AUC) (P = 0.02), and the five‐hour glucose AUC (P = 0.01). The paper also states that at the doses used in the trial, neither insulin lispro or repaglinide significantly changed the peak insulin level or the two‐hour insulin AUC compared with baseline (<a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>). </p> </section> <section id="CD004730-sec-0089"> <h6 class="title">2. Pulmonary function</h6> <section id="CD004730-sec-0090"> <p><b>FEV<sub>1</sub> </b></p> <p>Two trials reported on FEV<sub>1</sub> (% predicted) at 12 months (n = 112) (<a href="./references#CD004730-bbs2-0001" title="BallmannM , HubertD , AssaelBM , KronfeldK , HonerM , HollRW , et al. Open randomised prospective comparative multi-centre intervention study of patients with cystic fibrosis and early diagnosed diabetes mellitus. BMC Pediatrics2014;14:70. [CENTRAL: 1000301] [CFGD REGISTER: CO53c] [JID: 100967804] [OID: NLM: PMC3975280] [PMCID: PMC3975280] [PMID: 24620855]BallmannM , HubertD , AssaelBM , Mosnier-PudarH , Barao OcampoM , ScheunigN , et al. Repaglinide versus insulin in the treatment of CFRD diagnosed by screening: an open prospective randomized study. Pediatric Pulmonology2013;48 Suppl 26:421. [ABSTRACT NO.: 582] [CENTRAL: 962122] [CFGD REGISTER: CO53b] BallmannM , HubertD , AssaelBM , Mosnier-PudarH , SmacznyC , KesslerL , et al. Treatment of early diagnosed CFRD with oral drugs verus insulin: An open prospective randomized study. Journal of Cystic Fibrosis2013;12 Suppl 1:S32. [ABSTRACT NO.: WS16.1] [CENTRAL: 962115] [CFGD REGISTER: CO53a] BallmannM , HubertD , AssaelBM , StaabD , HebestreitA , NaehrlichL , et al. Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. The Lancet Diabetes and Endocrinology2018;6(2):114-21. [CFGD REGISTER: CO53e] [DOI: 10.1016/S2213-8587(17)30400-X]SchmidK , FinkK , HollRW , HebestreitH , BallmannM . Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2014;13(1):80-5. [CENTRAL: 1000302] [CFGD REGISTER: CO53d] [JID: 101128966] [PMID: 23809507] [SI: ClinicalTrials.gov/NCT00662714]">Ballmann 2018b</a>; <a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>), but there was no statistically significant result between groups, MD ‐0.51 % predicted (95% CI ‐4.22 to 3.20) (<a href="./references#CD004730-fig-0010" title="">Analysis 3.2</a>) (moderate‐quality evidence). Only Ballmann reported this outcome at the two‐year time point (n = 67) and again results showed no significant difference between groups, MD ‐0.10 % predicted (95% CI ‐4.12 to 3.92) (<a href="./references#CD004730-fig-0010" title="">Analysis 3.2</a>). </p> </section> <section id="CD004730-sec-0091"> <p><b>FVC</b></p> <p>The same two trials reported on FVC (% predicted) (n = 112) (<a href="./references#CD004730-bbs2-0001" title="BallmannM , HubertD , AssaelBM , KronfeldK , HonerM , HollRW , et al. Open randomised prospective comparative multi-centre intervention study of patients with cystic fibrosis and early diagnosed diabetes mellitus. BMC Pediatrics2014;14:70. [CENTRAL: 1000301] [CFGD REGISTER: CO53c] [JID: 100967804] [OID: NLM: PMC3975280] [PMCID: PMC3975280] [PMID: 24620855]BallmannM , HubertD , AssaelBM , Mosnier-PudarH , Barao OcampoM , ScheunigN , et al. Repaglinide versus insulin in the treatment of CFRD diagnosed by screening: an open prospective randomized study. Pediatric Pulmonology2013;48 Suppl 26:421. [ABSTRACT NO.: 582] [CENTRAL: 962122] [CFGD REGISTER: CO53b] BallmannM , HubertD , AssaelBM , Mosnier-PudarH , SmacznyC , KesslerL , et al. Treatment of early diagnosed CFRD with oral drugs verus insulin: An open prospective randomized study. Journal of Cystic Fibrosis2013;12 Suppl 1:S32. [ABSTRACT NO.: WS16.1] [CENTRAL: 962115] [CFGD REGISTER: CO53a] BallmannM , HubertD , AssaelBM , StaabD , HebestreitA , NaehrlichL , et al. Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. The Lancet Diabetes and Endocrinology2018;6(2):114-21. [CFGD REGISTER: CO53e] [DOI: 10.1016/S2213-8587(17)30400-X]SchmidK , FinkK , HollRW , HebestreitH , BallmannM . Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2014;13(1):80-5. [CENTRAL: 1000302] [CFGD REGISTER: CO53d] [JID: 101128966] [PMID: 23809507] [SI: ClinicalTrials.gov/NCT00662714]">Ballmann 2018b</a>; <a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). The analysis showed a non‐significant difference between groups at 12 months (n = 112), MD ‐1.00 % predicted (95% CI ‐4.29 to 2.29) (<a href="./references#CD004730-fig-0011" title="">Analysis 3.3</a>) (moderate‐quality evidence). Only Ballmann reported this outcome at the two‐year time point (n = 67) and again results showed no significant difference between groups, MD ‐3.40 % predicted (95% CI ‐7.37 to 0.57) (<a href="./references#CD004730-fig-0011" title="">Analysis 3.3</a>). </p> </section> </section> <section id="CD004730-sec-0092"> <h6 class="title">3. Assessment of nutritional status</h6> <p>One trial (n = 45) comparing insulin and repaglinide demonstrated a non‐significant MD in BMI of 0.24 (95% CI ‐0.34 to 0.82) (<a href="./references#CD004730-fig-0012" title="">Analysis 3.4</a>) (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>) (low‐quality evidence). </p> <p>The more recent study reported the change in BMI z score (<a href="./references#CD004730-bbs2-0001" title="BallmannM , HubertD , AssaelBM , KronfeldK , HonerM , HollRW , et al. Open randomised prospective comparative multi-centre intervention study of patients with cystic fibrosis and early diagnosed diabetes mellitus. BMC Pediatrics2014;14:70. [CENTRAL: 1000301] [CFGD REGISTER: CO53c] [JID: 100967804] [OID: NLM: PMC3975280] [PMCID: PMC3975280] [PMID: 24620855]BallmannM , HubertD , AssaelBM , Mosnier-PudarH , Barao OcampoM , ScheunigN , et al. Repaglinide versus insulin in the treatment of CFRD diagnosed by screening: an open prospective randomized study. Pediatric Pulmonology2013;48 Suppl 26:421. [ABSTRACT NO.: 582] [CENTRAL: 962122] [CFGD REGISTER: CO53b] BallmannM , HubertD , AssaelBM , Mosnier-PudarH , SmacznyC , KesslerL , et al. Treatment of early diagnosed CFRD with oral drugs verus insulin: An open prospective randomized study. Journal of Cystic Fibrosis2013;12 Suppl 1:S32. [ABSTRACT NO.: WS16.1] [CENTRAL: 962115] [CFGD REGISTER: CO53a] BallmannM , HubertD , AssaelBM , StaabD , HebestreitA , NaehrlichL , et al. Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. The Lancet Diabetes and Endocrinology2018;6(2):114-21. [CFGD REGISTER: CO53e] [DOI: 10.1016/S2213-8587(17)30400-X]SchmidK , FinkK , HollRW , HebestreitH , BallmannM . Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2014;13(1):80-5. [CENTRAL: 1000302] [CFGD REGISTER: CO53d] [JID: 101128966] [PMID: 23809507] [SI: ClinicalTrials.gov/NCT00662714]">Ballmann 2018b</a>). The updated analysis (using data from the full paper and not previous abstracts) no longer showed significant improvement in z score in the insulin treatment group compared to repaglinide at 12 months (n = 67), MD 0.00 (95%CI ‐0.49 to 0.49), and this difference remains non‐significant at the two‐year point (n = 67), MD 0.40 (95% CI ‐0.09 to 0.89) (<a href="./references#CD004730-fig-0013" title="">Analysis 3.5</a>). </p> </section> </section> <section id="CD004730-sec-0093"> <h5 class="title">Secondary Outcomes</h5> <section id="CD004730-sec-0094"> <h6 class="title">2. Prevalence of secondary infection complications</h6> <p>Only one trial reported the prevalence of secondary infection; while this was not detailed, the authors did state that there were no differences in the number of episodes of acute illness during the one‐year trial in either treatment arm (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). </p> </section> <section id="CD004730-sec-0095"> <h6 class="title">3. Complications of therapeutic management</h6> <section id="CD004730-sec-0096"> <p><b>a. hypoglycemia (specifically related to oral hypoglycemic and insulin agents)</b></p> <p>In the earlier trial, the investigators reported two incidences of hypoglycemia (glucose level 48 to 54 mg/dL, 2.7 to 3.0 mmol/L) after receiving insulin and one after administration of repaglinide. In all cases catecholamine‐related symptoms were present but easily tolerated. These episodes occurred on average four hours after the test meal and resolved spontaneously without glucose administration after 10 to 15 minutes (<a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>). When entered into the analysis, the result showed no difference between the groups, RR 0.50 (95% CI 0.06 to 4.33) (<a href="./references#CD004730-fig-0014" title="">Analysis 3.6</a>) (low‐quality evidence). </p> <p>The later trial also reported mild hypoglycemic events (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). These occurred in 16% of participants in the insulin group and 23% of participants in the repaglinide group at up to three months; after three months, this difference was no longer detected (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). Data were analysed in the graphs for the three‐month time point and did not give a statistically significant result, RR 1.38 (95% CI 0.48 to 4.01) (<a href="./references#CD004730-fig-0014" title="">Analysis 3.6</a>) (low‐quality evidence). No information was available as to whether these participants had CFRD or IGT. </p> </section> </section> <section id="CD004730-sec-0097"> <h6 class="title">4. Clinical status</h6> <section id="CD004730-sec-0098"> <p><b>b. HRQoL</b></p> <p>Only Moran assessed this outcome and specific data were not presented; however, the authors did state that CFQoL scores did not differ between groups at the end of the treatment year (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). </p> </section> <section id="CD004730-sec-0099"> <p><b>c. mortality</b></p> <p>Mortality was not specifically reported for either trial, but details of participants leaving the trial were recorded and none from insulin, repaglinide nor the placebo groups were excluded as a result of mortality (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). </p> </section> </section> </section> </section> <section id="CD004730-sec-0100"> <h4 class="title">NPH insulin versus glargine</h4> <p>Only one trial (n = 20) reported on this comparison; the trial was of cross‐over design, but we treated it as a parallel trial since data were not available to analyse them correctly (<a href="./references#CD004730-bbs2-0002" title="GroverP , ThomasW , MoranA . Glargine versus NPH insulin in cystic fibrosis related diabetes. Journal of Cystic Fibrosis2008;7(2):134-6. [CFGD REGISTER: CO39] ">Grover 2008</a>). There was a washout period of one month which separated either 12 weeks receiving NPH at bedtime or 12 weeks receiving glargine at bedtime. A summary of the evidence is presented in the tables (<a href="./full#CD004730-tbl-0004">summary of findings Table 4</a>). </p> <section id="CD004730-sec-0101"> <h5 class="title">Primary outcomes</h5> <section id="CD004730-sec-0102"> <h6 class="title">1. Biochemical measures of glycemic control</h6> <p>Results for neither fasting nor two‐hour post‐prandial glucose values were significant: fasting glucose, MD 10.00 mg/dl (95% CI ‐12.86 to 32.86); and two‐hour post‐prandial, MD 8.00 mg/dl (95% CI ‐10.07 to 26.07) (<a href="./references#CD004730-fig-0015" title="">Analysis 4.1</a>). </p> </section> <section id="CD004730-sec-0103"> <h6 class="title">3. Assessment of nutritional status</h6> <p>Grover reported a mean change in weight in the glargine group of 1.2 kg compared to a mean change of 0.2 kg in the NPH group resulting in a non‐significant MD ‐1.00 kg (95% CI ‐2.39 to 0.39) (<a href="./references#CD004730-fig-0016" title="">Analysis 4.2</a>). Grover also assessed both fat mass and lean mass measured by DEXA scans (<a href="./references#CD004730-bbs2-0002" title="GroverP , ThomasW , MoranA . Glargine versus NPH insulin in cystic fibrosis related diabetes. Journal of Cystic Fibrosis2008;7(2):134-6. [CFGD REGISTER: CO39] ">Grover 2008</a>). Neither outcome was statistically significant: fat mass, MD ‐0.30 kg (95% CI ‐1.41 to 0.81) (<a href="./references#CD004730-fig-0017" title="">Analysis 4.3</a>); and lean mass, MD ‐0.20 kg (95% CI ‐0.75 to 0.35) (<a href="./references#CD004730-fig-0018" title="">Analysis 4.4</a>). </p> </section> </section> <section id="CD004730-sec-0104"> <h5 class="title">Secondary Outcomes</h5> <section id="CD004730-sec-0105"> <h6 class="title">2. Prevalence of secondary infection complications</h6> <p>In the short time course of this study, no infectious complications were reported for either group of participants (<a href="./references#CD004730-bbs2-0002" title="GroverP , ThomasW , MoranA . Glargine versus NPH insulin in cystic fibrosis related diabetes. Journal of Cystic Fibrosis2008;7(2):134-6. [CFGD REGISTER: CO39] ">Grover 2008</a>). </p> </section> <section id="CD004730-sec-0106"> <h6 class="title">3. Complications of therapeutic management</h6> <section id="CD004730-sec-0107"> <p><b>a. hypoglycemia (specifically related to oral hypoglycemic and insulin agents)</b></p> <p>Grover reported the mean number of minor hypoglycemic episodes per participant, but there was no statistically significant difference between the groups, MD ‐1.00 (95% CI ‐3.77 to 1.77) (<a href="./references#CD004730-fig-0019" title="">Analysis 4.5</a>) (very low‐quality evidence). </p> </section> </section> <section id="CD004730-sec-0108"> <h6 class="title">4. Clinical status</h6> <section id="CD004730-sec-0109"> <p><b>b. HRQoL</b></p> <p>The paper reported that no difference in QoL was observed and that all participants opted to continue treatment with glargine after the trial was completed (<a href="./references#CD004730-bbs2-0002" title="GroverP , ThomasW , MoranA . Glargine versus NPH insulin in cystic fibrosis related diabetes. Journal of Cystic Fibrosis2008;7(2):134-6. [CFGD REGISTER: CO39] ">Grover 2008</a>). </p> </section> <section id="CD004730-sec-0110"> <p><b>c. mortality</b></p> <p>No mortality was reported for either treatment group; however, there was no reason given for the loss of the participant from the NPH group (<a href="./references#CD004730-bbs2-0002" title="GroverP , ThomasW , MoranA . Glargine versus NPH insulin in cystic fibrosis related diabetes. Journal of Cystic Fibrosis2008;7(2):134-6. [CFGD REGISTER: CO39] ">Grover 2008</a>). </p> </section> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD004730-sec-0111" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD004730-sec-0111"></div> <section id="CD004730-sec-0112"> <h3 class="title" id="CD004730-sec-0112">Summary of main results</h3> <p>The prevalence of diabetes in pwCF increases throughout adulthood to rates as high as 50% (<a href="./references#CD004730-bbs2-0043" title="MoranA , BrunzellC , CohenRC , KatzM , MarshallBC , OnadyG , et al. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care2010;33(12):2697-708.">Moran 2010</a>), with a 3.6‐fold increase in mortality from the additional complication of CFRD in the clinical course of disease (<a href="./references#CD004730-bbs2-0041" title="MoheetA , MoranA . CF-related diabetes: Containing the metabolic miscreant of cystic fibrosis. Pediatric Pulmonology2017;52(S48):S37-S43. [DOI: 10.1002/ppul.23762]">Moheet 2017</a>). The impact of therapy and the extent to which diabetic control can be achieved is just beginning to be addressed. </p> <p>We have included four trials (n = 145) in this review (<a href="./references#CD004730-bbs2-0001" title="BallmannM , HubertD , AssaelBM , KronfeldK , HonerM , HollRW , et al. Open randomised prospective comparative multi-centre intervention study of patients with cystic fibrosis and early diagnosed diabetes mellitus. BMC Pediatrics2014;14:70. [CENTRAL: 1000301] [CFGD REGISTER: CO53c] [JID: 100967804] [OID: NLM: PMC3975280] [PMCID: PMC3975280] [PMID: 24620855]BallmannM , HubertD , AssaelBM , Mosnier-PudarH , Barao OcampoM , ScheunigN , et al. Repaglinide versus insulin in the treatment of CFRD diagnosed by screening: an open prospective randomized study. Pediatric Pulmonology2013;48 Suppl 26:421. [ABSTRACT NO.: 582] [CENTRAL: 962122] [CFGD REGISTER: CO53b] BallmannM , HubertD , AssaelBM , Mosnier-PudarH , SmacznyC , KesslerL , et al. Treatment of early diagnosed CFRD with oral drugs verus insulin: An open prospective randomized study. Journal of Cystic Fibrosis2013;12 Suppl 1:S32. [ABSTRACT NO.: WS16.1] [CENTRAL: 962115] [CFGD REGISTER: CO53a] BallmannM , HubertD , AssaelBM , StaabD , HebestreitA , NaehrlichL , et al. Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. The Lancet Diabetes and Endocrinology2018;6(2):114-21. [CFGD REGISTER: CO53e] [DOI: 10.1016/S2213-8587(17)30400-X]SchmidK , FinkK , HollRW , HebestreitH , BallmannM . Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2014;13(1):80-5. [CENTRAL: 1000302] [CFGD REGISTER: CO53d] [JID: 101128966] [PMID: 23809507] [SI: ClinicalTrials.gov/NCT00662714]">Ballmann 2018b</a>; <a href="./references#CD004730-bbs2-0002" title="GroverP , ThomasW , MoranA . Glargine versus NPH insulin in cystic fibrosis related diabetes. Journal of Cystic Fibrosis2008;7(2):134-6. [CFGD REGISTER: CO39] ">Grover 2008</a>; <a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>; <a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). Three of these trials compared insulin to repaglinide (<a href="./references#CD004730-bbs2-0001" title="BallmannM , HubertD , AssaelBM , KronfeldK , HonerM , HollRW , et al. Open randomised prospective comparative multi-centre intervention study of patients with cystic fibrosis and early diagnosed diabetes mellitus. BMC Pediatrics2014;14:70. [CENTRAL: 1000301] [CFGD REGISTER: CO53c] [JID: 100967804] [OID: NLM: PMC3975280] [PMCID: PMC3975280] [PMID: 24620855]BallmannM , HubertD , AssaelBM , Mosnier-PudarH , Barao OcampoM , ScheunigN , et al. Repaglinide versus insulin in the treatment of CFRD diagnosed by screening: an open prospective randomized study. Pediatric Pulmonology2013;48 Suppl 26:421. [ABSTRACT NO.: 582] [CENTRAL: 962122] [CFGD REGISTER: CO53b] BallmannM , HubertD , AssaelBM , Mosnier-PudarH , SmacznyC , KesslerL , et al. Treatment of early diagnosed CFRD with oral drugs verus insulin: An open prospective randomized study. Journal of Cystic Fibrosis2013;12 Suppl 1:S32. [ABSTRACT NO.: WS16.1] [CENTRAL: 962115] [CFGD REGISTER: CO53a] BallmannM , HubertD , AssaelBM , StaabD , HebestreitA , NaehrlichL , et al. Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. The Lancet Diabetes and Endocrinology2018;6(2):114-21. [CFGD REGISTER: CO53e] [DOI: 10.1016/S2213-8587(17)30400-X]SchmidK , FinkK , HollRW , HebestreitH , BallmannM . Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2014;13(1):80-5. [CENTRAL: 1000302] [CFGD REGISTER: CO53d] [JID: 101128966] [PMID: 23809507] [SI: ClinicalTrials.gov/NCT00662714]">Ballmann 2018b</a>; <a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>; <a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>); one was a two‐arm parallel trial (<a href="./references#CD004730-bbs2-0001" title="BallmannM , HubertD , AssaelBM , KronfeldK , HonerM , HollRW , et al. Open randomised prospective comparative multi-centre intervention study of patients with cystic fibrosis and early diagnosed diabetes mellitus. BMC Pediatrics2014;14:70. [CENTRAL: 1000301] [CFGD REGISTER: CO53c] [JID: 100967804] [OID: NLM: PMC3975280] [PMCID: PMC3975280] [PMID: 24620855]BallmannM , HubertD , AssaelBM , Mosnier-PudarH , Barao OcampoM , ScheunigN , et al. Repaglinide versus insulin in the treatment of CFRD diagnosed by screening: an open prospective randomized study. Pediatric Pulmonology2013;48 Suppl 26:421. [ABSTRACT NO.: 582] [CENTRAL: 962122] [CFGD REGISTER: CO53b] BallmannM , HubertD , AssaelBM , Mosnier-PudarH , SmacznyC , KesslerL , et al. Treatment of early diagnosed CFRD with oral drugs verus insulin: An open prospective randomized study. Journal of Cystic Fibrosis2013;12 Suppl 1:S32. [ABSTRACT NO.: WS16.1] [CENTRAL: 962115] [CFGD REGISTER: CO53a] BallmannM , HubertD , AssaelBM , StaabD , HebestreitA , NaehrlichL , et al. Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. The Lancet Diabetes and Endocrinology2018;6(2):114-21. [CFGD REGISTER: CO53e] [DOI: 10.1016/S2213-8587(17)30400-X]SchmidK , FinkK , HollRW , HebestreitH , BallmannM . Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2014;13(1):80-5. [CENTRAL: 1000302] [CFGD REGISTER: CO53d] [JID: 101128966] [PMID: 23809507] [SI: ClinicalTrials.gov/NCT00662714]">Ballmann 2018b</a>), whereas the remaining two trials had a third arm of either no medication (<a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>) or placebo (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). One of these was a short‐term RCT (<a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>), which has evolved into a three‐arm multicenter RCT comparing insulin to repaglinide and placebo over a 12‐month period (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). The later trial allowed us to generate additional comparisons of insulin versus placebo and repaglinide versus placebo (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). The fourth included trial compared NPH insulin and glargine over a three‐month period (<a href="./references#CD004730-bbs2-0002" title="GroverP , ThomasW , MoranA . Glargine versus NPH insulin in cystic fibrosis related diabetes. Journal of Cystic Fibrosis2008;7(2):134-6. [CFGD REGISTER: CO39] ">Grover 2008</a>). </p> <section id="CD004730-sec-0113"> <h4 class="title">Insulin versus control</h4> <p>One cross‐over trial (n = 7) compared insulin to no treatment (<a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>) and the three‐arm parallel trial (n = 61, n = 39 for this comparison) compared insulin to a placebo (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). Only the placebo‐controlled trial provided analysable data and reported that A1C levels did not significantly change in the insulin group compared to the placebo group(very low‐quality evidence) (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). This trial also reported on lung function and nutritional status (BMI) finding no differences between insulin and placebo at 12 months for either of these outcomes (low‐quality evidence) (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). Neither trial showed any difference in incidences of hypoglycemia (low‐quality evidence) (<a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>; <a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). The placebo‐controlled trial reported no difference in the number of episodes of acute illness or CFQOL scores between groups and while mortality was not specifically reported, no participants were excluded due to mortality (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). </p> </section> <section id="CD004730-sec-0114"> <h4 class="title">Repaglinide versus control</h4> <p>The three‐arm parallel trial (n = 61, n = 38 for this comparison) compared repaglinide to placebo (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). Investigators found no differences in A1C levels (very low‐quality evidence), lung function (low‐quality evidence), nutritional status (BMI) (low‐quality evidence), the number of episodes of acute illness or hypoglycemia (very low‐quality evidence), or in CFQOL scores between groups (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). While mortality was not specifically reported, no participants were excluded due to mortality (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). </p> </section> <section id="CD004730-sec-0115"> <h4 class="title">Insulin versus repaglinide</h4> <p>Three trials (n = 119) compared insulin to repaglinide (<a href="./references#CD004730-bbs2-0001" title="BallmannM , HubertD , AssaelBM , KronfeldK , HonerM , HollRW , et al. Open randomised prospective comparative multi-centre intervention study of patients with cystic fibrosis and early diagnosed diabetes mellitus. BMC Pediatrics2014;14:70. [CENTRAL: 1000301] [CFGD REGISTER: CO53c] [JID: 100967804] [OID: NLM: PMC3975280] [PMCID: PMC3975280] [PMID: 24620855]BallmannM , HubertD , AssaelBM , Mosnier-PudarH , Barao OcampoM , ScheunigN , et al. Repaglinide versus insulin in the treatment of CFRD diagnosed by screening: an open prospective randomized study. Pediatric Pulmonology2013;48 Suppl 26:421. [ABSTRACT NO.: 582] [CENTRAL: 962122] [CFGD REGISTER: CO53b] BallmannM , HubertD , AssaelBM , Mosnier-PudarH , SmacznyC , KesslerL , et al. Treatment of early diagnosed CFRD with oral drugs verus insulin: An open prospective randomized study. Journal of Cystic Fibrosis2013;12 Suppl 1:S32. [ABSTRACT NO.: WS16.1] [CENTRAL: 962115] [CFGD REGISTER: CO53a] BallmannM , HubertD , AssaelBM , StaabD , HebestreitA , NaehrlichL , et al. Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. The Lancet Diabetes and Endocrinology2018;6(2):114-21. [CFGD REGISTER: CO53e] [DOI: 10.1016/S2213-8587(17)30400-X]SchmidK , FinkK , HollRW , HebestreitH , BallmannM . Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2014;13(1):80-5. [CENTRAL: 1000302] [CFGD REGISTER: CO53d] [JID: 101128966] [PMID: 23809507] [SI: ClinicalTrials.gov/NCT00662714]">Ballmann 2018b</a>; <a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>; <a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). Data from one parallel trial (n = 67) showed no difference in A1C levels between insulin and repaglinide at either 12 months (high‐quality evidence) or at 24 months (<a href="./references#CD004730-bbs2-0001" title="BallmannM , HubertD , AssaelBM , KronfeldK , HonerM , HollRW , et al. Open randomised prospective comparative multi-centre intervention study of patients with cystic fibrosis and early diagnosed diabetes mellitus. BMC Pediatrics2014;14:70. [CENTRAL: 1000301] [CFGD REGISTER: CO53c] [JID: 100967804] [OID: NLM: PMC3975280] [PMCID: PMC3975280] [PMID: 24620855]BallmannM , HubertD , AssaelBM , Mosnier-PudarH , Barao OcampoM , ScheunigN , et al. Repaglinide versus insulin in the treatment of CFRD diagnosed by screening: an open prospective randomized study. Pediatric Pulmonology2013;48 Suppl 26:421. [ABSTRACT NO.: 582] [CENTRAL: 962122] [CFGD REGISTER: CO53b] BallmannM , HubertD , AssaelBM , Mosnier-PudarH , SmacznyC , KesslerL , et al. Treatment of early diagnosed CFRD with oral drugs verus insulin: An open prospective randomized study. Journal of Cystic Fibrosis2013;12 Suppl 1:S32. [ABSTRACT NO.: WS16.1] [CENTRAL: 962115] [CFGD REGISTER: CO53a] BallmannM , HubertD , AssaelBM , StaabD , HebestreitA , NaehrlichL , et al. Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. The Lancet Diabetes and Endocrinology2018;6(2):114-21. [CFGD REGISTER: CO53e] [DOI: 10.1016/S2213-8587(17)30400-X]SchmidK , FinkK , HollRW , HebestreitH , BallmannM . Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2014;13(1):80-5. [CENTRAL: 1000302] [CFGD REGISTER: CO53d] [JID: 101128966] [PMID: 23809507] [SI: ClinicalTrials.gov/NCT00662714]">Ballmann 2018b</a>). The remaining two trials did not provide analysable data, but the cross‐over trial (n = 7) reported that insulin lispro seemed to have a more beneficial effect than repaglinide on post‐meal glucose excursion and peak glucose levels at both two and five hours (<a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>). The later parallel trial (n = 61, n = 45 for this comparison) did not report any differences in post‐prandial glucose or A1C levels between groups (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). The two parallel trials (n = 112) found no difference between insulin and repaglinide in lung function (moderate‐quality evidence), nutritional status (low‐quality evidence), or the number of hypoglycemic episodes (low‐quality evidence) (<a href="./references#CD004730-bbs2-0001" title="BallmannM , HubertD , AssaelBM , KronfeldK , HonerM , HollRW , et al. Open randomised prospective comparative multi-centre intervention study of patients with cystic fibrosis and early diagnosed diabetes mellitus. BMC Pediatrics2014;14:70. [CENTRAL: 1000301] [CFGD REGISTER: CO53c] [JID: 100967804] [OID: NLM: PMC3975280] [PMCID: PMC3975280] [PMID: 24620855]BallmannM , HubertD , AssaelBM , Mosnier-PudarH , Barao OcampoM , ScheunigN , et al. Repaglinide versus insulin in the treatment of CFRD diagnosed by screening: an open prospective randomized study. Pediatric Pulmonology2013;48 Suppl 26:421. [ABSTRACT NO.: 582] [CENTRAL: 962122] [CFGD REGISTER: CO53b] BallmannM , HubertD , AssaelBM , Mosnier-PudarH , SmacznyC , KesslerL , et al. Treatment of early diagnosed CFRD with oral drugs verus insulin: An open prospective randomized study. Journal of Cystic Fibrosis2013;12 Suppl 1:S32. [ABSTRACT NO.: WS16.1] [CENTRAL: 962115] [CFGD REGISTER: CO53a] BallmannM , HubertD , AssaelBM , StaabD , HebestreitA , NaehrlichL , et al. Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. The Lancet Diabetes and Endocrinology2018;6(2):114-21. [CFGD REGISTER: CO53e] [DOI: 10.1016/S2213-8587(17)30400-X]SchmidK , FinkK , HollRW , HebestreitH , BallmannM . Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2014;13(1):80-5. [CENTRAL: 1000302] [CFGD REGISTER: CO53d] [JID: 101128966] [PMID: 23809507] [SI: ClinicalTrials.gov/NCT00662714]">Ballmann 2018b</a>; <a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). Only the later Moran trial (n = 45) reported on secondary infections and CFQOL and found no difference between groups for either outcome (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). While mortality was not specifically reported, one trial (n = 45) reported that no participants were excluded due to mortality (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). </p> <p>The later Moran trial identified a slightly more favorable response to insulin and when factoring in the 12‐month pre‐treatment run‐in period the results demonstrated a significant advantage. There were clear differences in the slope of BMI change between the insulin and repaglinide groups during this run‐in period. In this review, when factoring out the run‐in period which was presented in the original paper, the significance of results vanished and there are no differences between treatment groups (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). </p> </section> <section id="CD004730-sec-0116"> <h4 class="title">NPH insulin versus glargine</h4> <p>One cross‐over trial (n = 20) compared receiving NPH at bedtime to receiving glargine at bedtime, with a washout period of one month separating each 12‐week treatment arm; however, due to the limited data available we analysed this trial as if it was of parallel design (<a href="./references#CD004730-bbs2-0002" title="GroverP , ThomasW , MoranA . Glargine versus NPH insulin in cystic fibrosis related diabetes. Journal of Cystic Fibrosis2008;7(2):134-6. [CFGD REGISTER: CO39] ">Grover 2008</a>). </p> <p>The trial did not report results for HbA1c, but did report no differences between groups in either fasting or two‐hour post‐prandial glucose values. The trial did not report lung function. In terms of nutritional status, BMI was not reported but there were no differences observed between groups for the change in weight (kg), fat mass (kg) or lean mass (kg). No infectious complications were reported by either group during the trial. There was no difference in the number of minor hypoglycemic episodes per participant between groups (very low‐quality evidence); and while there was no difference reported in QoL, all participants opted to continue treatment with glargine after the trial was completed. No mortality was reported for either treatment group; however, there was no reason given for the loss of the participant from the NPH group (<a href="./references#CD004730-bbs2-0002" title="GroverP , ThomasW , MoranA . Glargine versus NPH insulin in cystic fibrosis related diabetes. Journal of Cystic Fibrosis2008;7(2):134-6. [CFGD REGISTER: CO39] ">Grover 2008</a>). </p> <p>The only clear conclusion from the comparison NPH insulin and glargine over a three‐month period that we can draw at this time, is that while fasting glucose may be diminished by 2 mg/dL for the long‐acting insulin glargine, there is no significant therapeutic advantage in treating people with CFRD and fasting hyperglycemia with glargine insulin compared to protamine‐Hagedorn insulin (<a href="./references#CD004730-bbs2-0002" title="GroverP , ThomasW , MoranA . Glargine versus NPH insulin in cystic fibrosis related diabetes. Journal of Cystic Fibrosis2008;7(2):134-6. [CFGD REGISTER: CO39] ">Grover 2008</a>).  </p> </section> </section> <section id="CD004730-sec-0117"> <h3 class="title" id="CD004730-sec-0117">Overall completeness and applicability of evidence</h3> <p>The two Moran trials only investigated a subgroup of people with CFRD with normal fasting glucose values (<a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>; <a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). All of the studies reported in this Cochrane Review were focused on adults, so these results cannot be extrapolated to children which would demonstrate an earlier subset of diabetes onset (<a href="./references#CD004730-bbs2-0001" title="BallmannM , HubertD , AssaelBM , KronfeldK , HonerM , HollRW , et al. Open randomised prospective comparative multi-centre intervention study of patients with cystic fibrosis and early diagnosed diabetes mellitus. BMC Pediatrics2014;14:70. [CENTRAL: 1000301] [CFGD REGISTER: CO53c] [JID: 100967804] [OID: NLM: PMC3975280] [PMCID: PMC3975280] [PMID: 24620855]BallmannM , HubertD , AssaelBM , Mosnier-PudarH , Barao OcampoM , ScheunigN , et al. Repaglinide versus insulin in the treatment of CFRD diagnosed by screening: an open prospective randomized study. Pediatric Pulmonology2013;48 Suppl 26:421. [ABSTRACT NO.: 582] [CENTRAL: 962122] [CFGD REGISTER: CO53b] BallmannM , HubertD , AssaelBM , Mosnier-PudarH , SmacznyC , KesslerL , et al. Treatment of early diagnosed CFRD with oral drugs verus insulin: An open prospective randomized study. Journal of Cystic Fibrosis2013;12 Suppl 1:S32. [ABSTRACT NO.: WS16.1] [CENTRAL: 962115] [CFGD REGISTER: CO53a] BallmannM , HubertD , AssaelBM , StaabD , HebestreitA , NaehrlichL , et al. Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. The Lancet Diabetes and Endocrinology2018;6(2):114-21. [CFGD REGISTER: CO53e] [DOI: 10.1016/S2213-8587(17)30400-X]SchmidK , FinkK , HollRW , HebestreitH , BallmannM . Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2014;13(1):80-5. [CENTRAL: 1000302] [CFGD REGISTER: CO53d] [JID: 101128966] [PMID: 23809507] [SI: ClinicalTrials.gov/NCT00662714]">Ballmann 2018b</a>; <a href="./references#CD004730-bbs2-0002" title="GroverP , ThomasW , MoranA . Glargine versus NPH insulin in cystic fibrosis related diabetes. Journal of Cystic Fibrosis2008;7(2):134-6. [CFGD REGISTER: CO39] ">Grover 2008</a>; <a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>; <a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). </p> </section> <section id="CD004730-sec-0118"> <h3 class="title" id="CD004730-sec-0118">Quality of the evidence</h3> <p>The participant numbers in the trials included in this review were quite small, and the trials were not powered for important clinical outcomes such as FEV<sub>1</sub>. In the only trial where powering was adequate for comparisons of BMI, lead‐in bias places some concern as to the validity of the reported outcome (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). We had hoped to be able to pool data so as to improve on the quality of the currently available evidence, unfortunately there were too many differences between the trials included in the review to allow this, except for one lung function outcome at the 12‐month time point (<a href="./references#CD004730-fig-0010" title="">Analysis 3.2</a>). </p> <p>The quality of the evidence as evaluated by GRADE ranged from very low to high (<a href="./full#CD004730-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD004730-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD004730-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD004730-tbl-0004">summary of findings Table 4</a>). Reasons for downgrading the quality of the evidence included risks of bias across all domains, but particularly due to concerns surrounding allocation concealment and selective reporting. We also had some concerns due to imprecision from small sample sizes (numbers of participants ranged from seven to 67) and low event rates. </p> </section> <section id="CD004730-sec-0119"> <h3 class="title" id="CD004730-sec-0119">Potential biases in the review process</h3> <p>Any potential bias is limited due to comprehensive searches with no limit on publication status or language, with adherence to Cochrane methodology. </p> </section> <section id="CD004730-sec-0120"> <h3 class="title" id="CD004730-sec-0120">Agreements and disagreements with other studies or reviews</h3> <p>Some CF centers use oral medications to help control diabetes, yet insulin remains the accepted as the treatment or intervention of choice as reported in the CFRD Clinical Practice Guidelines (<a href="./references#CD004730-bbs2-0043" title="MoranA , BrunzellC , CohenRC , KatzM , MarshallBC , OnadyG , et al. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care2010;33(12):2697-708.">Moran 2010</a>) and as evident from the interventions investigated in the limited number of trials that have been evaluated for this Cochrane Review. A cohort study has demonstrated the use of insulin in maintaining a HbA1c below 7% and also a significant reduction in microvascular disease for CFRD (<a href="./references#CD004730-bbs2-0049" title="SchwarzenbergSJ , ThomasW , OlsenTW , GroverT , WalkD , MillaC , et al. Microvascular complications in cystic fibrosis-related diabetes. Diabetes Care2007;30(5):1056-61.">Schwarzenberg 2007</a>); however, trials have yet to significantly demonstrate the long‐term impact of insulin therapy on lung function. Outcomes reported in the trials included in this review did not demonstrate a significant impact on lung function between the insulins or oral agents identified from the trials. Despite this finding, a single negative outcome trial identified in this current Cochrane Review continues to be cited as a positive trial (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>) and used to further support insulin‐only therapy (<a href="./references#CD004730-bbs2-0050" title="WarrenRE . Cystic fibrosis and insulin therapy: a reality check. Diabetic Medicine2019;00:1-5. [DOI: 10.1111/dme.13959]">Warren 2019</a>). Such reporting needs to be placed in context when considering that a multicenter comprehensive prospective cohort study identifies that only 47% of people diagnosed with CFRD elect to start on insulin therapy, with 41% choosing no therapy (<a href="./references#CD004730-bbs2-0031" title="Ballmann, MW, WosnickJ , FischerD . Treatment of CFRD diagnosed by annual OGT screening: real life data from a longitudinal registry study from Germany. Pediatric Pulmonology2018;53 Supplement 2:398. [ABSTRACT NO.: 651]">Ballmann 2018a</a>). These authors conclude that the treatment burden of insulin is in part a reason that there is such a low acceptance to initiate therapy for managing diagnosed diabetes and oral hypoglycemic agents, e.g. repaglinide, are already being used as an alternative to insulin to reduce the treatment burden for pwCF diagnosed with diabetes. </p> <p>Similar to the two Moran trials which only investigated a subgroup of people with CFRD with normal fasting glucose values (<a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>; <a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>), other non‐randomized clinical trials of oral hypoglycemic agents have found that these drugs usually only demonstrate a clinical advantage in this subgroup of people with CF for about the first six months of therapy (<a href="./references#CD004730-bbs2-0032" title="CullerFL , McKeanLP , BuchananCN , CaplanDB , MeachamLR . Glipizide treatment of patients with cystic fibrosis and impaired glucose tolerance. Journal of Pediatric Gastroenterology and Nutrition1994;18(3):375-8.">Culler 1994</a>; <a href="./references#CD004730-bbs2-0046" title="RoseneckerJ , EichlerI , BarmeierH , von derHardtH . Diabetes mellitus and cystic fibrosis: comparison of clinical parameters in patients treated with insulin versus oral glucose-lowering agents. Pediatric Pulmonlogy2001;32(5):351-5.">Rosenecker 2001</a>). </p> <p>With this updated Cochrane Review, we have observed a trend of studies (that are out of the review's scope) but which are beginning to evaluate impaired glucose tolerance with a view to the potential benefits of earlier intervention using long‐acting insulin (<a href="./references#CD004730-bbs2-0044" title="PuMZ , Christensen-AdadFC , GonçalvesAC , MinicucciWJ , RibeiroJD , RibeiroAF . Insulin therapy in patients with cystic fibrosis in the pre-diabetes stage: a systematic review. Revista Paulistade Pediatria2016;34(3):367-73. [DOI: 10.1016/j.rpped.2015.12.010]">Pu 2016</a>; <a href="./references#CD004730-bbs2-0017" title="MinicucciL , CasciaroR , De AlessandriA , HauptM , CasoM , LucidiV , et al. Efficacy of slow release insulin in patients with cystic fibrosis and glucide intolerance. Journal of Cystic Fibrosis2009;8 (Suppl 2):S82. [ABSTRACT NO.: 331] [CFGD REGISTER: CO42b] MinicucciL , HauptM , CasciaroR , De AlessandriA , BagnascoF , LucidiV , et al. Slow-release insulin in cystic fibrosis patients with glucose intolerance: a randomized clinical trial. Pediatric Diabetes2012;13(2):197-202. [CFGD REGISTER: CO42c] MinicucciL . New diagnostic and therapeutic approaches in cystic fibrosis related diabetes (CFRD). Journal of Cystic Fibrosis2008;7(Suppl 3):S6. [ABSTRACT NO.: R25] [CFGD REGISTER: CO42a] ">Minicucci 2012</a>) or agents impacting incretin mechanisms (<a href="./references#CD004730-bbs2-0011" title="GeyerMC , SullivanT , TaiA , MortonJM , EdwardsS , MartinAJ , et al. Exenatide corrects postprandial hyperglycaemia in young people with cystic fibrosis and impaired glucose tolerance: a randomized crossover trial. Diabetes, Obesity &amp; Metabolism2019;21:700-704. [CFGD REGISTER: CO69] ">Geyer 2019</a>) in the management of these individuals who have a high risk of developing diabetes (<a href="./references#CD004730-bbs2-0047" title="SchmidK , FinkK , HollRW , HebestreitH , BallmannM . Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test. Journal of Cystic Fibrosis2014;13(1):80-5.">Schmid 2014</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD004730-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/urn:x-wiley:14651858:media:CD004730:CD004730-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Insulin versus placebo, Outcome 1: Change in FEV1 (% predicted)" data-id="CD004730-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/image_n/nCD004730-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/image_t/tCD004730-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Insulin versus placebo, Outcome 1: Change in FEV<sub>1</sub> (% predicted) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/references#CD004730-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/image_n/nCD004730-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004730-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/urn:x-wiley:14651858:media:CD004730:CD004730-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Insulin versus placebo, Outcome 2: Change in FVC (% predicted)" data-id="CD004730-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/image_n/nCD004730-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/image_t/tCD004730-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Insulin versus placebo, Outcome 2: Change in FVC (% predicted)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/references#CD004730-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/image_n/nCD004730-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004730-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/urn:x-wiley:14651858:media:CD004730:CD004730-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Insulin versus placebo, Outcome 3: Change in BMI" data-id="CD004730-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/image_n/nCD004730-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/image_t/tCD004730-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Insulin versus placebo, Outcome 3: Change in BMI</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/references#CD004730-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/image_n/nCD004730-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004730-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/urn:x-wiley:14651858:media:CD004730:CD004730-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Insulin versus placebo, Outcome 4: Hypoglycemia" data-id="CD004730-fig-0004" src="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/image_n/nCD004730-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/image_t/tCD004730-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Insulin versus placebo, Outcome 4: Hypoglycemia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/references#CD004730-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/image_n/nCD004730-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004730-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/urn:x-wiley:14651858:media:CD004730:CD004730-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Repaglinide versus placebo, Outcome 1: Change in FEV1 (% predicted)" data-id="CD004730-fig-0005" src="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/image_n/nCD004730-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/image_t/tCD004730-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Repaglinide versus placebo, Outcome 1: Change in FEV<sub>1</sub> (% predicted) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/references#CD004730-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/image_n/nCD004730-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004730-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/urn:x-wiley:14651858:media:CD004730:CD004730-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Repaglinide versus placebo, Outcome 2: Change in FVC (% predicted)" data-id="CD004730-fig-0006" src="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/image_n/nCD004730-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/image_t/tCD004730-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Repaglinide versus placebo, Outcome 2: Change in FVC (% predicted)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/references#CD004730-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/image_n/nCD004730-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004730-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/urn:x-wiley:14651858:media:CD004730:CD004730-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Repaglinide versus placebo, Outcome 3: Change in BMI" data-id="CD004730-fig-0007" src="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/image_n/nCD004730-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/image_t/tCD004730-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Repaglinide versus placebo, Outcome 3: Change in BMI</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/references#CD004730-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/image_n/nCD004730-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004730-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/urn:x-wiley:14651858:media:CD004730:CD004730-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Repaglinide versus placebo, Outcome 4: Hypoglycemia" data-id="CD004730-fig-0008" src="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/image_n/nCD004730-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/image_t/tCD004730-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Repaglinide versus placebo, Outcome 4: Hypoglycemia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/references#CD004730-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/image_n/nCD004730-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004730-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/urn:x-wiley:14651858:media:CD004730:CD004730-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Insulin versus repaglinide, Outcome 1: Change in HbA1c concentration ( % )" data-id="CD004730-fig-0009" src="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/image_n/nCD004730-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/image_t/tCD004730-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Insulin versus repaglinide, Outcome 1: Change in HbA1c concentration ( % ) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/references#CD004730-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/image_n/nCD004730-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004730-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/urn:x-wiley:14651858:media:CD004730:CD004730-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Insulin versus repaglinide, Outcome 2: Change in FEV1 (% predicted)" data-id="CD004730-fig-0010" src="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/image_n/nCD004730-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/image_t/tCD004730-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Insulin versus repaglinide, Outcome 2: Change in FEV<sub>1</sub> (% predicted) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/references#CD004730-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/image_n/nCD004730-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004730-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/urn:x-wiley:14651858:media:CD004730:CD004730-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Insulin versus repaglinide, Outcome 3: Change in FVC (% predicted)" data-id="CD004730-fig-0011" src="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/image_n/nCD004730-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/image_t/tCD004730-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Insulin versus repaglinide, Outcome 3: Change in FVC (% predicted)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/references#CD004730-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/image_n/nCD004730-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004730-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/urn:x-wiley:14651858:media:CD004730:CD004730-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Insulin versus repaglinide, Outcome 4: Change in BMI" data-id="CD004730-fig-0012" src="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/image_n/nCD004730-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/image_t/tCD004730-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Insulin versus repaglinide, Outcome 4: Change in BMI</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/references#CD004730-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/image_n/nCD004730-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004730-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/urn:x-wiley:14651858:media:CD004730:CD004730-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Insulin versus repaglinide, Outcome 5: Change in BMI z score" data-id="CD004730-fig-0013" src="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/image_n/nCD004730-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/image_t/tCD004730-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Insulin versus repaglinide, Outcome 5: Change in BMI z score</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/references#CD004730-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/image_n/nCD004730-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004730-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/urn:x-wiley:14651858:media:CD004730:CD004730-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Insulin versus repaglinide, Outcome 6: Hypoglycemia" data-id="CD004730-fig-0014" src="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/image_n/nCD004730-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/image_t/tCD004730-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Insulin versus repaglinide, Outcome 6: Hypoglycemia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/references#CD004730-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/image_n/nCD004730-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004730-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/urn:x-wiley:14651858:media:CD004730:CD004730-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: NPH insulin versus glargine, Outcome 1: Glucose levels (mg/dl)" data-id="CD004730-fig-0015" src="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/image_n/nCD004730-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/image_t/tCD004730-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: NPH insulin versus glargine, Outcome 1: Glucose levels (mg/dl)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/references#CD004730-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/image_n/nCD004730-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004730-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/urn:x-wiley:14651858:media:CD004730:CD004730-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: NPH insulin versus glargine, Outcome 2: Change in weight (kg)" data-id="CD004730-fig-0016" src="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/image_n/nCD004730-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/image_t/tCD004730-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: NPH insulin versus glargine, Outcome 2: Change in weight (kg)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/references#CD004730-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/image_n/nCD004730-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004730-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/urn:x-wiley:14651858:media:CD004730:CD004730-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: NPH insulin versus glargine, Outcome 3: Fat mass by DEXA (kg)" data-id="CD004730-fig-0017" src="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/image_n/nCD004730-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/image_t/tCD004730-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: NPH insulin versus glargine, Outcome 3: Fat mass by DEXA (kg)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/references#CD004730-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/image_n/nCD004730-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004730-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/urn:x-wiley:14651858:media:CD004730:CD004730-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: NPH insulin versus glargine, Outcome 4: Lean mass by DEXA (kg)" data-id="CD004730-fig-0018" src="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/image_n/nCD004730-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/image_t/tCD004730-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: NPH insulin versus glargine, Outcome 4: Lean mass by DEXA (kg)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/references#CD004730-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/image_n/nCD004730-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004730-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/urn:x-wiley:14651858:media:CD004730:CD004730-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: NPH insulin versus glargine, Outcome 5: Hypoglycemic events per participant" data-id="CD004730-fig-0019" src="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/image_n/nCD004730-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/image_t/tCD004730-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: NPH insulin versus glargine, Outcome 5: Hypoglycemic events per participant</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/references#CD004730-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/media/CDSR/CD004730/image_n/nCD004730-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD004730-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings: insulin versus placebo for CFRD</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Insulin versus placebo for cystic fibrosis‐related diabetes</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: adults with CFRD </p> <p><b>Settings</b>: outpatients </p> <p><b>Intervention</b>: insulin (0.5 unit insulin aspart/15 g dietary carbohydrate) 3 times daily </p> <p><b>Comparison:</b> oral placebo 3 times daily </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Insulin</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HbA1c</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>1 study reported that HbA1C levels did not significantly change in either the insulin or the placebo group (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>a,c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data were available for this outcome and results have been reported narratively (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). </p> <p>One trial (n = 7) reported that there was a benefit seen glucose AUC (reduction) at both the two‐hour time point (P &lt; 0.05) and the five‐hour time point (P &lt; 0.05) (<a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> % predicted</b>: change from baseline </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FEV<sub>1</sub> % predicted in the control group was<br/>‐ 3% predicted. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FEV<sub>1</sub> % predicted in the intervention group was 1.2% higher (5.6% lower to 8.0% higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD</b> 1.20 (‐5.63 to 8.03) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>b,c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No difference was observed between groups, P = 0.3 for overall effect (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FVC % predicted</b>: </p> <p>change from baseline</p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FVC % predicted in the control group was ‐1.1% predicted.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FVC % predicted in the intervention group was 0.6% higher (5.7% lower to 6.9% higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD</b> 0.60 (‐5.67 to 6.87) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>b,c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No difference was observed between groups,</p> <p>P = 0.85 for overall effect (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>BMI</b> <b>(kg/m²)</b>: </p> <p>change from baseline</p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in BMI in the control group was ‐0.02 kg/m².</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in BMI in the intervention groups was 0.41 kg/m² higher (0.23 kg/m² lower to 1.1 kg/m² higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD</b> 0.41 (‐0.23 to 1.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>b,c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no significant difference between the placebo group and intervention group, P = 0.21 for overall effect (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hypoglycemia</b>: </p> <p>number of episodes</p> <p>Follow‐up: 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There were no hypoglycemic events in the placebo group, therefore it is not possible to calculate the corresponding risk. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR</b> 9.23 (0.53 to 159.14) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>b,d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no significant difference between groups after 3 months, but it is not clear whether the hypoglycemic events occurred in those with CFRD or those with impaired glucose tolerance (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). </p> <p>The earlier Moran trial (n = 7) reported hypoglycemic events at 2 months and these data did not give a significant result, RR 2.00 (95% CI 0.23 to 17.34) (<a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>BMI</b> : body mass index; <b>CFRD</b> : cystic fibrosis‐related diabetes; <b>CI</b> : confidence interval; <b>HbA1c</b> : glycated hemoglobin; <b>FEV<sub>1</sub> </b> : forced expiratory volume in 1 second; <b>FVC</b> : forced vital capacity; <b>MD</b> : mean difference; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>a. Downgraded twice due to risk of bias in the included study, particularly around the domains of allocation concealment and selective outcome reporting. No data were reported for this outcome. </p> <p>b. Downgraded once due to an unclear risk of bias in the single included study. Although the study was deemed to be at low risk across the domains of randomization and blinding, the allocation process was not clearly described. The study was also deemed to be at high risk of bias due to selective reporting, although that does not affect this particular outcome. </p> <p>c. Downgraded once due to imprecision from small sample size; one study was 3‐armed study which therefore reduces the number of participants in each arm. </p> <p>d. Downgraded once due to imprecision from both small sample size and low event rates.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings: insulin versus placebo for CFRD</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/full#CD004730-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004730-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings: repaglinide versus placebo for CFRD</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Repaglinide versus placebo for CFRD</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: adults with CFRD </p> <p><b>Settings</b>: outpatients </p> <p><b>Intervention</b>: repaglinide (2.0 mg) orally 3 times daily </p> <p><b>Comparison</b>: oral placebo 3 times daily </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Repaglinide</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>HbA1c</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>1 trial reported that HbA1C levels did not significantly change in either the repaglinide or the placebo group (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>a,b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data were available for this outcome and results have been reported narratively (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> % predicted</b>; change from baseline </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FEV<sub>1</sub> % predicted in the control group was<br/>‐3% predicted. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FEV<sub>1</sub> % predicted in the intervention group was 1.7% higher (5.1% lower to 8.5% higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD</b> 1.70 (‐5.13 to 8.53) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>b,c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No difference was observed between groups, P = 0.6 for overall effect (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FVC % predicted</b>: change from baseline </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FVC % predicted in the control group was ‐1.1% predicted.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FVC % predicted in the intervention groups was 1.0% higher (7.4% lower to 5.4% higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD</b> ‐1.00 (‐7.40 to 5.40) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>b,c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No difference was observed between groups, P = 0.76 for overall effect (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>BMI (kg/m²)</b>: </p> <p>change from baseline</p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in BMI in the control group was ‐0.02 kg/m².</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in BMI in the intervention groups was 0.2 kg/m² higher (0.5 kg/m² lower to 0.8 kg/m² higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD</b> 0.17 (‐0.47 to 0.81) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>b,c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no significant difference between the placebo group and intervention group, P = 0.6 for overall effect (<a href="./references#CD004730-bbs2-0004" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] ">Moran 2009</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hypoglycemia</b>: </p> <p>number of episodes</p> <p>Follow‐up: 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There were mild hypoglycemic events reported in 23% of repaglinide participants, but no placebo participants reported hypoglycemia (P &lt; 0.04); therefore it is not possible to calculate the corresponding risk. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR</b> 12.52 (0.74 to 211.20) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>a,d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The earlier Moran study also reported on this outcome but at 2 months. These data did not give a significant result, RR 2.00 (95% CI 0.23 to 17.34) (<a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>BMI</b> : body mass index; <b>CFRD</b> : cystic fibrosis‐related diabetes; <b>CI</b> : confidence interval; <b>HbA1c</b> : glycated hemoglobin; <b>FEV<sub>1</sub> </b> : forced expiratory volume in 1 second; <b>FVC</b> : forced vital capacity; <b>MD</b> : mean difference; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>a. Downgraded twice due to risk of bias in the included study, particularly around the domains of allocation concealment and selective outcome reporting. No data were reported for this outcome. </p> <p>b. Downgraded once due to imprecision from small sample size. This was a 3‐armed study which therefore reduces the number of participants in each arm. </p> <p>c. Downgraded once due to an unclear risk of bias in the single included trial. Although the study was deemed to be at low risk across the domains of randomisation and blinding, the allocation process was not clearly described. The trial was also deemed to be at high risk of bias due to selective reporting although that does not affect this particular outcome. </p> <p>d. Downgraded once due to imprecision from both small sample size and low event rates.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings: repaglinide versus placebo for CFRD</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/full#CD004730-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004730-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings: repaglinide versus insulin for CFRD</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Repaglinide versus insulin for CFRD</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children over 12 and adults with CFRD </p> <p><b>Settings:</b> home </p> <p><b>Intervention:</b> oral repaglinide (0.5 mg ‐ 2 mg) 3 times daily </p> <p><b>Comparison:</b> insulin 3 times daily </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Insulin</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Repaglinide</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HbA1c (%)</b> </p> <p>change from baseline</p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in HbA1c in the control group was ‐0.1%.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in HbA1c in the intervention group was 0.3% higher<br/>(0.14% lower to 0.74% higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD</b> 0.30 (‐0.14 to 0.74) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ballmann also reported the change from baseline in HbA1c at 24 months, but found no significant difference between groups MD 0.4% (95% CI ‐0.09 to 0.89) (<a href="./references#CD004730-bbs2-0001" title="BallmannM , HubertD , AssaelBM , KronfeldK , HonerM , HollRW , et al. Open randomised prospective comparative multi-centre intervention study of patients with cystic fibrosis and early diagnosed diabetes mellitus. BMC Pediatrics2014;14:70. [CENTRAL: 1000301] [CFGD REGISTER: CO53c] [JID: 100967804] [OID: NLM: PMC3975280] [PMCID: PMC3975280] [PMID: 24620855]BallmannM , HubertD , AssaelBM , Mosnier-PudarH , Barao OcampoM , ScheunigN , et al. Repaglinide versus insulin in the treatment of CFRD diagnosed by screening: an open prospective randomized study. Pediatric Pulmonology2013;48 Suppl 26:421. [ABSTRACT NO.: 582] [CENTRAL: 962122] [CFGD REGISTER: CO53b] BallmannM , HubertD , AssaelBM , Mosnier-PudarH , SmacznyC , KesslerL , et al. Treatment of early diagnosed CFRD with oral drugs verus insulin: An open prospective randomized study. Journal of Cystic Fibrosis2013;12 Suppl 1:S32. [ABSTRACT NO.: WS16.1] [CENTRAL: 962115] [CFGD REGISTER: CO53a] BallmannM , HubertD , AssaelBM , StaabD , HebestreitA , NaehrlichL , et al. Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. The Lancet Diabetes and Endocrinology2018;6(2):114-21. [CFGD REGISTER: CO53e] [DOI: 10.1016/S2213-8587(17)30400-X]SchmidK , FinkK , HollRW , HebestreitH , BallmannM . Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2014;13(1):80-5. [CENTRAL: 1000302] [CFGD REGISTER: CO53d] [JID: 101128966] [PMID: 23809507] [SI: ClinicalTrials.gov/NCT00662714]">Ballmann 2018b</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> % predicted</b> </p> <p>change from baseline</p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FEV<sub>1</sub> % predicted ranged across control groups from ‐1.8% to ‐1.7%. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean FEV<sub>1</sub> in the intervention groups was<br/>0.51% lower (4.22% lower to 3.2% higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD</b> ‐0.51 (‐4.22 to 3.20) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112<br/>(2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The Ballmann study also reported this outcome at 24 months, but found no significant difference between groups MD ‐0.10% predicted (95% CI ‐4.12 to 3.92) (<a href="./references#CD004730-bbs2-0001" title="BallmannM , HubertD , AssaelBM , KronfeldK , HonerM , HollRW , et al. Open randomised prospective comparative multi-centre intervention study of patients with cystic fibrosis and early diagnosed diabetes mellitus. BMC Pediatrics2014;14:70. [CENTRAL: 1000301] [CFGD REGISTER: CO53c] [JID: 100967804] [OID: NLM: PMC3975280] [PMCID: PMC3975280] [PMID: 24620855]BallmannM , HubertD , AssaelBM , Mosnier-PudarH , Barao OcampoM , ScheunigN , et al. Repaglinide versus insulin in the treatment of CFRD diagnosed by screening: an open prospective randomized study. Pediatric Pulmonology2013;48 Suppl 26:421. [ABSTRACT NO.: 582] [CENTRAL: 962122] [CFGD REGISTER: CO53b] BallmannM , HubertD , AssaelBM , Mosnier-PudarH , SmacznyC , KesslerL , et al. Treatment of early diagnosed CFRD with oral drugs verus insulin: An open prospective randomized study. Journal of Cystic Fibrosis2013;12 Suppl 1:S32. [ABSTRACT NO.: WS16.1] [CENTRAL: 962115] [CFGD REGISTER: CO53a] BallmannM , HubertD , AssaelBM , StaabD , HebestreitA , NaehrlichL , et al. Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. The Lancet Diabetes and Endocrinology2018;6(2):114-21. [CFGD REGISTER: CO53e] [DOI: 10.1016/S2213-8587(17)30400-X]SchmidK , FinkK , HollRW , HebestreitH , BallmannM . Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2014;13(1):80-5. [CENTRAL: 1000302] [CFGD REGISTER: CO53d] [JID: 101128966] [PMID: 23809507] [SI: ClinicalTrials.gov/NCT00662714]">Ballmann 2018b</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FVC % predicted</b> </p> <p>change from baseline</p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FVC % predicted ranged across control groups from ‐0.8% to ‐0.5%.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FVC % predicted in the intervention groups was<br/>1.0% lower (4.29% lower to 2.3% higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD</b> ‐1.00 (‐4.29 to 2.29) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112<br/>(2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The Ballmann study also reported this outcome at 24 months, but found no significant difference between groups MD ‐3.40% predicted (95% CI ‐7.37 to 0.57) (<a href="./references#CD004730-bbs2-0001" title="BallmannM , HubertD , AssaelBM , KronfeldK , HonerM , HollRW , et al. Open randomised prospective comparative multi-centre intervention study of patients with cystic fibrosis and early diagnosed diabetes mellitus. BMC Pediatrics2014;14:70. [CENTRAL: 1000301] [CFGD REGISTER: CO53c] [JID: 100967804] [OID: NLM: PMC3975280] [PMCID: PMC3975280] [PMID: 24620855]BallmannM , HubertD , AssaelBM , Mosnier-PudarH , Barao OcampoM , ScheunigN , et al. Repaglinide versus insulin in the treatment of CFRD diagnosed by screening: an open prospective randomized study. Pediatric Pulmonology2013;48 Suppl 26:421. [ABSTRACT NO.: 582] [CENTRAL: 962122] [CFGD REGISTER: CO53b] BallmannM , HubertD , AssaelBM , Mosnier-PudarH , SmacznyC , KesslerL , et al. Treatment of early diagnosed CFRD with oral drugs verus insulin: An open prospective randomized study. Journal of Cystic Fibrosis2013;12 Suppl 1:S32. [ABSTRACT NO.: WS16.1] [CENTRAL: 962115] [CFGD REGISTER: CO53a] BallmannM , HubertD , AssaelBM , StaabD , HebestreitA , NaehrlichL , et al. Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. The Lancet Diabetes and Endocrinology2018;6(2):114-21. [CFGD REGISTER: CO53e] [DOI: 10.1016/S2213-8587(17)30400-X]SchmidK , FinkK , HollRW , HebestreitH , BallmannM . Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2014;13(1):80-5. [CENTRAL: 1000302] [CFGD REGISTER: CO53d] [JID: 101128966] [PMID: 23809507] [SI: ClinicalTrials.gov/NCT00662714]">Ballmann 2018b</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>BMI (kg/m²)</b> change from baseline </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in BMI kg/m² in the control group was 0.15 kg/m².</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the intervention group was 0.24 kg/m² higher (0.34 kg/m² lower to 0.82 kg/m² higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD</b> 0.24 (‐0.34 to 0.82) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>b,c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A further trial reported BMI z score and found no significant improvement in z score in the repaglinide treatment group compared to insulin at 12 months (n = 67), MD 0.00 (95%CI ‐0.49 to 0.49). This difference remained non‐significant at 24 months (n = 67), MD 0.40 (95% CI ‐0.09 to 0.89) (<a href="./references#CD004730-bbs2-0001" title="BallmannM , HubertD , AssaelBM , KronfeldK , HonerM , HollRW , et al. Open randomised prospective comparative multi-centre intervention study of patients with cystic fibrosis and early diagnosed diabetes mellitus. BMC Pediatrics2014;14:70. [CENTRAL: 1000301] [CFGD REGISTER: CO53c] [JID: 100967804] [OID: NLM: PMC3975280] [PMCID: PMC3975280] [PMID: 24620855]BallmannM , HubertD , AssaelBM , Mosnier-PudarH , Barao OcampoM , ScheunigN , et al. Repaglinide versus insulin in the treatment of CFRD diagnosed by screening: an open prospective randomized study. Pediatric Pulmonology2013;48 Suppl 26:421. [ABSTRACT NO.: 582] [CENTRAL: 962122] [CFGD REGISTER: CO53b] BallmannM , HubertD , AssaelBM , Mosnier-PudarH , SmacznyC , KesslerL , et al. Treatment of early diagnosed CFRD with oral drugs verus insulin: An open prospective randomized study. Journal of Cystic Fibrosis2013;12 Suppl 1:S32. [ABSTRACT NO.: WS16.1] [CENTRAL: 962115] [CFGD REGISTER: CO53a] BallmannM , HubertD , AssaelBM , StaabD , HebestreitA , NaehrlichL , et al. Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. The Lancet Diabetes and Endocrinology2018;6(2):114-21. [CFGD REGISTER: CO53e] [DOI: 10.1016/S2213-8587(17)30400-X]SchmidK , FinkK , HollRW , HebestreitH , BallmannM . Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2014;13(1):80-5. [CENTRAL: 1000302] [CFGD REGISTER: CO53d] [JID: 101128966] [PMID: 23809507] [SI: ClinicalTrials.gov/NCT00662714]">Ballmann 2018b</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hypoglycemia</b> </p> <p>number of episodes</p> <p>Follow‐up: 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>167 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>230 per 1000</b><br/>(80 to 670) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR</b> 1.38 (0.48 to 4.01) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56<br/>(2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>b,c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The earlier Moran trial also reported on episodes of hypoglycaemia over 2 months, but reported no significant differences between groups, RR 0.50 (95% CI 0.06 to 4.33) (<a href="./references#CD004730-bbs2-0003" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 (Suppl 22):335. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>BMI</b> : body mass index; <b>CFRD</b> : cystic fibrosis‐related diabetes; <b>CI</b> : confidence interval; <b>HbA1c</b> : glycated hemoglobin; <b>FEV<sub>1</sub> </b> : forced expiratory volume in 1 second; <b>FVC</b> : forced vital capacity; <b>MD</b> : mean difference; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>a. Downgraded once due to risk of bias within the included studies. The larger Ballmann study was at low of risk of bias across most domains but was deemed to be at high risk of performance bias due to the study being open‐label. The Moran study was at high or unclear risk of bias across 3 domains and so, when taken together, there was enough risk of bias to affect the results. </p> <p>b. Downgraded once due to an unclear risk of bias in the single included study. Although the study was deemed to be at low risk across the domains of randomisation and blinding, the allocation process wasn't clearly described. The study was also deemed to be at high risk of bias due to selective reporting although that does not affect this particular outcome. </p> <p>c. Downgraded once due to imprecision from small sample size. This was a 3‐armed study which therefore reduces the number of participants in each arm. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings: repaglinide versus insulin for CFRD</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/full#CD004730-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004730-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Summary of findings: NPH insulin versus glargine for CFRD</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>NPH insulin versus glargine for CFRD</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: adults with CFRD and fasting hyperglycemia </p> <p><b>Settings</b>: home </p> <p><b>Intervention</b>: NPH insulin (individually dosed based on insulin to carbohydrate ratio) at bedtime </p> <p><b>Comparison</b>: insulin glargine given at bedtime </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Insulin glargine</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>NPH insulin</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HbA1c</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study reported on fasting and 2‐hour post‐prandial glucose. There was no significant difference between groups for either measure, MD 10.00 mg/dL (95% CI ‐12.86 to 32.86) and MD 8.00 mg/dL (95% CI ‐10.07 to 26.07) respectively (<a href="./references#CD004730-bbs2-0002" title="GroverP , ThomasW , MoranA . Glargine versus NPH insulin in cystic fibrosis related diabetes. Journal of Cystic Fibrosis2008;7(2):134-6. [CFGD REGISTER: CO39] ">Grover 2008</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> % predicted</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FVC % predicted</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>BMI kg/m²</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BMI was not reported for this comparison. The Grover study did however report on mean change in: weight, MD ‐1.00 kg (95% CI ‐2.39 to 0.39); fat mass, MD ‐0.30 kg (95% CI ‐1.41 to 0.81); and lean mass, MD ‐0.20 kg (95% CI ‐0.75 to 0.35). None of the results showed any significant difference between NPH insulin and glargine (<a href="./references#CD004730-bbs2-0002" title="GroverP , ThomasW , MoranA . Glargine versus NPH insulin in cystic fibrosis related diabetes. Journal of Cystic Fibrosis2008;7(2):134-6. [CFGD REGISTER: CO39] ">Grover 2008</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hypoglycemia</b> </p> <p>mean number of events per participant</p> <p>Follow‐up: 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of hypoglycaemic events in the control group was 6 per participant.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of hypoglycaemic events in the intervention group was 1 event lower (4 events lower to 2 events higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD</b> ‐1.00 (‐3.77 to 1.77) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>a,b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>BMI</b> : body mass index; <b>CFRD</b> : cystic fibrosis‐related diabetes; <b>CI</b> : confidence interval; <b>HbA1c</b> : glycated hemoglobin; <b>FEV<sub>1</sub> </b> : forced expiratory volume in 1 second; <b>FVC</b> : forced vital capacity; <b>MD</b> : mean difference; <b>NPH</b>: neutral protamine hagedorn. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>a. Downgraded twice for risk of bias. There was an unclear or high risk of bias across all domains for this study. </p> <p>b. Downgraded once due to imprecision caused by small sample size and low event rates.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Summary of findings: NPH insulin versus glargine for CFRD</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/full#CD004730-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004730-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Insulin versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Change in FEV<sub>1</sub> (% predicted) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [‐5.63, 8.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Change in FVC (% predicted) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [‐5.67, 6.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Change in BMI <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [‐0.23, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Hypoglycemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 At 2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [0.23, 17.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 At 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.23 [0.53, 159.14]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Insulin versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/references#CD004730-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004730-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Repaglinide versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Change in FEV<sub>1</sub> (% predicted) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [‐5.13, 8.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Change in FVC (% predicted) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.00 [‐7.40, 5.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Change in BMI <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [‐0.47, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Hypoglycemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 At 2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.08, 13.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.2 At 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.52 [0.74, 211.20]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Repaglinide versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/references#CD004730-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004730-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Insulin versus repaglinide</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Change in HbA1c concentration ( % ) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [‐0.14, 0.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 At 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [‐0.09, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Change in FEV<sub>1</sub> (% predicted) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.51 [‐4.22, 3.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.2 At 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐4.12, 3.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Change in FVC (% predicted) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.00 [‐4.29, 2.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.2 At 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.40 [‐7.37, 0.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Change in BMI <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.1 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Change in BMI z score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.1 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.2 At 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Hypoglycemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.1 At 2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.2 At 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Insulin versus repaglinide</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/references#CD004730-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004730-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">NPH insulin versus glargine</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Glucose levels (mg/dl) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 Fasting (at 3 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.2 2 hour post‐prandial (at 3 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Change in weight (kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.1 At 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Fat mass by DEXA (kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.1 At 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Lean mass by DEXA (kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.1 At 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 Hypoglycemic events per participant <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.1 At 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">NPH insulin versus glargine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004730.pub5/references#CD004730-tbl-0008">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD004730.pub5&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD004730-note-0014">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD004730-note-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD004730-note-0012">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD004730-note-0013">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD004730-note-0009">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD004730-note-0010">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004730\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004730\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004730\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004730\x2epub5"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004730\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004730\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004730\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004730\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004730\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004730\x2epub5"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004730\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004730\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004730\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004730\x2epub5"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004730\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004730\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004730\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004730\x2epub5"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PSzzz2OT&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004730.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004730.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD004730.pub5/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD004730.pub5/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004730.pub5%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740718870168"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004730.pub5/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740718870172"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004730.pub5/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ddae3bde8935f',t:'MTc0MDcxODg3MC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 